tokens,ner_tags,id,nct_id,text,ner_manual_ct_target
"['Effectiveness', 'of', 'Bio', '-', 'Electro', 'Stimulation', 'Therapy', 'for', 'the', 'Treatment', 'of', 'Motor', 'and', 'Non', '-', 'Motor', 'Symptoms', 'in', 'Parkinson', ""'s"", 'Disease', '-', 'A', 'Pilot', 'Study', '|', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', 'is', 'a', 'neurodegenerative', 'disorder', 'characterized', 'by', 'motor', 'dysfunction', 'and', 'non', '-', 'motor', 'symptoms', '.', 'Here', ',', 'the', 'investigators', 'propose', 'in', 'a', 'pilot', 'device', 'feasibility', 'trial', 'to', 'examine', 'whether', '""', 'Bio', 'Electro', 'Stimulation', 'Therapy', '""', '(', 'B.E.S.T.', ')', 'with', 'a', 'small', ',', 'non', '-', 'invasive', ',', 'handheld', 'electronic', 'device', 'designed', 'to', 'apply', 'micro', 'current', 'stimulation', 'to', 'a', 'person', ""'s"", 'hand', 'can', 'ameliorate', 'some', 'of', 'the', 'symptoms', 'of', 'PD', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT03014050,NCT03014050,"Effectiveness of Bio-Electro Stimulation Therapy for the Treatment of Motor and Non-Motor Symptoms in Parkinson's Disease - A Pilot Study | Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor dysfunction and non-motor symptoms. Here, the investigators propose in a pilot device feasibility trial to examine whether ""Bio Electro Stimulation Therapy"" (B.E.S.T.) with a small, non-invasive, handheld electronic device designed to apply micro current stimulation to a person's hand can ameliorate some of the symptoms of PD.","[(17, 48, 'OTHER', 'Bio-Electro Stimulation Therapy'), (102, 121, 'CONDITION', ""Parkinson's Disease""), (140, 159, 'CONDITION', ""Parkinson's disease""), (161, 163, 'CONDITION', 'PD'), (344, 375, 'OTHER', 'Bio Electro Stimulation Therapy'), (378, 386, 'OTHER', 'B.E.S.T.'), (545, 547, 'CONDITION', 'PD')]"
"['18F', '-', 'DOPA', 'II', '-', 'PET', 'Imaging', 'Optimization', '|', 'A', 'single', 'centre', 'non', '-', 'randomized', ',', 'non', '-', 'blinded', 'phase', 'III', 'prospective', 'cohort', 'study', 'of', '18F', '-', 'DOPA', 'PET', '/', 'CT', 'imaging', 'in', 'specific', 'patient', 'populations', ':', '\n\n', 'Pediatric', 'patients', '(', 'less', 'than', '18', 'years', 'old', ')', 'with', 'congenital', 'hyperinsulinism', '.', '\n', 'Pediatric', 'patients', '(', 'less', 'than', '18', 'years', 'old', ')', 'with', 'neuroblastoma', '.', '\n', 'Pediatric', '(', 'less', 'than', '18', 'years', 'old', ')', 'or', 'Adult', 'patients', '(', '18', 'or', 'older', ')', 'with', 'known', 'or', 'clinically', 'suspected', 'neuroendocrine', 'tumor', '.', '\n', 'Adult', 'patients', '(', '18', 'or', 'older', ')', 'with', 'a', 'clinical', 'suspicion', 'of', 'Parkinson', ""'s"", 'disease', 'or', 'Lewy', 'body', 'dementia', '.', '\n', 'Pediatric', '(', 'less', 'than', '18', 'years', 'old', ')', 'or', 'Adult', 'patients', '(', '18', 'or', 'older', ')', 'with', 'brain', 'tumors', '.', '\n\n', 'Image', 'optimization', '(', 'the', 'primary', 'study', 'objective', ')', 'and', 'gallbladder', 'activity', 'pattern', '(', 'the', 'secondary', 'objective', ')', 'will', 'be', 'evaluated', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04706910,NCT04706910,"18F-DOPA II - PET Imaging Optimization | A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET/CT imaging in specific patient populations:

Pediatric patients (less than 18 years old) with congenital hyperinsulinism.
Pediatric patients (less than 18 years old) with neuroblastoma.
Pediatric (less than 18 years old) or Adult patients (18 or older) with known or clinically suspected neuroendocrine tumor.
Adult patients (18 or older) with a clinical suspicion of Parkinson's disease or Lewy body dementia.
Pediatric (less than 18 years old) or Adult patients (18 or older) with brain tumors.

Image optimization (the primary study objective) and gallbladder activity pattern (the secondary objective) will be evaluated.","[(230, 256, 'CONDITION', 'congenital hyperinsulinism'), (307, 320, 'CONDITION', 'neuroblastoma'), (424, 444, 'CONDITION', 'neuroendocrine tumor'), (527, 545, 'CONDITION', 'Lewy body dementia'), (619, 631, 'CONDITION', 'brain tumors')]"
"['Neurologic', 'Music', 'Therapy', 'for', 'Enhancing', 'Fine', 'Motor', 'Control', 'in', 'Parkinson', ""'s"", 'Disease', '|', 'Parkinson', ""'s"", 'Disease', '(', 'PD', ')', 'is', 'defined', 'by', 'characteristic', 'motor', 'symptoms', 'including', 'slow', 'movements', ',', 'small', 'movements', ',', 'difficulty', 'with', 'movement', 'initiation', 'and', 'disruptions', 'in', 'timing', '.', 'Besides', 'gross', 'motor', 'symptoms', ',', 'fine', 'motor', 'impairments', 'in', 'PD', 'cause', 'difficulties', 'with', 'everyday', 'tasks', 'such', 'as', 'writing', ',', 'self', '-', 'care', ',', 'and', 'fine', 'object', 'manipulation', '.', 'These', 'activity', 'limitations', 'can', 'lead', 'to', 'disability', ',', 'social', 'isolation', ',', 'and', 'a', 'reduced', 'quality', 'of', 'life', '.', 'In', 'a', 'series', 'of', 'breakthrough', 'studies', 'Michael', 'Thaut', 'and', 'colleagues', 'developed', 'Neurologic', 'Music', 'Therapy', '(', 'NMT', ')', 'and', 'found', 'it', 'can', 'address', 'many', 'gross', 'motor', 'impairments', 'and', 'improve', 'gait', 'and', 'balance', '.', 'Other', 'music', 'therapies', 'such', 'as', 'Music', '-', 'supported', 'Therapy', '(', 'MST', ')', 'have', 'proven', 'motor', 'benefits', 'in', 'stroke', 'patients', 'through', 'movement', 'exercises', 'with', 'musical', 'instruments', '.', 'However', ',', 'the', 'pathological', 'basal', 'ganglia', '(', 'BG', ')', 'in', 'PD', 'brains', 'leads', 'to', 'a', 'reduced', 'supply', 'of', 'those', 'internally', 'generated', 'movements', '.', 'In', 'contrast', ',', 'externally', 'cued', 'movements', '(', 'eg', '.', 'via', 'a', 'beat', 'or', 'a', 'rhythm', ')', 'during', 'NMT', 'sessions', 'are', 'instantaneously', 'entrained', 'to', 'the', 'period', 'of', 'a', 'rhythmic', 'stimulus', 'possibly', 'without', 'involvement', 'of', 'the', 'BG', '.', 'The', 'underlying', 'idea', 'is', 'that', 'rhythm', 'is', 'the', 'essential', 'component', 'relating', 'music', 'specifically', 'to', 'motor', 'behavior', '.', 'The', 'mechanism', 'of', 'action', 'is', 'called', '""', 'rhythmic', 'entrainment', '""', 'where', 'one', 'system', ""'s"", 'motion', 'or', 'signal', 'frequency', 'entrains', 'the', 'frequency', 'of', 'another', 'system', '.', 'The', 'effect', 'of', 'NMT', 'on', 'fine', 'motor', 'function', 'has', 'not', 'been', 'investigated', 'yet', '.', 'Music', 'activities', 'are', 'important', 'in', 'the', 'lives', 'of', 'many', 'older', 'adults', '.', 'Notably', ',', 'the', 'use', 'of', 'music', 'has', 'been', 'associated', 'with', 'increased', 'well', '-', 'being', 'for', 'older', 'adults', ',', 'as', 'it', 'fosters', 'social', 'connection', 'and', 'mood', 'regulation', '.', 'Furthermore', ',', 'many', 'musical', 'activities', 'have', 'limited', 'physical', 'demands', ',', 'making', 'them', 'attainable', 'for', 'individuals', 'who', 'are', 'living', 'with', 'mobility', 'impairments', 'or', 'other', 'physical', 'restrictions', '.', 'Based', 'on', 'the', 'literature', 'and', 'the', 'investigators', 'preliminary', 'studies', ',', 'the', 'investigators', 'propose', 'to', 'test', 'the', 'efficacy', 'of', 'Neurologic', 'Music', 'Therapy', 'in', 'comparison', 'to', 'Music', 'Supported', 'Therapy', 'and', 'Occupational', 'Therapy', '(', 'OT', ')', 'as', 'standard', 'of', 'care', 'on', 'adults', 'in', 'the', 'Parkinson', ""'s"", 'spectrum', '.', 'The', 'investigators', 'have', 'defined', 'a', 'working', 'plan', 'using', 'different', 'musical', 'instruments', 'and', 'growing', 'tempo', 'to', 'specifically', 'improve', 'fine', 'motor', 'movements', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03049033,NCT03049033,"Neurologic Music Therapy for Enhancing Fine Motor Control in Parkinson's Disease | Parkinson's Disease (PD) is defined by characteristic motor symptoms including slow movements, small movements, difficulty with movement initiation and disruptions in timing. Besides gross motor symptoms, fine motor impairments in PD cause difficulties with everyday tasks such as writing, self-care, and fine object manipulation. These activity limitations can lead to disability, social isolation, and a reduced quality of life. In a series of breakthrough studies Michael Thaut and colleagues developed Neurologic Music Therapy (NMT) and found it can address many gross motor impairments and improve gait and balance. Other music therapies such as Music-supported Therapy (MST) have proven motor benefits in stroke patients through movement exercises with musical instruments. However, the pathological basal ganglia (BG) in PD brains leads to a reduced supply of those internally generated movements. In contrast, externally cued movements (eg. via a beat or a rhythm) during NMT sessions are instantaneously entrained to the period of a rhythmic stimulus possibly without involvement of the BG. The underlying idea is that rhythm is the essential component relating music specifically to motor behavior. The mechanism of action is called ""rhythmic entrainment"" where one system's motion or signal frequency entrains the frequency of another system. The effect of NMT on fine motor function has not been investigated yet. Music activities are important in the lives of many older adults. Notably, the use of music has been associated with increased well-being for older adults, as it fosters social connection and mood regulation. Furthermore, many musical activities have limited physical demands, making them attainable for individuals who are living with mobility impairments or other physical restrictions. Based on the literature and the investigators preliminary studies, the investigators propose to test the efficacy of Neurologic Music Therapy in comparison to Music Supported Therapy and Occupational Therapy (OT) as standard of care on adults in the Parkinson's spectrum. The investigators have defined a working plan using different musical instruments and growing tempo to specifically improve fine motor movements.","[(0, 24, 'OTHER', 'Neurologic Music Therapy'), (61, 80, 'CONDITION', ""Parkinson's Disease""), (83, 102, 'CONDITION', ""Parkinson's Disease""), (104, 106, 'CONDITION', 'PD'), (314, 316, 'CONDITION', 'PD'), (589, 613, 'OTHER', 'Neurologic Music Therapy'), (615, 618, 'OTHER', 'NMT'), (734, 757, 'CONTROL', 'Music-supported Therapy'), (759, 762, 'CONTROL', 'MST'), (911, 913, 'CONDITION', 'PD'), (1063, 1066, 'OTHER', 'NMT'), (1451, 1454, 'OTHER', 'NMT'), (2015, 2039, 'OTHER', 'Neurologic Music Therapy'), (2057, 2080, 'CONTROL', 'Music Supported Therapy'), (2085, 2105, 'CONTROL', 'Occupational Therapy'), (2107, 2109, 'CONTROL', 'OT'), (2148, 2168, 'CONDITION', ""Parkinson's spectrum"")]"
"['Developing', 'and', 'Evaluating', 'In', '-', 'Home', 'Supportive', 'Technology', 'for', 'Dementia', 'Caregivers', '|', 'This', 'study', 'aims', 'to', 'develop', 'and', 'evaluate', 'in', '-', 'home', 'assistive', 'technology', 'that', 'is', 'designed', 'to', 'alleviate', 'anxiety', ',', 'burden', ',', 'and', 'loneliness', 'in', 'spousal', 'and', 'familial', 'caregivers', 'of', 'individuals', 'with', 'Alzheimer', ""'s"", 'disease', 'and', 'frontotemporal', 'dementia', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O']",NCT03828383,NCT03828383,"Developing and Evaluating In-Home Supportive Technology for Dementia Caregivers | This study aims to develop and evaluate in-home assistive technology that is designed to alleviate anxiety, burden, and loneliness in spousal and familial caregivers of individuals with Alzheimer's disease and frontotemporal dementia.","[(26, 55, 'OTHER', 'In-Home Supportive Technology'), (60, 68, 'CONDITION', 'Dementia'), (122, 150, 'OTHER', 'in-home assistive technology'), (181, 188, 'CONDITION', 'anxiety'), (202, 212, 'CONDITION', 'loneliness'), (268, 287, 'CONDITION', ""Alzheimer's disease""), (292, 315, 'CONDITION', 'frontotemporal dementia')]"
"['Effect', 'of', 'Heparinization', 'on', 'Intracranial', 'Aneurysm', '|', 'The', 'goal', 'of', 'this', 'clinical', 'trial', 'is', 'to', 'compare', 'intracranial', 'aneurysm', 'patients', '.', 'The', 'main', 'question', 'it', 'aims', 'to', 'answer', 'are', ':', 'Which', 'heparinization', 'regimen', 'is', 'most', 'beneficial', 'to', 'patients', 'during', 'surgery', 'for', 'intracranial', 'aneurysms', '.', 'Participants', 'will', 'be', 'randomized', 'to', 'different', 'intraoperative', 'heparinization', 'regimens', ':', '(', 'i', ')', '50', 'U', '/', 'kg', 'intravenous', '(', 'IV', ')', 'at', '1', '-', 'h', 'intervals', 'reduced', 'by', 'half', 'to', 'a', 'minimum', 'of', '1000', 'u', '/', 'h', ';', '(', 'ii', ')', '60', 'U', '/', 'kg', 'IV', 'at', '1', '-', 'h', 'intervals', 'reduced', 'by', 'half', 'to', 'a', 'minimum', 'of', '1000', 'u', '/', 'h', ';', '(', 'iii', ')', '70', 'U', '/', 'kg', 'IV', 'at', '1', '-', 'h', 'intervals', 'reduced', 'by', 'half', 'to', 'a', 'minimum', 'of', '1000', 'u', '/', 'h.', 'MRI', 'will', 'be', 'performed', 'within', '72', 'h', 'after', 'surgery', ',', 'and', 'the', 'DWI', 'sequence', 'of', 'MRI', 'will', 'be', 'analyzed', '.', 'If', 'there', 'is', 'a', 'comparison', 'group', ':', 'Researchers', 'will', 'compare', 'different', 'intraoperative', 'heparinization', 'protocol', 'groups', 'to', 'see', 'which', 'dose', 'of', 'intraoperative', 'heparin', 'has', 'the', 'best', 'prognosis', 'for', 'use', '.']","['O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05749393,NCT05749393,"Effect of Heparinization on Intracranial Aneurysm | The goal of this clinical trial is to compare intracranial aneurysm patients. The main question it aims to answer are: Which heparinization regimen is most beneficial to patients during surgery for intracranial aneurysms. Participants will be randomized to different intraoperative heparinization regimens: (i) 50 U/kg intravenous (IV) at 1-h intervals reduced by half to a minimum of 1000 u/h; (ii) 60 U/kg IV at 1-h intervals reduced by half to a minimum of 1000 u/h; (iii) 70 U/kg IV at 1-h intervals reduced by half to a minimum of 1000 u/h. MRI will be performed within 72 h after surgery, and the DWI sequence of MRI will be analyzed. If there is a comparison group: Researchers will compare different intraoperative heparinization protocol groups to see which dose of intraoperative heparin has the best prognosis for use.","[(10, 24, 'DRUG', 'Heparinization'), (28, 49, 'CONDITION', 'Intracranial Aneurysm'), (98, 119, 'CONDITION', 'intracranial aneurysm'), (177, 191, 'DRUG', 'heparinization'), (238, 245, 'CONDITION', 'surgery'), (250, 272, 'CONDITION', 'intracranial aneurysms'), (334, 348, 'DRUG', 'heparinization'), (775, 789, 'DRUG', 'heparinization'), (842, 849, 'DRUG', 'heparin')]"
"['A', 'Randomized', 'Clinical', 'Trial', 'of', 'Immediate', 'Versus', 'Standard', 'Antiretroviral', 'Therapy', 'for', 'HIV', '-', 'infected', 'Adults', 'Presenting', 'With', 'Cryptococcal', 'Meningitis', '|', 'The', 'goal', 'of', 'this', 'randomized', 'clinical', 'trial', 'is', 'to', 'compare', 'early', 'versus', 'standard', 'timing', 'of', 'initiation', 'of', 'antiretroviral', 'therapy', '(', 'ART', ')', 'with', 'respect', 'to', 'clearance', 'of', 'Cryptococcus', 'neoformans', 'from', 'cerebrospinal', 'fluid', '(', 'CSF', ')', 'among', 'HIV', '-', 'infected', 'adults', 'with', 'Cryptococcal', 'Meningitis', '.', '\n\n', 'The', 'investigators', 'hypothesize', 'that', 'early', 'ART', 'mediates', 'more', 'rapid', 'clearance', 'of', 'C.', 'neoformans', 'from', 'CSF', ',', 'as', 'manifested', 'by', 'a', 'greater', 'rate', 'of', 'decrease', 'in', 'C.', 'neoformans', 'colony', 'forming', 'units', '(', 'CFUs', ')', 'during', 'the', 'first', '28', 'days', 'after', 'initiating', 'antifungal', 'treatment', '.', '\n\n', 'Secondary', 'hypotheses', 'are', 'that', 'recovery', 'of', 'pathogen', 'specific', 'cellular', 'immunity', 'directed', 'at', 'C.', 'neoformans', ',', 'as', 'manifested', 'by', 'increases', 'in', 'the', 'number', 'and', 'function', 'of', 'C.', 'neoformans', '-', 'specific', 'peripheral', 'blood', 'mononuclear', 'cells', 'is', 'associated', 'with', '1', ')', 'ART', 'and', '2', ')', 'pathogen', 'clearance', '.', 'In', 'addition', ',', 'patients', 'randomized', 'to', 'the', 'intervention', 'arm', 'will', 'have', 'more', 'rapid', 'clearance', 'of', 'antigen', 'levels', 'in', 'CSF', 'and', 'serum', 'and', 'will', 'have', 'a', 'lower', 'incidence', 'of', 'grade', '3', 'and', '4', 'Adverse', 'events', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00976040,NCT00976040,"A Randomized Clinical Trial of Immediate Versus Standard Antiretroviral Therapy for HIV-infected Adults Presenting With Cryptococcal Meningitis | The goal of this randomized clinical trial is to compare early versus standard timing of initiation of antiretroviral therapy (ART) with respect to clearance of Cryptococcus neoformans from cerebrospinal fluid (CSF) among HIV-infected adults with Cryptococcal Meningitis.

The investigators hypothesize that early ART mediates more rapid clearance of C. neoformans from CSF, as manifested by a greater rate of decrease in C. neoformans colony forming units (CFUs) during the first 28 days after initiating antifungal treatment.

Secondary hypotheses are that recovery of pathogen specific cellular immunity directed at C. neoformans, as manifested by increases in the number and function of C. neoformans-specific peripheral blood mononuclear cells is associated with 1) ART and 2) pathogen clearance. In addition, patients randomized to the intervention arm will have more rapid clearance of antigen levels in CSF and serum and will have a lower incidence of grade 3 and 4 Adverse events.","[(31, 79, 'OTHER', 'Immediate Versus Standard Antiretroviral Therapy'), (84, 87, 'CONDITION', 'HIV'), (120, 143, 'CONDITION', 'Cryptococcal Meningitis'), (203, 271, 'OTHER', 'early versus standard timing of initiation of antiretroviral therapy'), (273, 276, 'OTHER', 'ART'), (368, 371, 'CONDITION', 'HIV'), (393, 416, 'CONDITION', 'Cryptococcal Meningitis'), (454, 463, 'OTHER', 'early ART'), (917, 920, 'OTHER', 'ART')]"
"['A', 'Phase', '2a', 'Safety', ',', 'Tolerability', ',', 'Pharmacokinetic', '(', 'PK', ')', ',', 'and', 'Pharmacodynamic', '(', 'PD', ')', 'Study', 'of', 'Intravenous', 'ANX005', 'in', 'Subjects', 'With', 'Amyotrophic', 'Lateral', 'Sclerosis', '(', 'ALS', ')', '|', 'This', 'study', 'is', 'a', 'multi', '-', 'center', ',', 'open', '-', 'label', 'study', 'of', 'intravenous', '(', 'IV', ')', 'ANX005', 'in', 'participants', 'with', 'ALS', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O']",NCT04569435,NCT04569435,"A Phase 2a Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Study of Intravenous ANX005 in Subjects With Amyotrophic Lateral Sclerosis (ALS) | This study is a multi-center, open-label study of intravenous (IV) ANX005 in participants with ALS.","[(101, 107, 'DRUG', 'ANX005'), (125, 154, 'CONDITION', 'Amyotrophic Lateral Sclerosis'), (156, 159, 'CONDITION', 'ALS'), (230, 236, 'DRUG', 'ANX005'), (258, 261, 'CONDITION', 'ALS')]"
"['Restoring', 'Hand', 'Function', 'Using', 'Nerve', 'Transfers', 'in', 'Persons', 'With', 'Spinal', 'Cord', 'Injury', '|', 'Nerve', 'Transfer', 'surgery', 'can', 'provide', 'improved', 'hand', 'function', 'following', 'cervical', 'spinal', 'cord', 'injuries']","['O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND']",NCT01714349,NCT01714349,Restoring Hand Function Using Nerve Transfers in Persons With Spinal Cord Injury | Nerve Transfer surgery can provide improved hand function following cervical spinal cord injuries,"[(30, 45, 'SURGICAL', 'Nerve Transfers'), (62, 80, 'CONDITION', 'Spinal Cord Injury'), (83, 97, 'SURGICAL', 'Nerve Transfer'), (151, 180, 'CONDITION', 'cervical spinal cord injuries')]"
"['Cognitive', 'Recovery', 'After', 'Electroconvulsive', 'Therapy', 'and', 'General', 'Anesthesia', 'Reconstitution', 'of', 'Consciousness', 'and', 'Cognition', '(', 'Phase', '2', ')', '|', 'This', 'study', 'is', 'geared', 'toward', 'characterizing', 'the', 'recovery', 'of', 'brain', 'activity', 'and', 'cognitive', 'function', 'following', 'treatments', 'of', 'electroconvulsive', 'therapy', 'and', 'ketamine', 'general', 'anesthesia', '.']","['O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT02761330,NCT02761330,Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia Reconstitution of Consciousness and Cognition (Phase 2) | This study is geared toward characterizing the recovery of brain activity and cognitive function following treatments of electroconvulsive therapy and ketamine general anesthesia.,"[(25, 50, 'CONDITION', 'Electroconvulsive Therapy'), (55, 73, 'CONDITION', 'General Anesthesia'), (253, 278, 'CONDITION', 'electroconvulsive therapy'), (283, 310, 'CONDITION', 'ketamine general anesthesia')]"
"['Virtual', 'Reality', 'Exposure', 'Therapy', 'for', 'Acrophobia', 'in', 'a', 'Single', 'Session', 'Design', 'and', 'the', 'Role', 'of', 'Respiration', 'for', 'Fear', 'Extinction', '|', 'In', 'recent', 'years', ',', 'in', 'the', 'treatment', 'of', 'phobias', ',', 'exposure', 'therapy', 'in', 'virtual', 'reality', 'is', 'becoming', 'more', 'and', 'more', 'popular', 'as', 'an', 'alternative', 'for', 'in', '-', 'vivo', 'exposure', '.', 'Effectiveness', 'of', 'virtual', 'reality', 'exposure', 'therapy', '(', 'VRET', ')', 'is', 'comparable', 'to', 'in', '-', 'vivo', 'exposure', 'therapy', ',', 'though', 'several', 'characteristics', 'of', 'the', 'VRET', 'have', 'an', 'impact', 'on', 'the', 'outcome', 'of', 'the', 'therapy', '(', 'e.g.', ',', 'immersion', 'into', 'the', 'virtual', 'environment', '(', 'VE', ')', ',', 'familiarity', 'with', 'the', 'VE', ')', '.', 'Additionally', ',', 'the', 'use', 'of', 'VRET', 'varies', 'from', 'multiple', 'exposure', 'sessions', 'to', 'single', '-', 'session', 'VRET', '.', 'Single', '-', 'session', 'therapy', 'has', 'an', 'economic', 'advantage', 'and', 'in', 'in', '-', 'vivo', ',', 'post', 'therapy', 'outcomes', 'show', 'good', 'results', '.', 'In', 'virtual', 'reality', ',', 'the', 'assessment', 'of', 'outcome', 'post', 'therapy', 'and', 'in', 'follow', '-', 'up', 'of', 'single', '-', 'session', 'therapies', 'is', 'still', 'needed', 'for', 'an', 'evaluation', 'of', 'this', 'approach', '.', 'As', 'an', 'outcome', 'measure', ',', 'behavioral', 'assessments', 'are', 'especially', 'relevant', 'for', 'effectiveness', 'studies', 'as', 'in', 'fear', 'of', 'heights', 'it', 'is', 'closer', 'to', 'the', 'individual', ""'s"", 'life', 'to', 'know', 'how', 'high', 'they', 'voluntarily', 'go', 'up', 'a', 'building', 'than', 'to', 'have', 'hypothetical', 'self', '-', 'report', 'questionnaire', 'results', '.', '\n\n', 'Much', 'research', 'has', 'been', 'conducted', 'on', 'physiological', 'correlates', 'of', 'the', 'subjective', 'experience', 'of', 'fear', 'in', 'exposure', 'therapy', 'as', 'they', 'are', 'assumed', 'to', 'be', 'a', 'prerequisite', 'for', 'effective', 'exposure', 'treatment', '.', 'Skin', 'conductance', 'level', '(', 'SCL', ')', 'and', 'heart', 'rate', 'can', 'be', 'used', 'for', 'objective', 'manipulation', 'checks', 'of', 'exposure', 'therapy', '.', 'SCL', 'is', 'found', 'to', 'increase', 'during', 'fearful', 'situations', 'independent', 'of', 'setting', 'while', 'heart', 'rate', 'only', 'increases', 'during', 'in', '-', 'vivo', 'exposure', '.', 'Contrary', 'to', 'heart', 'rate', ',', 'heart', 'rate', 'variability', '(', 'HRV', ')', 'is', 'not', 'thoroughly', 'studied', 'in', 'VRET', 'yet', '.', 'HRV', 'is', 'associated', 'with', 'the', 'adaptability', 'of', 'an', 'organism', 'to', 'new', 'environments', 'and', 'cognitive', 'functioning', '.', 'High', 'Frequency', 'HRV', 'is', 'found', 'to', 'be', 'reduced', 'in', 'individuals', 'with', 'mental', 'disorders', ',', 'and', 'positive', 'and', 'negative', 'mood', 'inductions', 'lead', 'to', 'differential', 'HRV', 'responses', 'overall', '.', '\n\n', 'Respiration', 'is', 'a', 'well', '-', 'studied', 'correlate', 'of', 'emotional', 'experience', 'and', 'especially', 'of', 'the', 'experience', 'of', 'fear', 'and', 'anxiety', '.', 'In', 'a', 'series', 'of', 'experiments', ',', 'it', 'was', 'found', 'that', 'sighing', 'is', 'tightly', 'associated', 'with', 'relief', 'in', 'or', 'after', 'fearful', 'or', 'stressful', 'situations', 'and', 'might', 'become', 'maladaptive', 'when', 'used', 'disproportionally', 'often', '.', 'This', 'study', 'shows', 'that', 'respiration', 'parameters', 'have', 'an', 'impact', 'on', 'the', 'handling', 'of', 'fearful', 'situations', 'in', 'a', 'reciprocal', 'way', '.', 'On', 'the', 'one', 'hand', ',', 'fear', 'leads', 'to', 'an', 'increased', 'respiration', 'rate', 'and', 'sigh', 'rate', 'while', 'on', 'the', 'other', 'hand', ',', 'an', 'altered', 'sigh', 'rate', 'or', 'respiration', 'rate', 'might', 'have', 'an', 'impact', 'on', 'the', 'experience', 'of', 'fear', 'and', 'be', 'used', 'as', 'a', 'defensive', 'reaction', 'to', 'a', 'fearful', 'situation', '.', 'As', 'such', ',', 'specific', 'respiration', 'patterns', 'might', 'act', 'as', 'emotion', '-', 'driven', 'behaviors', '(', 'EDB', ')', '.', 'EDBs', 'are', 'responses', 'to', 'emotions', 'that', 'result', 'in', 'a', 'short', '-', 'term', 'reduction', 'of', 'a', 'negative', 'state', 'while', 'in', 'long', '-', 'term', 'support', 'the', 'maintenance', 'of', 'the', 'phobia', '.', '\n\n', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'examine', 'the', 'effectiveness', 'of', 'a', 'single', '-', 'session', 'VRET', 'for', 'acrophobia', 'with', 'a', 'multimethod', 'outcome', 'design', '.', 'Familiarity', 'of', 'the', 'setting', 'will', 'be', 'high', 'with', 'the', 'use', 'of', 'a', 'well', '-', 'known', 'tower', 'in', 'this', 'area', '.', 'Immersion', 'into', 'the', 'VE', 'will', 'be', 'assessed', 'with', 'a', 'presence', 'questionnaire', '.', 'For', 'a', 'manipulation', 'check', ',', 'physiological', 'data', 'will', 'be', 'assessed', ',', 'i.e.', ',', 'SCL', ',', 'heart', 'rate', 'and', 'HRV', '.', 'Primary', 'outcome', 'measure', 'will', 'be', 'a', 'behavioral', 'approach', 'test', '(', 'BAT', ')', 'as', 'behavioral', 'assessment', '.', 'Additionally', ',', 'after', 'four', 'weeks', ',', 'a', 'follow', '-', 'up', 'assessment', 'will', 'investigate', 'the', 'stability', 'of', 'the', 'effectiveness', 'of', 'the', 'VRET', 'in', 'comparison', 'to', 'a', 'waitlist', 'control', 'group', '.', 'A', 'second', 'aim', 'of', 'this', 'study', 'is', 'to', 'investigate', 'the', 'impact', 'of', 'respiration', 'as', 'an', 'EDB', 'on', 'the', 'effectiveness', 'of', 'an', 'exposure', 'therapy', '.', 'Therefore', ',', 'the', 'association', 'between', 'respiration', 'and', 'outcome', 'of', 'the', 'VRET', 'will', 'be', 'analyzed', '.', '\n\n', 'Hypothesis', '1', ':', 'Participants', 'in', 'the', 'VRET', 'condition', 'show', 'less', 'height', 'avoidance', 'in', 'the', 'BAT', 'after', 'the', 'intervention', 'than', 'participants', 'in', 'the', 'control', 'condition', '.', '\n\n', 'Hypothesis', '2', ':', 'Participants', 'in', 'the', 'VRET', 'condition', 'show', 'less', 'height', 'avoidance', 'in', 'the', 'BAT', 'in', 'a', 'four', '-', 'week', 'follow', '-', 'up', 'assessment', 'than', 'participants', 'in', 'the', 'control', 'condition', '.', '\n\n', 'Hypothesis', '3', ':', 'Participants', 'in', 'the', 'VRET', 'condition', 'score', 'significantly', 'lower', 'on', 'the', 'Acrophobia', 'Questionnaire', 'at', 'follow', '-', 'up', 'than', 'participants', 'in', 'the', 'control', 'condition', '.', '\n\n', 'Hypothesis', '4', ':', 'During', 'the', 'VRET', ',', 'breath', 'holding', 'is', 'used', 'as', 'EDB', '.', 'Participants', 'that', 'hold', 'their', 'breath', ',', 'profit', 'less', 'from', 'the', 'VRET', 'than', 'participants', 'that', 'do', 'not', 'hold', 'their', 'breath', '.', '\n\n', 'Hypothesis', '5', ':', 'During', 'the', 'VRET', ',', 'sighing', 'is', 'used', 'as', 'EDB', '.', 'Participants', 'that', 'sigh', ',', 'profit', 'less', 'from', 'the', 'VRET', 'than', 'participants', 'that', 'do', 'not', 'sigh', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03893214,NCT03893214,"Virtual Reality Exposure Therapy for Acrophobia in a Single Session Design and the Role of Respiration for Fear Extinction | In recent years, in the treatment of phobias, exposure therapy in virtual reality is becoming more and more popular as an alternative for in-vivo exposure. Effectiveness of virtual reality exposure therapy (VRET) is comparable to in-vivo exposure therapy, though several characteristics of the VRET have an impact on the outcome of the therapy (e.g., immersion into the virtual environment (VE), familiarity with the VE). Additionally, the use of VRET varies from multiple exposure sessions to single-session VRET. Single-session therapy has an economic advantage and in in-vivo, post therapy outcomes show good results. In virtual reality, the assessment of outcome post therapy and in follow-up of single-session therapies is still needed for an evaluation of this approach. As an outcome measure, behavioral assessments are especially relevant for effectiveness studies as in fear of heights it is closer to the individual's life to know how high they voluntarily go up a building than to have hypothetical self-report questionnaire results.

Much research has been conducted on physiological correlates of the subjective experience of fear in exposure therapy as they are assumed to be a prerequisite for effective exposure treatment. Skin conductance level (SCL) and heart rate can be used for objective manipulation checks of exposure therapy. SCL is found to increase during fearful situations independent of setting while heart rate only increases during in-vivo exposure. Contrary to heart rate, heart rate variability (HRV) is not thoroughly studied in VRET yet. HRV is associated with the adaptability of an organism to new environments and cognitive functioning. High Frequency HRV is found to be reduced in individuals with mental disorders, and positive and negative mood inductions lead to differential HRV responses overall.

Respiration is a well-studied correlate of emotional experience and especially of the experience of fear and anxiety. In a series of experiments, it was found that sighing is tightly associated with relief in or after fearful or stressful situations and might become maladaptive when used disproportionally often. This study shows that respiration parameters have an impact on the handling of fearful situations in a reciprocal way. On the one hand, fear leads to an increased respiration rate and sigh rate while on the other hand, an altered sigh rate or respiration rate might have an impact on the experience of fear and be used as a defensive reaction to a fearful situation. As such, specific respiration patterns might act as emotion-driven behaviors (EDB). EDBs are responses to emotions that result in a short-term reduction of a negative state while in long-term support the maintenance of the phobia.

The aim of this study is to examine the effectiveness of a single-session VRET for acrophobia with a multimethod outcome design. Familiarity of the setting will be high with the use of a well-known tower in this area. Immersion into the VE will be assessed with a presence questionnaire. For a manipulation check, physiological data will be assessed, i.e., SCL, heart rate and HRV. Primary outcome measure will be a behavioral approach test (BAT) as behavioral assessment. Additionally, after four weeks, a follow-up assessment will investigate the stability of the effectiveness of the VRET in comparison to a waitlist control group. A second aim of this study is to investigate the impact of respiration as an EDB on the effectiveness of an exposure therapy. Therefore, the association between respiration and outcome of the VRET will be analyzed.

Hypothesis 1: Participants in the VRET condition show less height avoidance in the BAT after the intervention than participants in the control condition.

Hypothesis 2: Participants in the VRET condition show less height avoidance in the BAT in a four-week follow-up assessment than participants in the control condition.

Hypothesis 3: Participants in the VRET condition score significantly lower on the Acrophobia Questionnaire at follow-up than participants in the control condition.

Hypothesis 4: During the VRET, breath holding is used as EDB. Participants that hold their breath, profit less from the VRET than participants that do not hold their breath.

Hypothesis 5: During the VRET, sighing is used as EDB. Participants that sigh, profit less from the VRET than participants that do not sigh.","[(0, 32, 'OTHER', 'Virtual Reality Exposure Therapy'), (37, 47, 'CONDITION', 'Acrophobia'), (162, 169, 'CONDITION', 'phobias'), (298, 330, 'OTHER', 'virtual reality exposure therapy'), (332, 336, 'OTHER', 'VRET'), (419, 423, 'OTHER', 'VRET'), (572, 576, 'OTHER', 'VRET'), (634, 638, 'OTHER', 'VRET'), (1004, 1019, 'CONDITION', 'fear of heights'), (1688, 1692, 'OTHER', 'VRET'), (2871, 2877, 'CONDITION', 'phobia'), (2954, 2958, 'OTHER', 'VRET'), (2963, 2973, 'CONDITION', 'acrophobia'), (3467, 3471, 'OTHER', 'VRET'), (3491, 3499, 'CONTROL', 'waitlist'), (3707, 3711, 'OTHER', 'VRET'), (3765, 3769, 'OTHER', 'VRET'), (3790, 3806, 'CONDITION', 'height avoidance'), (3920, 3924, 'OTHER', 'VRET'), (3945, 3961, 'CONDITION', 'height avoidance'), (4088, 4092, 'OTHER', 'VRET'), (4136, 4146, 'CONDITION', 'Acrophobia'), (4244, 4248, 'OTHER', 'VRET'), (4339, 4343, 'OTHER', 'VRET'), (4419, 4423, 'OTHER', 'VRET'), (4494, 4498, 'OTHER', 'VRET')]"
"['Evaluation', 'of', 'the', 'Long', '-', 'term', 'Safety', ',', 'Tolerability', ',', 'and', 'Pharmacokinetics', 'of', 'Cariprazine', 'in', 'Patients', 'With', 'Schizophrenia', '|', 'The', 'objective', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'long', '-', 'term', 'safety', ',', 'tolerability', ',', 'and', 'pharmacokinetics', 'of', 'cariprazine', 'in', 'patients', 'with', 'schizophrenia', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O']",NCT01104792,NCT01104792,"Evaluation of the Long-term Safety, Tolerability, and Pharmacokinetics of Cariprazine in Patients With Schizophrenia | The objective of this study is to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with schizophrenia.","[(74, 85, 'DRUG', 'Cariprazine'), (103, 116, 'CONDITION', 'Schizophrenia'), (222, 233, 'DRUG', 'cariprazine'), (251, 264, 'CONDITION', 'schizophrenia')]"
"['A', 'Double', '-', 'Blind', 'Placebo', '-', 'Controlled', 'Preliminary', 'Study', 'of', 'the', 'Efficacy', ',', 'Safety', 'and', 'Tolerability', 'of', 'ST101', 'Tablets', 'in', 'the', 'Treatment', 'of', 'Alzheimer', ""'s"", 'Disease', 'in', 'Subjects', 'Concurrently', 'Receiving', 'Donepezil', '(', 'Aricept', '®', ')', '|', 'This', 'study', 'will', 'investigate', 'the', 'ability', 'of', 'ST101', 'to', 'improve', 'memory', 'in', 'people', 'with', 'Alzheimer', ""'s"", 'disease', 'who', 'currently', 'receive', '10', 'mg', 'Aricept', '®', '(', 'donepezil', ')', 'per', 'day', '.', 'This', 'study', 'also', 'will', 'examine', 'the', 'safety', 'and', 'tolerability', 'of', 'the', 'drug', '.', 'This', 'study', 'is', 'evaluating', '3', 'different', 'dose', 'levels', 'of', 'ST101', 'and', 'placebo', '.', 'Patients', 'will', 'have', 'a', '1', 'in', '4', 'chance', 'of', 'getting', 'placebo', '.', 'All', 'eligible', 'subjects', 'will', 'be', 'provided', 'with', 'bottles', 'of', '10', 'mg', 'Aricept', '(', 'donepezil', ')', 'during', 'the', 'study', 'drug', 'administration', 'part', 'of', 'the', 'study', '.']","['O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00842816,NCT00842816,"A Double-Blind Placebo-Controlled Preliminary Study of the Efficacy, Safety and Tolerability of ST101 Tablets in the Treatment of Alzheimer's Disease in Subjects Concurrently Receiving Donepezil (Aricept®) | This study will investigate the ability of ST101 to improve memory in people with Alzheimer's disease who currently receive 10 mg Aricept® (donepezil) per day. This study also will examine the safety and tolerability of the drug. This study is evaluating 3 different dose levels of ST101 and placebo. Patients will have a 1 in 4 chance of getting placebo. All eligible subjects will be provided with bottles of 10 mg Aricept (donepezil) during the study drug administration part of the study.","[(15, 22, 'CONTROL', 'Placebo'), (96, 101, 'DRUG', 'ST101'), (130, 149, 'CONDITION', ""Alzheimer's Disease""), (185, 194, 'DRUG', 'Donepezil'), (196, 203, 'DRUG', 'Aricept'), (251, 256, 'DRUG', 'ST101'), (290, 309, 'CONDITION', ""Alzheimer's disease""), (338, 345, 'DRUG', 'Aricept'), (348, 357, 'DRUG', 'donepezil'), (490, 495, 'DRUG', 'ST101'), (500, 507, 'CONTROL', 'placebo'), (555, 562, 'CONTROL', 'placebo'), (625, 632, 'DRUG', 'Aricept'), (634, 643, 'DRUG', 'donepezil')]"
"['Randomised', 'Factorial', 'Design', 'Controlled', 'Trial', 'Comparing', 'Carbamazepine', ',', 'Levetiracetam', 'or', 'Active', 'Monitoring', 'Combined', 'With', 'or', 'Without', 'Sleep', 'Behaviour', 'Intervention', 'in', 'Treatment', 'Naive', 'Children', 'With', 'Rolandic', 'Epilepsy', '|', 'Rolandic', 'epilepsy', '(', 'RE', ')', 'is', 'the', 'most', 'common', 'type', 'of', 'epilepsy', '.', 'Children', 'with', 'RE', 'have', 'seizures', 'and', 'can', 'often', 'find', 'that', 'their', 'learning', ',', 'sleep', ',', 'behaviour', ',', 'self', '-', 'esteem', 'and', 'mood', 'are', 'affected', '.', '\n\n', 'As', 'part', 'of', 'standard', 'NHS', 'care', ',', 'children', 'diagnosed', 'with', 'RE', 'may', 'be', 'treated', 'with', 'standard', 'anti', '-', 'epileptic', 'medicines', ',', 'like', 'carbamazepine', ',', 'or', 'no', 'medicine', 'at', 'all', '.', 'The', 'medicines', 'used', 'to', 'treat', 'epilepsy', 'often', 'slow', 'down', 'a', 'child', ""'s"", 'thinking', 'and', 'learning', '.', 'In', 'the', 'past', ',', 'doctors', 'believed', 'this', 'was', 'an', 'acceptable', 'price', 'to', 'pay', 'to', 'reduce', 'seizures', '.', 'However', ',', 'with', 'RE', ',', 'where', 'the', 'seizures', 'usually', 'stop', 'in', 'teenage', 'years', ',', 'investigators', 'do', 'not', 'know', 'if', 'it', 'is', 'better', 'to', 'treat', 'these', 'children', 'with', 'medicines', 'or', 'not', ',', 'especially', 'if', 'the', 'medicines', 'might', 'have', 'a', 'negative', 'effect', 'on', 'their', 'learning', '.', '\n\n', 'A', 'newer', 'medicine', 'called', 'levetiracetam', 'has', 'also', 'been', 'found', 'to', 'work', 'in', 'children', 'with', 'RE', 'and', 'has', 'shown', 'less', 'problems', 'with', 'thinking', 'and', 'learning', 'in', 'adults', '.', 'However', ',', 'it', 'is', 'still', 'no', 'known', 'if', 'this', 'is', 'also', 'the', 'case', 'for', 'children', 'and', 'it', 'has', 'not', 'been', 'proven', 'which', 'of', 'the', 'three', 'options', '(', 'carbamazepine', ',', 'levetiracetam', 'or', 'no', 'treatment', ')', 'would', 'be', 'best', 'for', 'RE', 'patients', '.', 'The', 'CASTLE', 'study', 'aims', 'to', 'find', 'this', 'out', '.', '\n\n', 'In', 'addition', ',', 'it', 'has', 'been', 'found', 'that', 'seizures', 'often', 'happen', 'when', 'a', 'child', 'has', 'had', 'poor', 'sleep', 'and', 'they', 'often', 'come', 'at', 'night', 'or', 'early', 'in', 'the', 'morning', '.', 'It', 'has', 'been', 'shown', 'that', 'sleep', 'can', 'be', 'improved', 'through', 'practice', 'without', 'the', 'need', 'of', 'medicines', '.', 'There', 'are', 'established', 'guidelines', 'to', 'help', 'toddlers', 'go', 'to', 'sleep', ',', 'but', 'nothing', 'available', 'that', 'helps', 'young', 'people', 'with', 'epilepsy', 'and', 'their', 'parents', 'improve', 'their', 'sleep', 'quality', '.', 'In', 'the', 'CASTLE', 'study', ',', 'a', 'sleep', 'training', 'plan', 'has', 'been', 'developed', 'for', 'children', 'with', 'epilepsy', 'and', 'the', 'trial', 'aims', 'to', 'find', 'out', 'whether', 'following', 'this', 'sleep', 'training', 'plan', 'results', 'in', 'less', 'seizures', 'than', 'using', 'no', 'sleep', 'training', 'at', 'all', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O']",NCT04610879,NCT04610879,"Randomised Factorial Design Controlled Trial Comparing Carbamazepine, Levetiracetam or Active Monitoring Combined With or Without Sleep Behaviour Intervention in Treatment Naive Children With Rolandic Epilepsy | Rolandic epilepsy (RE) is the most common type of epilepsy. Children with RE have seizures and can often find that their learning, sleep, behaviour, self-esteem and mood are affected.

As part of standard NHS care, children diagnosed with RE may be treated with standard anti-epileptic medicines, like carbamazepine, or no medicine at all. The medicines used to treat epilepsy often slow down a child's thinking and learning. In the past, doctors believed this was an acceptable price to pay to reduce seizures. However, with RE, where the seizures usually stop in teenage years, investigators do not know if it is better to treat these children with medicines or not, especially if the medicines might have a negative effect on their learning.

A newer medicine called levetiracetam has also been found to work in children with RE and has shown less problems with thinking and learning in adults. However, it is still no known if this is also the case for children and it has not been proven which of the three options (carbamazepine, levetiracetam or no treatment) would be best for RE patients. The CASTLE study aims to find this out.

In addition, it has been found that seizures often happen when a child has had poor sleep and they often come at night or early in the morning. It has been shown that sleep can be improved through practice without the need of medicines. There are established guidelines to help toddlers go to sleep, but nothing available that helps young people with epilepsy and their parents improve their sleep quality. In the CASTLE study, a sleep training plan has been developed for children with epilepsy and the trial aims to find out whether following this sleep training plan results in less seizures than using no sleep training at all.","[(55, 68, 'DRUG', 'Carbamazepine'), (70, 83, 'DRUG', 'Levetiracetam'), (130, 158, 'BEHAVIOURAL', 'Sleep Behaviour Intervention'), (192, 209, 'CONDITION', 'Rolandic Epilepsy'), (212, 229, 'CONDITION', 'Rolandic epilepsy'), (231, 233, 'CONDITION', 'RE'), (262, 270, 'CONDITION', 'epilepsy'), (286, 288, 'CONDITION', 'RE'), (294, 302, 'CONDITION', 'seizures'), (451, 453, 'CONDITION', 'RE'), (514, 527, 'DRUG', 'carbamazepine'), (580, 588, 'CONDITION', 'epilepsy'), (714, 722, 'CONDITION', 'seizures'), (738, 740, 'CONDITION', 'RE'), (752, 760, 'CONDITION', 'seizures'), (982, 995, 'DRUG', 'levetiracetam'), (1041, 1043, 'CONDITION', 'RE'), (1233, 1246, 'DRUG', 'carbamazepine'), (1248, 1261, 'DRUG', 'levetiracetam'), (1265, 1277, 'CONTROL', 'no treatment'), (1297, 1299, 'CONDITION', 'RE'), (1387, 1395, 'CONDITION', 'seizures'), (1702, 1710, 'CONDITION', 'epilepsy'), (1781, 1795, 'BEHAVIOURAL', 'sleep training'), (1838, 1846, 'CONDITION', 'epilepsy'), (1901, 1915, 'BEHAVIOURAL', 'sleep training'), (1937, 1945, 'CONDITION', 'seizures'), (1957, 1974, 'CONTROL', 'no sleep training')]"
"['REACT', '-', 'Recovery', 'Enhancement', 'From', 'TBI', 'Using', 'ACT', '.', 'A', 'Pilot', 'Study', '.', '|', 'Is', 'Acceptance', 'and', 'Commitment', 'Therapy', '(', 'ACT', ')', 'feasible', 'and', 'acceptable', 'for', 'adults', 'with', 'severe', 'Traumatic', 'Brain', 'Injury', '(', 'sTBI', ')', 'in', 'inpatient', 'services', '?', 'sTBI', 'is', 'associated', 'with', 'depression', ',', 'anxiety', 'and', 'low', 'self', 'awareness', '.', 'A', 'key', 'factor', 'in', 'recovery', 'is', 'adjustment', 'to', 'the', 'effects', 'of', 'injury', '.', 'Psychological', 'intervention', 'may', 'facilitate', 'this', 'change;', 'however', 'what', 'works', 'is', 'unclear', '.', 'ACT', 'seeks', 'to', 'improve', 'psychological', 'flexibility;', 'the', 'ability', 'to', 'be', 'present', 'with', 'difficult', 'thoughts', 'and', 'emotions', ',', 'rather', 'than', 'fighting', 'them', ',', 'and', 'to', 'accept', 'ourselves', 'as', 'we', 'are', ',', 'not', 'what', 'we', 'believe', 'we', 'should', 'be', '.', 'Current', 'research', 'is', 'limited', ',', 'but', 'what', 'is', 'published', 'suggests', 'it', 'may', 'be', 'useful', 'for', 'this', 'group', '.', '\n\n', 'Due', 'to', 'the', 'limited', 'research', 'this', 'pilot', 'study', 'aims', 'to', 'conduct', 'preliminary', 'analysis', 'on', 'the', 'acceptability', 'and', 'feasibility', 'of', 'ACT', 'for', 'people', 'with', 'sTBI', 'whilst', 'also', 'examining', 'the', 'suitability', 'of', 'the', 'study', 'protocol', 'in', 'order', 'to', 'make', 'recommendations', 'for', 'future', 'studies', '.', 'Clients', 'and', 'staff', 'from', 'three', 'Brain', 'Injury', 'Rehabilitation', 'Trust', '(', 'BIRT', ')', 'centres', 'will', 'be', 'recruited', ',', 'one', 'of', 'which', 'will', 'serve', 'as', 'the', 'intervention', 'centre', '.', '\n\n', 'Clients', 'in', 'the', 'intervention', 'group', 'will', 'be', 'asked', 'to', 'complete', 'questionnaires', 'a', 'week', 'before', 'and', 'after', 'participation', 'in', 'the', '6', 'week', 'ACT', 'programme', '.', 'Clients', 'in', 'the', 'comparison', 'group', 'will', 'be', 'asked', 'to', 'complete', 'questionnaires', 'a', 'week', 'before', 'and', 'after', 'receiving', '6', 'weeks', 'of', 'treatment', 'as', 'usual', '(', 'TAU', ')', '.', 'The', 'treatment', 'group', 'will', 'also', 'receive', 'TAU', '.', 'All', 'participants', 'will', 'be', 'invited', 'to', 'participate', 'in', 'a', 'focus', 'group', 'at', 'the', 'end', 'of', 'this', '8', 'week', 'period', 'to', 'discuss', 'their', 'involvement', 'in', 'the', 'study', '.', '\n\n', 'Staff', 'will', 'be', 'asked', 'to', 'complete', 'a', 'parallel', 'version', 'of', 'one', 'of', 'the', 'client', 'questionnaires', 'within', 'a', 'similar', 'timeframe', '.', 'In', 'addition', 'staff', 'at', 'the', 'intervention', 'centre', 'will', 'be', 'invited', 'to', 'attend', 'a', 'focus', 'group', 'and', 'complete', 'an', 'additional', 'questionnaire', 'after', 'the', 'eight', 'week', 'period', '.']","['O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02337114,NCT02337114,"REACT - Recovery Enhancement From TBI Using ACT. A Pilot Study. | Is Acceptance and Commitment Therapy (ACT) feasible and acceptable for adults with severe Traumatic Brain Injury (sTBI) in inpatient services? sTBI is associated with depression, anxiety and low self awareness. A key factor in recovery is adjustment to the effects of injury. Psychological intervention may facilitate this change; however what works is unclear. ACT seeks to improve psychological flexibility; the ability to be present with difficult thoughts and emotions, rather than fighting them, and to accept ourselves as we are, not what we believe we should be. Current research is limited, but what is published suggests it may be useful for this group.

Due to the limited research this pilot study aims to conduct preliminary analysis on the acceptability and feasibility of ACT for people with sTBI whilst also examining the suitability of the study protocol in order to make recommendations for future studies. Clients and staff from three Brain Injury Rehabilitation Trust (BIRT) centres will be recruited, one of which will serve as the intervention centre.

Clients in the intervention group will be asked to complete questionnaires a week before and after participation in the 6 week ACT programme. Clients in the comparison group will be asked to complete questionnaires a week before and after receiving 6 weeks of treatment as usual (TAU). The treatment group will also receive TAU. All participants will be invited to participate in a focus group at the end of this 8 week period to discuss their involvement in the study.

Staff will be asked to complete a parallel version of one of the client questionnaires within a similar timeframe. In addition staff at the intervention centre will be invited to attend a focus group and complete an additional questionnaire after the eight week period.","[(34, 37, 'CONDITION', 'TBI'), (44, 47, 'BEHAVIOURAL', 'ACT'), (69, 102, 'BEHAVIOURAL', 'Acceptance and Commitment Therapy'), (104, 107, 'BEHAVIOURAL', 'ACT'), (149, 178, 'CONDITION', 'severe Traumatic Brain Injury'), (180, 184, 'CONDITION', 'sTBI'), (209, 213, 'CONDITION', 'sTBI'), (233, 243, 'CONDITION', 'depression'), (245, 252, 'CONDITION', 'anxiety'), (428, 431, 'BEHAVIOURAL', 'ACT'), (852, 855, 'BEHAVIOURAL', 'ACT'), (872, 876, 'CONDITION', 'sTBI'), (1267, 1270, 'BEHAVIOURAL', 'ACT'), (1400, 1418, 'CONTROL', 'treatment as usual'), (1420, 1423, 'CONTROL', 'TAU'), (1464, 1467, 'CONTROL', 'TAU')]"
"['An', 'Open', '-', 'Label', ',', 'Randomized', ',', 'Crossover', 'Pharmacokinetic', 'Study', 'to', 'Determine', 'the', 'Bioavailability', ',', 'Safety', 'and', 'Tolerability', 'of', 'Single', 'Doses', 'of', 'Diazepam', 'Nasal', 'Spray', 'Versus', 'Diazepam', 'Rectal', 'Gel', '(', 'Diastat', '®', ')', 'in', 'Patients', 'With', 'Refractory', 'Epilepsy', '|', 'This', 'is', 'a', 'multi', '-', 'center', ',', 'open', '-', 'label', ',', 'crossover', ',', 'pharmacokinetic', ',', 'bio', '-', 'availability', 'study', 'involving', 'adolescents', 'and', 'adults', 'with', 'refractory', '(', 'drug', '-', 'resistant', ')', 'epilepsy', '.', 'Cohort', '1', 'comprises', 'the', 'subjects', 'used', 'to', 'determine', 'the', 'relative', 'bioavailability', 'of', 'DZNS', 'versus', 'DRG', '(', 'Diastat', ')']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O']",NCT02474407,NCT02474407,"An Open-Label, Randomized, Crossover Pharmacokinetic Study to Determine the Bioavailability, Safety and Tolerability of Single Doses of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®) in Patients With Refractory Epilepsy | This is a multi-center, open-label, crossover, pharmacokinetic, bio-availability study involving adolescents and adults with refractory (drug-resistant) epilepsy. Cohort 1 comprises the subjects used to determine the relative bioavailability of DZNS versus DRG (Diastat)","[(136, 144, 'DRUG', 'Diazepam'), (164, 172, 'DRUG', 'Diazepam'), (185, 192, 'DRUG', 'Diastat'), (212, 231, 'CONDITION', 'Refractory Epilepsy'), (359, 395, 'CONDITION', 'refractory (drug-resistant) epilepsy'), (496, 503, 'DRUG', 'Diastat')]"
"['Central', 'Mechanisms', 'of', 'Calmare', ':', 'an', 'fMRI', 'Trial', '|', 'Pilot', 'one', '-', 'treatment', 'and', 'extended', '10', '-', 'treatment', 'studies', 'are', 'carried', 'out', 'on', 'participants', 'with', 'peripheral', 'neuropathy', 'comparing', 'traditional', 'TENS', 'and', 'Calmare', 'stimulation', 'protocols', 'using', 'a', 'double', '-', 'blind', 'apparatus', '.', 'Resting', 'fMRI', 'scans', 'are', 'obtained', 'before', 'and', 'after', 'the', 'treatment', ',', 'as', 'well', 'as', 'after', 'most', 'of', 'the', 'pain', 'has', 'returned', '.']","['O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-CTRL', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O']",NCT04242797,NCT04242797,"Central Mechanisms of Calmare: an fMRI Trial | Pilot one-treatment and extended 10-treatment studies are carried out on participants with peripheral neuropathy comparing traditional TENS and Calmare stimulation protocols using a double-blind apparatus. Resting fMRI scans are obtained before and after the treatment, as well as after most of the pain has returned.","[(22, 29, 'OTHER', 'Calmare'), (138, 159, 'CONDITION', 'peripheral neuropathy'), (182, 186, 'CONTROL', 'TENS'), (191, 198, 'OTHER', 'Calmare'), (346, 350, 'CONDITION', 'pain')]"
"['Open', '-', 'label', 'Biomarker', 'Study', 'of', 'Rosuvastatin', '(', 'Crestor', ')', 'for', 'the', 'Treatment', 'of', 'Patients', 'With', 'Friedreich', 'Ataxia', '|', 'This', 'study', 'is', 'an', 'exploratory', 'open', '-', 'label', 'clinical', 'trial', 'of', 'Rosuvastatin', 'in', 'patients', 'with', 'Friedreich', 'ataxia', '(', 'FRDA', ')', '.', 'This', 'is', 'an', 'outpatient', 'trial', 'with', 'the', 'goal', 'of', 'enrolling', '10', 'evaluable', 'adults', 'with', 'genetically', 'confirmed', 'FRDA', 'who', 'are', 'between', 'the', 'ages', 'of', '18', '-', '65', '.', 'Subjects', 'will', 'receive', '10', 'mg', 'of', 'oral', 'Rosuvastatin', 'daily', 'for', 'three', 'months', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O']",NCT02705547,NCT02705547,Open-label Biomarker Study of Rosuvastatin (Crestor) for the Treatment of Patients With Friedreich Ataxia | This study is an exploratory open-label clinical trial of Rosuvastatin in patients with Friedreich ataxia (FRDA). This is an outpatient trial with the goal of enrolling 10 evaluable adults with genetically confirmed FRDA who are between the ages of 18-65. Subjects will receive 10mg of oral Rosuvastatin daily for three months.,"[(30, 42, 'DRUG', 'Rosuvastatin'), (44, 51, 'DRUG', 'Crestor'), (88, 105, 'CONDITION', 'Friedreich Ataxia'), (166, 178, 'DRUG', 'Rosuvastatin'), (196, 213, 'CONDITION', 'Friedreich ataxia'), (215, 219, 'CONDITION', 'FRDA'), (324, 328, 'CONDITION', 'FRDA'), (399, 411, 'DRUG', 'Rosuvastatin')]"
"['Xuanwu', 'Hospital', 'Capital', 'Medical', 'University', '|', 'Fragile', 'brain', 'is', 'the', 'most', 'common', 'phenomenon', 'seen', 'in', 'the', 'patients', 'undergoing', 'CEA', '.', 'The', 'patients', 'with', 'fragile', 'brain', 'have', 'a', 'high', 'incidence', 'of', 'postoperative', 'brain', 'dysfunction', '.', 'This', 'study', 'intends', 'to', 'apply', 'EEG', 'monitoring', '(', 'Sedline', ')', 'to', 'CEA', 'to', 'investigate', 'whether', 'EEG', 'monitoring', 'can', 'reduce', 'the', 'incidence', 'of', 'postoperative', 'neurological', 'complications', 'in', 'CEA', 'patients', 'and', 'improve', 'their', 'prognosis', '.', '\n\n', '220', 'patients', 'with', 'CEA', 'were', 'randomly', 'divided', 'into', '2', 'groups', '.', 'Group', 'S', '[', 'Sedline', 'monitoring', '+', 'Transcranial', 'Doppler', '(', 'TCD', ')', '+', 'regional', 'cerebral', 'oxygen', 'saturation', '(', 'rS02)，n=110', ']', 'and', 'group', 'C', '[', 'Bispectral', 'index', '(', 'BIS)/Sedline', 'monitoring', '+', 'TCD', '+', 'rSO2,n=110', ']', ',', 'recording', 'intraoperative', 'and', 'postoperative', 'conditions', ',', 'neuropsychology', 'scale', 'assessment', ',', 'blood', 'examination', 'and', 'imaging', 'examination', '.', 'The', 'incidence', 'of', 'postoperative', 'neurological', 'complications', 'was', 'compared', 'between', 'the', 'two', 'groups', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03622515,NCT03622515,"Xuanwu Hospital Capital Medical University | Fragile brain is the most common phenomenon seen in the patients undergoing CEA. The patients with fragile brain have a high incidence of postoperative brain dysfunction. This study intends to apply EEG monitoring (Sedline) to CEA to investigate whether EEG monitoring can reduce the incidence of postoperative neurological complications in CEA patients and improve their prognosis.

220 patients with CEA were randomly divided into 2 groups. Group S [Sedline monitoring + Transcranial Doppler (TCD) + regional cerebral oxygen saturation (rS02)，n=110] and group C [Bispectral index (BIS)/Sedline monitoring + TCD +rSO2,n=110], recording intraoperative and postoperative conditions, neuropsychology scale assessment, blood examination and imaging examination. The incidence of postoperative neurological complications was compared between the two groups.","[(45, 58, 'CONDITION', 'Fragile brain'), (121, 124, 'CONDITION', 'CEA'), (144, 157, 'CONDITION', 'fragile brain'), (272, 275, 'CONDITION', 'CEA'), (386, 389, 'CONDITION', 'CEA'), (447, 450, 'CONDITION', 'CEA')]"
"['Large', 'Scale', 'Safety', 'Study', 'of', 'IMOVAX', 'Polio', 'in', 'Selected', 'Cities', 'in', 'China', ',', 'an', 'Observational', 'Post', 'Marketing', 'Study', '|', 'The', 'aim', 'of', 'the', 'study', 'is', 'to', 'collect', 'post', 'marketing', 'safety', 'data', 'on', 'IMOVAX', 'Polio', 'vaccine', 'in', 'China', '.', '\n\n', 'Objective', ':', '\n\n', 'To', 'describe', 'serious', 'adverse', 'events', '30', 'days', 'after', 'each', 'dose', 'of', 'IMOVAX', 'Polio', '™', 'administered', 'at', '2', ',', '3', ',', 'and', '4', 'months', 'of', 'age', 'among', 'infants', 'living', 'in', 'the', 'study', 'cities', 'of', 'China', '.']","['O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01278433,NCT01278433,"Large Scale Safety Study of IMOVAX Polio in Selected Cities in China, an Observational Post Marketing Study | The aim of the study is to collect post marketing safety data on IMOVAX Polio vaccine in China.

Objective:

To describe serious adverse events 30 days after each dose of IMOVAX Polio™ administered at 2, 3, and 4 months of age among infants living in the study cities of China.","[(28, 40, 'DRUG', 'IMOVAX Polio'), (175, 187, 'DRUG', 'IMOVAX Polio'), (281, 293, 'DRUG', 'IMOVAX Polio')]"
"['A', 'Phase', '2', ',', 'Randomized', ',', 'Placebo', '-', 'Controlled', 'Study', 'to', 'Evaluate', 'Safety', ',', 'Tolerability', ',', 'and', 'Efficacy', 'of', 'TAK-079', 'in', 'Patients', 'With', 'Generalized', 'Myasthenia', 'Gravis', '|', 'Myasthenia', 'gravis', 'is', 'an', 'autoimmune', 'condition', 'that', 'causes', 'muscle', 'weakness', '.', 'Autoimmune', 'means', 'the', 'body', 'makes', 'antibodies', 'that', 'attack', 'its', 'own', 'cells', 'and', 'tissues', '.', 'These', 'types', 'of', 'antibodies', 'are', 'also', 'known', 'as', 'autoantibodies', '.', 'People', 'with', 'generalized', 'myasthenia', 'gravis', 'have', 'a', 'weakness', 'in', 'many', 'muscles', '.', '\n\n', 'TAK-079', 'is', 'a', 'medicine', 'to', 'help', 'people', 'with', 'generalized', 'myasthenia', 'gravis', '.', '\n\n', 'The', 'main', 'aim', 'of', 'this', 'study', 'is', 'to', 'check', 'if', 'people', 'with', 'generalized', 'myasthenia', 'gravis', 'have', 'side', 'effects', 'from', '2', 'doses', 'of', 'TAK-079', '.', 'Other', 'aims', 'are', 'to', 'learn', 'if', 'TAK-079', 'improves', 'their', 'clinical', 'condition', 'and', 'lowers', 'their', 'autoantibody', 'levels', '.', '\n\n', 'At', 'the', 'first', 'visit', ',', 'the', 'study', 'doctor', 'will', 'check', 'if', 'each', 'person', 'can', 'take', 'part', '.', 'For', 'those', 'who', 'can', 'take', 'part', ',', 'participants', 'will', 'continue', 'with', 'their', 'standard', 'medicines', 'for', 'this', 'condition', 'during', 'the', 'study', '.', 'Each', 'participant', 'will', 'have', 'a', 'check', '-', 'up', 'by', 'the', 'study', 'doctor', '.', '\n\n', 'Then', ',', 'the', 'participants', 'will', 'have', '1', 'of', '3', 'treatments', ':', '\n\n', 'A', 'low', 'dose', 'of', 'TAK-079', '.', '\n', 'A', 'high', 'dose', 'of', 'TAK-079', '.', '\n', 'A', 'placebo', '.', 'In', 'this', 'study', ',', 'a', 'placebo', 'looks', 'like', 'TAK-079', 'but', 'does', 'not', 'have', 'any', 'medicine', 'in', 'it', '.', '\n\n', 'Participants', 'will', 'not', 'know', 'which', 'treatment', 'they', 'received', ',', 'nor', 'will', 'their', 'study', 'doctors', '.', 'This', 'is', 'to', 'help', 'make', 'sure', 'the', 'results', 'are', 'more', 'reliable', '.', '\n\n', 'For', 'each', 'treatment', ',', 'participants', 'will', 'receive', 'injections', 'just', 'under', 'the', 'skin', ',', 'once', 'a', 'week', 'for', '8', 'weeks', '.', 'The', 'study', 'doctors', 'will', 'check', 'for', 'side', 'effects', 'from', 'the', 'study', 'treatments', '.', 'The', 'study', 'doctors', 'can', 'stop', 'or', 'delay', 'the', 'injections', 'in', 'each', 'participant', 'if', 'needed', '.', '\n\n', 'Then', ',', 'the', 'study', 'doctors', 'will', 'continue', 'to', 'check', 'for', 'side', 'effects', 'for', 'up', 'to', '24', 'weeks', 'after', 'treatment', '.', 'They', 'will', 'also', 'check', 'the', 'clinical', 'condition', 'of', 'the', 'participants', ',', 'including', 'their', 'autoantibody', 'levels', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04159805,NCT04159805,"A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Generalized Myasthenia Gravis | Myasthenia gravis is an autoimmune condition that causes muscle weakness. Autoimmune means the body makes antibodies that attack its own cells and tissues. These types of antibodies are also known as autoantibodies. People with generalized myasthenia gravis have a weakness in many muscles.

TAK-079 is a medicine to help people with generalized myasthenia gravis.

The main aim of this study is to check if people with generalized myasthenia gravis have side effects from 2 doses of TAK-079. Other aims are to learn if TAK-079 improves their clinical condition and lowers their autoantibody levels.

At the first visit, the study doctor will check if each person can take part. For those who can take part, participants will continue with their standard medicines for this condition during the study. Each participant will have a check-up by the study doctor.

Then, the participants will have 1 of 3 treatments:

A low dose of TAK-079.
A high dose of TAK-079.
A placebo. In this study, a placebo looks like TAK-079 but does not have any medicine in it.

Participants will not know which treatment they received, nor will their study doctors. This is to help make sure the results are more reliable.

For each treatment, participants will receive injections just under the skin, once a week for 8 weeks. The study doctors will check for side effects from the study treatments. The study doctors can stop or delay the injections in each participant if needed.

Then, the study doctors will continue to check for side effects for up to 24 weeks after treatment. They will also check the clinical condition of the participants, including their autoantibody levels.","[(23, 30, 'CONTROL', 'Placebo'), (98, 105, 'DRUG', 'TAK-079'), (123, 152, 'CONDITION', 'Generalized Myasthenia Gravis'), (155, 172, 'CONDITION', 'Myasthenia gravis'), (383, 412, 'CONDITION', 'generalized myasthenia gravis'), (447, 454, 'DRUG', 'TAK-079'), (489, 518, 'CONDITION', 'generalized myasthenia gravis'), (575, 604, 'CONDITION', 'generalized myasthenia gravis'), (639, 646, 'DRUG', 'TAK-079'), (675, 682, 'DRUG', 'TAK-079'), (1084, 1091, 'DRUG', 'TAK-079'), (1108, 1115, 'DRUG', 'TAK-079'), (1119, 1126, 'CONTROL', 'placebo'), (1145, 1152, 'CONTROL', 'placebo'), (1164, 1171, 'DRUG', 'TAK-079')]"
"['Diz', 'Osteoartritinde', 'Farklı', 'Proprioseptif', 'Nöromüsküler', 'Fasilitasyon', 'Tekniklerinin', ',', 'Ağrı', ',', 'Propriosepsiyon', ',', 'Postural', 'Kontrol', ',', 'Kas', 'Kuvveti', ',', 'Eklem', 'Hareket', 'Açıklığı', 've', 'Diz', 'Fonksiyonları', 'Üzerine', 'Olan', 'Etkileri', '|', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'investigate', 'the', 'effects', 'of', '6', '-', 'week', 'physiotherapy', 'and', 'rehabilitation', 'programs', 'involving', 'different', ""'"", 'Proprioceptive', 'Neuromuscular', 'Facilitation', ""'"", '(', 'PNF', ')', 'techniques', 'in', 'patients', 'with', 'knee', 'osteoarthritis', 'on', 'pain', ',', 'proprioception', ',', 'postural', 'control', ',', 'muscle', 'strength', ',', 'range', 'of', 'motion', 'and', 'knee', 'functions']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03615521,NCT03615521,"Diz Osteoartritinde Farklı Proprioseptif Nöromüsküler Fasilitasyon Tekniklerinin, Ağrı, Propriosepsiyon, Postural Kontrol, Kas Kuvveti, Eklem Hareket Açıklığı ve Diz Fonksiyonları Üzerine Olan Etkileri | The aim of this study is to investigate the effects of 6-week physiotherapy and rehabilitation programs involving different 'Proprioceptive Neuromuscular Facilitation' (PNF) techniques in patients with knee osteoarthritis on pain, proprioception, postural control, muscle strength, range of motion and knee functions","[(266, 307, 'PHYSICAL', 'physiotherapy and rehabilitation programs'), (329, 370, 'PHYSICAL', 'Proprioceptive Neuromuscular Facilitation'), (373, 376, 'PHYSICAL', 'PNF'), (406, 425, 'CONDITION', 'knee osteoarthritis')]"
"['Short', '-', 'Term', 'Effects', 'of', 'Whole', '-', 'Body', 'Vibration', 'on', 'Upper', 'Extremity', 'Function', 'in', 'Subjects', 'With', 'Poststroke', 'Hemiplegia', '|', 'To', 'investigate', 'the', 'effect', 'of', 'whole', 'body', 'vibration', 'on', 'upper', 'limb', 'motor', 'function', 'in', 'hemiplegic', 'patients', 'with', 'subacute', 'stroke']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND']",NCT03963258,NCT03963258,Short-Term Effects of Whole-Body Vibration on Upper Extremity Function in Subjects With Poststroke Hemiplegia | To investigate the effect of whole body vibration on upper limb motor function in hemiplegic patients with subacute stroke,"[(22, 42, 'OTHER', 'Whole-Body Vibration'), (88, 109, 'CONDITION', 'Poststroke Hemiplegia'), (141, 161, 'OTHER', 'whole body vibration'), (194, 204, 'CONDITION', 'hemiplegic'), (219, 234, 'CONDITION', 'subacute stroke')]"
"['Pilot', 'Study', 'of', 'the', 'Environmental', 'Skill', 'Building', 'Program', 'for', 'Dementia', 'Caregivers', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'pilot', 'the', 'home', 'Environmental', 'Skill', '-', 'Building', 'Program', '(', 'ESP', ')', 'and', 'an', 'educational', 'control', 'intervention', 'with', 'persons', 'with', 'dementia', 'and', 'their', 'caregivers', '(', 'n=40', ')', 'in', 'preparation', 'for', 'a', 'larger', 'double', '-', 'blind', 'randomized', 'controlled', 'trial', '.', 'Caregivers', 'of', 'persons', 'with', 'dementia', 'often', 'deal', 'with', 'difficult', 'behaviors', '.', 'The', 'ESP', 'is', 'an', 'occupational', 'therapy', 'intervention', 'that', 'helps', 'caregivers', 'adapt', 'to', 'their', 'environment', 'and', 'build', 'care', '-', 'giving', 'skills', '.', 'The', 'areas', 'addressed', 'include', 'changes', 'to', 'the', 'home', 'set', '-', 'up', ',', 'adaptive', 'equipment', ',', 'instruction', 'in', 'strategies', 'of', 'problem', '-', 'solving', ',', 'energy', 'conservation', ',', 'safe', 'task', 'performance', ',', 'and', 'fall', 'recovery', 'techniques', '.', 'A', 'trial', 'is', 'needed', 'with', 'methodological', 'rigor', 'and', 'to', 'determine', 'if', 'the', 'intervention', 'is', 'feasible', 'in', 'the', 'Canadian', 'health', 'care', 'system', '.', 'Results', 'will', 'contribute', 'to', 'understanding', 'how', 'caregivers', 'and', 'people', 'with', 'dementia', 'can', 'be', 'supported', 'in', 'their', 'home', 'environments', '.']","['O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00908492,NCT00908492,"Pilot Study of the Environmental Skill Building Program for Dementia Caregivers | The purpose of this study is to pilot the home Environmental Skill-Building Program (ESP) and an educational control intervention with persons with dementia and their caregivers (n=40) in preparation for a larger double-blind randomized controlled trial. Caregivers of persons with dementia often deal with difficult behaviors. The ESP is an occupational therapy intervention that helps caregivers adapt to their environment and build care-giving skills. The areas addressed include changes to the home set-up, adaptive equipment, instruction in strategies of problem-solving, energy conservation, safe task performance, and fall recovery techniques. A trial is needed with methodological rigor and to determine if the intervention is feasible in the Canadian health care system. Results will contribute to understanding how caregivers and people with dementia can be supported in their home environments.","[(19, 55, 'BEHAVIOURAL', 'Environmental Skill Building Program'), (60, 68, 'CONDITION', 'Dementia'), (129, 165, 'BEHAVIOURAL', 'Environmental Skill-Building Program'), (167, 170, 'BEHAVIOURAL', 'ESP'), (230, 238, 'CONDITION', 'dementia'), (364, 372, 'CONDITION', 'dementia'), (414, 417, 'BEHAVIOURAL', 'ESP'), (934, 942, 'CONDITION', 'dementia')]"
"['A', 'Prospective', ',', 'Multi', '-', 'Center', ',', 'Randomized', 'Controlled', 'Study', 'to', 'Compare', 'the', 'Spinal', 'Sealant', 'System', 'as', 'an', 'Adjunct', 'to', 'Sutured', 'Dural', 'Repair', 'With', 'Standard', 'of', 'Care', 'Methods', 'During', 'Spinal', 'Surgery', '|', 'To', 'evaluate', 'a', 'spinal', 'sealant', 'as', 'an', 'adjunct', 'to', 'sutured', 'dural', 'repair', 'compared', 'to', 'standard', 'of', 'care', 'techniques', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O']",NCT00444067,NCT00444067,"A Prospective, Multi-Center, Randomized Controlled Study to Compare the Spinal Sealant System as an Adjunct to Sutured Dural Repair With Standard of Care Methods During Spinal Surgery | To evaluate a spinal sealant as an adjunct to sutured dural repair compared to standard of care techniques.","[(72, 93, 'SURGICAL', 'Spinal Sealant System'), (111, 131, 'SURGICAL', 'Sutured Dural Repair'), (169, 183, 'CONDITION', 'Spinal Surgery'), (200, 214, 'SURGICAL', 'spinal sealant'), (232, 252, 'SURGICAL', 'sutured dural repair'), (265, 281, 'CONTROL', 'standard of care')]"
"['Prospective', 'Randomized', 'Evaluation', 'of', 'the', 'WATCHMAN', 'LAA', 'Closure', 'Device', 'in', 'Patients', 'With', 'Atrial', 'Fibrillation', '(', 'AF', ')', 'Versus', 'Long', 'Term', 'Warfarin', 'Therapy', '|', 'This', 'was', 'a', 'prospective', ',', 'randomized', ',', 'multicenter', 'study', 'to', 'provide', 'additional', 'information', 'on', 'the', 'safety', 'and', 'efficacy', 'of', 'the', 'WATCHMAN', 'LAA', 'Closure', 'Technology', '.', 'The', 'purpose', 'of', 'the', 'PREVAIL', 'study', 'was', 'to', 'confirm', 'the', 'efficacy', 'endpoint', 'as', 'demonstrated', 'in', 'the', 'PROTECT', 'AF', 'pivotal', 'study', 'and', 'to', 'further', 'demonstrate', 'that', 'the', 'WATCHMAN', 'LAA', 'Closure', 'Technology', 'is', 'safe', 'and', 'effective', 'in', 'subjects', 'with', 'non', '-', 'valvular', 'atrial', 'fibrillation', 'who', 'require', 'anticoagulation', 'therapy', 'for', 'potential', 'thrombus', 'formation', '.']","['O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT01182441,NCT01182441,"Prospective Randomized Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation (AF) Versus Long Term Warfarin Therapy | This was a prospective, randomized, multicenter study to provide additional information on the safety and efficacy of the WATCHMAN LAA Closure Technology. The purpose of the PREVAIL study was to confirm the efficacy endpoint as demonstrated in the PROTECT AF pivotal study and to further demonstrate that the WATCHMAN LAA Closure Technology is safe and effective in subjects with non-valvular atrial fibrillation who require anticoagulation therapy for potential thrombus formation.","[(41, 68, 'SURGICAL', 'WATCHMAN LAA Closure Device'), (86, 105, 'CONDITION', 'Atrial Fibrillation'), (107, 109, 'CONDITION', 'AF'), (128, 136, 'DRUG', 'Warfarin'), (269, 300, 'SURGICAL', 'WATCHMAN LAA Closure Technology'), (403, 405, 'CONDITION', 'AF'), (456, 487, 'SURGICAL', 'WATCHMAN LAA Closure Technology'), (527, 559, 'CONDITION', 'non-valvular atrial fibrillation'), (610, 618, 'CONDITION', 'thrombus')]"
"['Utilizing', 'Gaming', 'Mechanics', 'to', 'Optimize', 'Telerehabilitation', 'Adherence', 'in', 'Persons', 'With', 'Stroke', '|', 'This', 'trial', 'studies', 'the', 'impact', 'of', 'motivational', 'strategies', 'designed', 'by', 'the', 'gaming', 'industry', 'on', 'adherence', 'to', 'a', 'home', 'tele', '-', 'rehabilitation', 'program', 'designed', 'to', 'improve', 'hand', 'function', 'in', 'persons', 'with', 'stroke', '.', 'A', 'growing', 'literature', 'suggests', 'that', 'the', 'extended', 'practice', 'of', 'challenging', 'hand', 'tasks', 'can', 'produce', 'measurable', 'changes', 'in', 'hand', 'function', 'in', 'persons', 'with', 'stroke', '.', 'Current', 'health', 'care', 'delivery', 'systems', 'do', 'not', 'support', 'this', 'volume', 'of', 'directly', 'supervised', 'rehabilitation', ',', 'making', 'it', 'necessary', 'for', 'patients', 'to', 'perform', 'a', 'substantial', 'amount', 'of', 'activity', 'at', 'home', ',', 'unsupervised', '.', 'Unfortunately', ',', 'adherence', 'to', 'unsupervised', 'home', 'exercise', 'regimens', 'is', 'quite', 'poor', 'in', 'this', 'population', '.', 'The', 'investigator', ""'s"", 'goal', 'is', 'to', 'assess', 'the', 'impact', 'of', 'several', 'well', '-', 'established', 'game', 'design', 'strategies', ':', '1', ')', 'Scaffolded', 'increases', 'in', 'game', 'difficulty', '2', ')', 'In', '-', 'game', 'rewards', '3', ')', 'Quests', 'with', 'enhanced', 'narrative', '.', 'The', 'investigator', ""'s"", 'will', 'utilize', 'these', 'enhancements', 'to', 'study', 'their', 'impact', 'on', 'motivation', 'to', 'perform', 'a', 'tele', '-', 'rehabilitation-', 'based', 'home', 'exercise', 'program', ',', 'adherence', 'to', 'the', 'program', 'and', 'changes', 'in', 'hand', 'function', '.', 'The', 'proposed', 'study', 'will', 'utilize', 'a', 'system', 'of', 'novel', 'rehabilitation', 'technologies', 'designed', 'to', 'facilitate', 'home', 'exercise', 'performance', '.', 'Subjects', 'will', 'perform', '3', 'simulated', 'rehabilitation', 'activities', 'supported', 'by', 'a', 'passive', 'exoskeleton', ',', 'an', 'infrared', 'camera', 'and', 'software', 'that', 'will', 'allow', 'subjects', 'to', 'exercise', 'at', 'home', '.', 'The', 'investigator', ""'s"", 'will', 'investigate', ':', '1', ')', 'Differences', 'in', 'measures', 'of', 'motivation', 'elicited', 'by', 'motivationally', 'enhanced', 'simulations', 'and', 'un', '-', 'enhanced', 'control', 'versions.2', ')', 'The', 'impact', 'of', 'motivational', 'enhancements', 'on', 'actual', 'adherence', 'to', 'a', 'tele', '-', 'rehabilitation', 'program', 'in', 'persons', 'with', 'stroke', 'and', '3', ')', 'The', 'impact', 'of', 'motivational', 'enhancement', 'on', 'improvements', 'in', 'hand', 'function', 'achieved', 'by', 'these', 'subjects', '.', 'This', 'proposal', 'will', 'address', 'a', 'critical', 'gap', 'in', 'modern', 'rehabilitation', '-', 'adherence', 'to', 'autonomous', 'rehabilitation', 'programs', '.', 'Patient', 'participation', 'in', 'unsupervised', 'rehabilitation', 'is', 'one', 'of', 'the', 'assumptions', 'underpinning', 'our', 'health', 'care', 'system', '.', 'This', 'said', ',', 'no', 'data', 'collected', 'to', 'date', 'supports', 'that', 'adherence', 'is', 'acceptable', '.', 'The', 'technology', 'and', 'methodology', 'in', 'this', 'proposal', 'are', 'an', 'important', 'step', 'towards', 'leveraging', 'extensive', 'research', 'and', 'development', 'done', 'by', 'the', 'computer', 'gaming', 'industry', 'into', 'improved', 'rehabilitation', 'practice', '.']","['O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03985761,NCT03985761,"Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke | This trial studies the impact of motivational strategies designed by the gaming industry on adherence to a home tele-rehabilitation program designed to improve hand function in persons with stroke. A growing literature suggests that the extended practice of challenging hand tasks can produce measurable changes in hand function in persons with stroke. Current health care delivery systems do not support this volume of directly supervised rehabilitation, making it necessary for patients to perform a substantial amount of activity at home, unsupervised. Unfortunately, adherence to unsupervised home exercise regimens is quite poor in this population. The investigator's goal is to assess the impact of several well-established game design strategies: 1) Scaffolded increases in game difficulty 2) In-game rewards 3) Quests with enhanced narrative. The investigator's will utilize these enhancements to study their impact on motivation to perform a tele-rehabilitation- based home exercise program, adherence to the program and changes in hand function. The proposed study will utilize a system of novel rehabilitation technologies designed to facilitate home exercise performance. Subjects will perform 3 simulated rehabilitation activities supported by a passive exoskeleton, an infrared camera and software that will allow subjects to exercise at home. The investigator's will investigate: 1) Differences in measures of motivation elicited by motivationally enhanced simulations and un-enhanced control versions.2) The impact of motivational enhancements on actual adherence to a tele-rehabilitation program in persons with stroke and 3) The impact of motivational enhancement on improvements in hand function achieved by these subjects. This proposal will address a critical gap in modern rehabilitation - adherence to autonomous rehabilitation programs. Patient participation in unsupervised rehabilitation is one of the assumptions underpinning our health care system. This said, no data collected to date supports that adherence is acceptable. The technology and methodology in this proposal are an important step towards leveraging extensive research and development done by the computer gaming industry into improved rehabilitation practice.","[(10, 26, 'OTHER', 'Gaming Mechanics'), (39, 57, 'PHYSICAL', 'Telerehabilitation'), (84, 90, 'CONDITION', 'Stroke'), (126, 149, 'BEHAVIOURAL', 'motivational strategies'), (200, 232, 'PHYSICAL', 'home tele-rehabilitation program'), (283, 289, 'CONDITION', 'stroke'), (438, 444, 'CONDITION', 'stroke'), (1044, 1092, 'PHYSICAL', 'tele-rehabilitation- based home exercise program'), (1250, 1263, 'PHYSICAL', 'home exercise'), (1301, 1336, 'PHYSICAL', 'simulated rehabilitation activities'), (1352, 1371, 'PHYSICAL', 'passive exoskeleton'), (1433, 1449, 'PHYSICAL', 'exercise at home'), (1541, 1576, 'BEHAVIOURAL', 'motivationally enhanced simulations'), (1581, 1600, 'CONTROL', 'un-enhanced control'), (1627, 1652, 'BEHAVIOURAL', 'motivational enhancements'), (1678, 1705, 'PHYSICAL', 'tele-rehabilitation program'), (1722, 1728, 'CONDITION', 'stroke'), (1750, 1774, 'BEHAVIOURAL', 'motivational enhancement'), (1918, 1952, 'PHYSICAL', 'autonomous rehabilitation programs')]"
"['Safety', 'and', 'Efficacy', 'of', 'Remote', 'Ischemic', 'Conditioning', 'in', 'Patients', 'With', 'Spontaneous', 'Intracerebral', 'Hemorrhage', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'treatment', 'with', 'remote', 'ischemic', 'conditioning', 'is', 'of', 'sufficient', 'promise', 'to', 'improve', 'outcome', 'before', 'conducting', 'a', 'larger', 'clinical', 'trial', 'to', 'examine', 'its', 'effectiveness', 'as', 'a', 'treatment', 'for', 'intracerebral', 'hemorrhage', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT03484936,NCT03484936,Safety and Efficacy of Remote Ischemic Conditioning in Patients With Spontaneous Intracerebral Hemorrhage | The purpose of this study is to determine whether treatment with remote ischemic conditioning is of sufficient promise to improve outcome before conducting a larger clinical trial to examine its effectiveness as a treatment for intracerebral hemorrhage.,"[(23, 51, 'OTHER', 'Remote Ischemic Conditioning'), (69, 105, 'CONDITION', 'Spontaneous Intracerebral Hemorrhage'), (173, 201, 'OTHER', 'remote ischemic conditioning'), (336, 360, 'CONDITION', 'intracerebral hemorrhage')]"
"['Sarcopenia', 'Physical', 'Activity', 'and', 'Metabolomic', '|', 'Muscle', 'failure', '(', 'sarcopenia', 'or', 'dynapenia', ')', 'is', 'a', 'factor', 'of', 'frailty', 'and', 'therefore', ',', 'ultimately', ',', 'of', 'loss', 'of', 'autonomy', 'in', 'the', 'elderly', '.', 'Currently', ',', 'no', 'biomarker', 'of', 'muscle', 'failure', 'has', 'a', 'high', 'sensitivity', ',', 'specificity', 'and', 'positive', 'predictive', 'value', '.', 'Several', 'results', ',', 'although', 'preliminary', ',', 'suggest', 'that', 'metabolomics', 'could', 'facilitate', 'the', 'early', 'identification', 'of', 'frail', 'patients', ',', 'allowing', 'the', 'implementation', 'of', 'primary', 'prevention', 'strategies', '.', 'Untargeted', 'high', '-', 'resolution', 'metabolomics', 'analysis', 'would', 'identify', 'discriminative', 'biomarkers', 'and', 'biological', 'mechanisms', 'associated', 'with', 'frailty', '.', 'Finally', ',', 'the', 'hypothesis', 'that', 'metabolic', 'signatures', 'can', 'be', 'identified', 'as', 'risk', 'factors', 'for', 'the', 'development', 'of', 'age', '-', 'related', 'dynapenia', 'should', 'be', 'tested', 'in', 'a', 'longitudinal', 'design', '.']","['B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05199207,NCT05199207,"Sarcopenia Physical Activity and Metabolomic | Muscle failure (sarcopenia or dynapenia) is a factor of frailty and therefore, ultimately, of loss of autonomy in the elderly. Currently, no biomarker of muscle failure has a high sensitivity, specificity and positive predictive value. Several results, although preliminary, suggest that metabolomics could facilitate the early identification of frail patients, allowing the implementation of primary prevention strategies. Untargeted high-resolution metabolomics analysis would identify discriminative biomarkers and biological mechanisms associated with frailty. Finally, the hypothesis that metabolic signatures can be identified as risk factors for the development of age-related dynapenia should be tested in a longitudinal design.","[(0, 10, 'CONDITION', 'Sarcopenia'), (47, 61, 'CONDITION', 'Muscle failure'), (63, 73, 'CONDITION', 'sarcopenia'), (77, 86, 'CONDITION', 'dynapenia'), (201, 215, 'CONDITION', 'muscle failure'), (731, 740, 'CONDITION', 'dynapenia')]"
"['Evaluation', 'of', 'a', 'Computerized', 'Attention', 'Training', '(', 'CAT', ')', 'to', 'Modify', 'Attention', 'Bias', 'for', 'Food', 'Cues', 'in', 'Anorexia', 'Nervosa', 'Patients', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'test', 'the', 'therapeutic', 'effects', 'of', 'a', 'computerized', 'attention', 'training', 'for', 'patients', 'with', 'Anorexia', 'Nervosa', '(', 'AN', ')', '.', 'The', 'primary', 'aim', 'is', 'to', 'determine', 'if', 'a', 'computerized', 'attention', 'training', 'can', 'modify', 'attention', 'towards', 'food', 'and', 'ameliorate', 'eating', 'disorder', 'symptoms', 'and', 'related', 'difficulties', ',', 'such', 'as', 'anxiety', '.', 'The', 'secondary', 'aim', 'is', 'to', 'explore', 'underlying', 'mechanisms', 'that', 'contribute', 'to', 'these', 'improvements', '.', 'The', 'stability', 'of', 'potentially', 'observed', 'effects', 'over', 'a', 'one', '-', 'month', 'period', 'will', 'also', 'be', 'determined', '.']","['O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02484599,NCT02484599,"Evaluation of a Computerized Attention Training (CAT) to Modify Attention Bias for Food Cues in Anorexia Nervosa Patients | The purpose of this study is to test the therapeutic effects of a computerized attention training for patients with Anorexia Nervosa (AN). The primary aim is to determine if a computerized attention training can modify attention towards food and ameliorate eating disorder symptoms and related difficulties, such as anxiety. The secondary aim is to explore underlying mechanisms that contribute to these improvements. The stability of potentially observed effects over a one-month period will also be determined.","[(16, 47, 'BEHAVIOURAL', 'Computerized Attention Training'), (49, 52, 'BEHAVIOURAL', 'CAT'), (96, 112, 'CONDITION', 'Anorexia Nervosa'), (190, 221, 'BEHAVIOURAL', 'computerized attention training'), (240, 256, 'CONDITION', 'Anorexia Nervosa'), (258, 260, 'CONDITION', 'AN'), (300, 331, 'BEHAVIOURAL', 'computerized attention training'), (381, 396, 'CONDITION', 'eating disorder'), (440, 447, 'CONDITION', 'anxiety')]"
"['Intensity', '-', 'dependent', 'Impacts', 'of', 'Training', 'on', 'Growth', 'Factors', 'BDNF', 'and', 'Cognitive', 'Functions', 'in', 'Persons', 'With', 'Multiple', 'Sclerosis', '-', 'a', 'Single', '-', 'center', 'Randomized', 'Controlled', 'Trial', '|', 'Multiple', 'Sclerosis', '(', 'MS', ')', 'is', 'a', 'chronic', 'immune', '-', 'mediated', 'disease', 'of', 'the', 'central', 'nervous', 'system', ',', 'accompanied', 'by', 'varying', 'inflammatory', 'manifestations', ',', 'demyelinization', 'and', 'axonal', 'loss', '.', 'With', 'chronic', 'progressive', 'or', 'relapsing', '-', 'remitting', 'disease', 'onsets', 'persons', 'with', 'MS', '(', 'pwMS', ')', 'progressively', 'develop', 'impaired', 'functional', 'capacity', 'and', 'show', 'reduced', 'physical', 'activity', 'and', 'cognitive', 'decline', 'compared', 'to', 'healthy', 'controls', '.', 'The', 'primary', 'aims', 'of', 'rehabilitation', 'in', 'pwMS', 'are', 'therefore', 'to', 'increase', 'levels', 'of', 'activity', 'and', 'participation', 'leading', 'to', 'increase', 'independence', 'of', 'the', 'participants', '.', 'In', 'general', 'exercise', 'ranges', 'from', 'passive', 'physiotherapy', '-', 'based', 'interventions', 'to', 'submaximal', 'endurance', 'training', 'sessions', '.', 'Current', 'recommendations', 'advise', 'pwMS', 'that', 'exercise', 'should', 'be', 'matched', 'with', 'the', 'individual', 'performance', 'capacities', '.', 'Exercise', 'training', 'in', 'pwMS', 'then', 'has', 'the', 'potential', 'to', 'target', 'and', 'improve', 'many', 'components', 'outlined', 'in', 'the', 'ICF', '-', 'model', '.', '\n\n', 'Cytokines', 'and', 'neurotrophic', 'factors', 'have', 'received', 'increased', 'attention', 'in', 'MS', 'research', 'and', 'addressed', 'the', 'brain', '-', 'derived', 'neurotrophic', 'factor', '(', 'BDNF', ')', 'as', 'an', 'important', 'mediator', 'of', 'neuronal', 'regeneration', 'linking', 'the', 'effects', 'of', 'exercise', 'with', 'MS', 'pathogenesis', '.', 'Data', 'show', 'positive', 'connections', 'between', 'elevated', 'neurotrophin', 'concentrations', ',', 'induction', 'of', 'neuroplasticity', ',', 'recovery', 'of', 'the', 'motor', 'and', 'cognitive', 'functions', 'and', 'the', 'applied', 'training', 'intensities', '.', 'Similarly', ',', 'intensive', 'and', 'progressive', 'exercise', 'bouts', 'seem', 'to', 'have', 'greater', 'benefits', 'on', 'cardiorespiratory', 'fitness', 'and', 'maximum', 'voluntary', 'strength', 'in', 'elderly', 'and', 'seniors', 'with', 'dementia', '.', 'Therefore', ',', 'specific', 'exercise', 'prescriptions', 'may', 'be', 'necessary', 'for', 'targeting', 'the', 'specific', 'impairments', 'also', 'in', 'pwMS', '.', '\n\n', 'This', 'study', 'aims', 'to', 'evaluate', 'two', 'different', 'training', 'modalities', '(', 'intensive', 'versus', 'normal', ')', 'in', 'pwMS', '.', 'It', 'is', 'expected', 'that', 'both', 'modalities', 'will', 'improve', 'cardiorespiratory', 'fitness', 'and', 'cognitive', 'functions', 'in', 'pwMS', '.', 'Based', 'on', 'the', 'findings', 'that', 'higher', 'training', 'intensities', 'facilitate', 'greater', 'benefits', ',', 'it', 'is', 'expected', 'that', 'pwMS', 'will', 'tolerate', 'the', 'intensive', 'training', 'intensities', 'and', 'show', 'positive', 'connections', 'to', 'elevated', 'neurotrophin', 'concentrations', '.', '\n\n', 'The', 'results', 'will', 'to', 'help', 'to', 'clearer', 'understand', 'the', 'benefits', 'of', 'each', 'type', 'of', 'exercise', 'conveyed', 'for', 'pwMS', 'and', 'will', 'assist', 'in', 'the', 'development', 'of', 'patient', '-', 'specific', 'exercise', 'prescriptions', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O']",NCT02571335,NCT02571335,"Intensity-dependent Impacts of Training on Growth Factors BDNF and Cognitive Functions in Persons With Multiple Sclerosis - a Single-center Randomized Controlled Trial | Multiple Sclerosis (MS) is a chronic immune-mediated disease of the central nervous system, accompanied by varying inflammatory manifestations, demyelinization and axonal loss. With chronic progressive or relapsing-remitting disease onsets persons with MS (pwMS) progressively develop impaired functional capacity and show reduced physical activity and cognitive decline compared to healthy controls. The primary aims of rehabilitation in pwMS are therefore to increase levels of activity and participation leading to increase independence of the participants. In general exercise ranges from passive physiotherapy-based interventions to submaximal endurance training sessions. Current recommendations advise pwMS that exercise should be matched with the individual performance capacities. Exercise training in pwMS then has the potential to target and improve many components outlined in the ICF-model.

Cytokines and neurotrophic factors have received increased attention in MS research and addressed the brain-derived neurotrophic factor (BDNF) as an important mediator of neuronal regeneration linking the effects of exercise with MS pathogenesis. Data show positive connections between elevated neurotrophin concentrations, induction of neuroplasticity, recovery of the motor and cognitive functions and the applied training intensities. Similarly, intensive and progressive exercise bouts seem to have greater benefits on cardiorespiratory fitness and maximum voluntary strength in elderly and seniors with dementia. Therefore, specific exercise prescriptions may be necessary for targeting the specific impairments also in pwMS.

This study aims to evaluate two different training modalities (intensive versus normal) in pwMS. It is expected that both modalities will improve cardiorespiratory fitness and cognitive functions in pwMS. Based on the findings that higher training intensities facilitate greater benefits, it is expected that pwMS will tolerate the intensive training intensities and show positive connections to elevated neurotrophin concentrations.

The results will to help to clearer understand the benefits of each type of exercise conveyed for pwMS and will assist in the development of patient-specific exercise prescriptions.","[(103, 121, 'CONDITION', 'Multiple Sclerosis'), (170, 188, 'CONDITION', 'Multiple Sclerosis'), (190, 192, 'CONDITION', 'MS'), (423, 425, 'CONDITION', 'MS'), (455, 483, 'CONDITION', 'impaired functional capacity'), (493, 518, 'CONDITION', 'reduced physical activity'), (523, 540, 'CONDITION', 'cognitive decline'), (889, 897, 'PHYSICAL', 'exercise'), (960, 977, 'PHYSICAL', 'Exercise training'), (1147, 1149, 'CONDITION', 'MS'), (1291, 1299, 'PHYSICAL', 'exercise'), (1305, 1307, 'CONDITION', 'MS'), (1524, 1564, 'PHYSICAL', 'intensive and progressive exercise bouts'), (1713, 1721, 'PHYSICAL', 'exercise'), (1849, 1868, 'PHYSICAL', 'training modalities'), (1870, 1879, 'PHYSICAL', 'intensive'), (1887, 1893, 'CONTROL', 'normal'), (2039, 2066, 'PHYSICAL', 'higher training intensities'), (2139, 2169, 'PHYSICAL', 'intensive training intensities'), (2318, 2326, 'PHYSICAL', 'exercise'), (2400, 2408, 'PHYSICAL', 'exercise')]"
"['The', 'Impact', 'of', 'Pain', 'on', 'Behavioural', 'Disturbances', 'in', 'Patients', 'With', 'Moderate', 'and', 'Severe', 'Dementia', '.', 'A', 'Cluster', 'Randomized', 'Trial', '|', 'In', 'nursing', 'homes', '(', 'NHs', ')', '80', '%', 'of', 'the', 'patients', 'have', 'dementia', ',', 'between', '60%-80', '%', 'exhibit', 'behavioural', 'disturbances', '(', 'BPSD', ')', ',', 'and', 'more', 'than', '60', '%', 'have', 'pain', '.', 'Both', 'pain', 'and', 'BPSD', 'is', 'more', 'common', 'in', 'those', 'with', 'severe', 'dementia', '.', 'Since', 'older', 'persons', 'with', 'dementia', 'have', 'less', 'communicative', 'skills', ',', 'suffer', 'from', 'more', 'pain', 'and', 'exhibit', 'more', 'agitation', ',', 'pain', 'may', 'be', 'a', 'contributing', 'factor', 'in', 'these', 'patients', '.', 'More', 'than', '40', '%', 'of', 'patients', 'with', 'BPSD', 'are', 'treated', 'with', 'neuroleptics', 'despite', 'described', 'side', '-', 'effects', '.', 'There', 'is', 'an', 'urgent', 'need', 'to', 'investigate', 'the', 'impact', 'of', 'individual', 'pain', 'management', 'on', 'BPSD', 'in', 'patients', 'with', 'dementia', '.', '\n\n', 'It', 'was', 'hypothesized', 'that', '\n\n', 'pain', 'increase', 'BPSD', 'in', 'patients', 'with', 'dementia', '\n', 'individual', 'pain', 'treatment', 'decrease', 'BPSD', 'in', 'patients', 'with', 'dementia']","['O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND']",NCT01021696,NCT01021696,"The Impact of Pain on Behavioural Disturbances in Patients With Moderate and Severe Dementia. A Cluster Randomized Trial | In nursing homes (NHs) 80% of the patients have dementia, between 60%-80% exhibit behavioural disturbances (BPSD), and more than 60% have pain. Both pain and BPSD is more common in those with severe dementia. Since older persons with dementia have less communicative skills, suffer from more pain and exhibit more agitation, pain may be a contributing factor in these patients. More than 40% of patients with BPSD are treated with neuroleptics despite described side-effects. There is an urgent need to investigate the impact of individual pain management on BPSD in patients with dementia.

It was hypothesized that

pain increase BPSD in patients with dementia
individual pain treatment decrease BPSD in patients with dementia","[(22, 46, 'CONDITION', 'Behavioural Disturbances'), (64, 92, 'CONDITION', 'Moderate and Severe Dementia'), (171, 179, 'CONDITION', 'dementia'), (205, 229, 'CONDITION', 'behavioural disturbances'), (231, 235, 'CONDITION', 'BPSD'), (281, 285, 'CONDITION', 'BPSD'), (315, 330, 'CONDITION', 'severe dementia'), (357, 365, 'CONDITION', 'dementia'), (532, 536, 'CONDITION', 'BPSD'), (652, 678, 'OTHER', 'individual pain management'), (682, 686, 'CONDITION', 'BPSD'), (704, 712, 'CONDITION', 'dementia'), (755, 759, 'CONDITION', 'BPSD'), (777, 785, 'CONDITION', 'dementia'), (786, 811, 'OTHER', 'individual pain treatment'), (821, 825, 'CONDITION', 'BPSD'), (843, 851, 'CONDITION', 'dementia')]"
"['A', 'Multicenter', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Controlled', 'Study', 'of', 'NGX-4010', 'for', 'the', 'Treatment', 'of', 'Postherpetic', 'Neuralgia', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'assess', 'the', 'efficacy', 'and', 'safety', 'of', 'NGX-4010', 'applied', 'for', '60', 'minutes', 'for', 'the', 'treatment', 'of', 'postherpetic', 'neuralgia', '(', 'PHN', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT00300222,NCT00300222,"A Multicenter Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia | The purpose of the study is to assess the efficacy and safety of NGX-4010 applied for 60 minutes for the treatment of postherpetic neuralgia (PHN).","[(60, 68, 'DRUG', 'NGX-4010'), (90, 112, 'CONDITION', 'Postherpetic Neuralgia'), (180, 188, 'DRUG', 'NGX-4010'), (233, 255, 'CONDITION', 'postherpetic neuralgia'), (257, 260, 'CONDITION', 'PHN')]"
"['Repetitive', 'Transcranial', 'Magnetic', 'Stimulation', '(', 'rTMS', ')', 'for', 'the', 'Treatment', 'of', 'Epilepsy', '-', 'Case', 'Study', 'in', 'Patients', 'With', 'Epilepsia', 'Partialis', 'Continua', '(', 'EPC', ')', 'and', 'Refractory', 'Status', 'Epilepticus', '(', 'SE', ')', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'assess', 'the', 'effects', 'of', 'repetitive', 'transcranial', 'magnetic', 'stimulation', '(', 'rTMS', ')', 'as', 'a', 'treatment', 'for', 'Epilepsia', 'Partialis', 'Continua', '(', 'EPC', ')', 'or', 'refractory', 'Status', 'Epilepticus', '(', 'SE', ')', ',', 'when', 'standard', 'clinical', 'treatments', 'have', 'failed', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02560597,NCT02560597,"Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Epilepsy - Case Study in Patients With Epilepsia Partialis Continua (EPC) and Refractory Status Epilepticus (SE) | The purpose of this study is to assess the effects of repetitive transcranial magnetic stimulation (rTMS) as a treatment for Epilepsia Partialis Continua (EPC) or refractory Status Epilepticus (SE), when standard clinical treatments have failed.","[(0, 44, 'OTHER', 'Repetitive Transcranial Magnetic Stimulation'), (46, 50, 'OTHER', 'rTMS'), (73, 81, 'CONDITION', 'Epilepsy'), (112, 140, 'CONDITION', 'Epilepsia Partialis Continua'), (142, 145, 'CONDITION', 'EPC'), (151, 180, 'CONDITION', 'Refractory Status Epilepticus'), (182, 184, 'CONDITION', 'SE'), (242, 286, 'OTHER', 'repetitive transcranial magnetic stimulation'), (288, 292, 'OTHER', 'rTMS'), (313, 341, 'CONDITION', 'Epilepsia Partialis Continua'), (343, 346, 'CONDITION', 'EPC'), (351, 380, 'CONDITION', 'refractory Status Epilepticus'), (382, 384, 'CONDITION', 'SE')]"
"['Precision', 'Radiation', 'Treatment', 'for', 'Epilepsy', '(', 'PRECISION', ')', '|', 'The', 'PRECISION', '-', 'study', 'offers', 'a', 'non', '-', 'invasive', ',', 'curative', 'intervention', 'for', 'drug', '-', 'resistant', 'localised', 'epilepsy', 'patients', 'who', 'are', 'not', 'eligible', 'for', 'surgery', '.', 'The', 'intervention', 'will', 'consist', 'of', 'a', 'single', 'LINAC', 'based', 'SRT', 'treatment', 'and', 'is', 'given', 'by', 'the', 'radiation', '-', 'oncologist', 'after', 'detailed', 'localisation', 'of', 'the', 'epileptogenic', 'zone', 'with', 'the', 'neurologist', ',', 'radiologist', 'and', 'neurosurgeon', '.', 'This', 'intervention', 'will', 'make', 'curative', '-', 'intent', 'treatment', 'possible', 'where', 'this', 'could', 'otherwise', 'not', 'be', 'given', 'and', 'is', 'a', 'non', '-', 'invasive', 'and', 'non', '-', 'competitive', 'alternative', 'to', 'epilepsy', 'surgery', '.', 'It', 'is', 'expected', 'that', 'the', 'health', 'costs', 'for', 'this', 'curative', 'treatment', 'will', 'not', 'exceed', 'standard', 'treatment', ',', 'such', 'as', 'lifelong', 'medication', 'and', 'neuromodulation', '.']","['B-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05182437,NCT05182437,"Precision Radiation Treatment for Epilepsy (PRECISION) | The PRECISION-study offers a non-invasive, curative intervention for drug-resistant localised epilepsy patients who are not eligible for surgery. The intervention will consist of a single LINAC based SRT treatment and is given by the radiation-oncologist after detailed localisation of the epileptogenic zone with the neurologist, radiologist and neurosurgeon. This intervention will make curative-intent treatment possible where this could otherwise not be given and is a non-invasive and non-competitive alternative to epilepsy surgery. It is expected that the health costs for this curative treatment will not exceed standard treatment, such as lifelong medication and neuromodulation.","[(0, 29, 'RADIOTHERAPY', 'Precision Radiation Treatment'), (34, 42, 'CONDITION', 'Epilepsy'), (126, 159, 'CONDITION', 'drug-resistant localised epilepsy'), (245, 270, 'RADIOTHERAPY', 'LINAC based SRT treatment'), (578, 586, 'CONDITION', 'epilepsy')]"
"['Study', 'of', 'Clinical', 'Types', 'and', 'Surgical', 'Out', 'Come', 'of', 'Pediatic', 'Exotropia', '|', 'study', 'aiming', 'to', 'evaluate', 'all', 'children', 'presented', 'to', 'strabismus', 'clinic', 'in', 'ophthalmology', 'department', 'at', 'sohag', 'university', 'hospital', 'with', 'divergent', 'squint', '(', 'exotropia', ')', 'and', 'to', 'record', 'surgical', 'outcome', 'of', 'those', 'who', 'underwent', 'strabismus', 'surgery', 'in', 'our', 'hospital']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O']",NCT05089422,NCT05089422,Study of Clinical Types and Surgical Out Come of Pediatic Exotropia | study aiming to evaluate all children presented to strabismus clinic in ophthalmology department at sohag university hospital with divergent squint (exotropia) and to record surgical outcome of those who underwent strabismus surgery in our hospital,"[(58, 67, 'CONDITION', 'Exotropia'), (201, 217, 'CONDITION', 'divergent squint'), (219, 228, 'CONDITION', 'exotropia'), (284, 302, 'SURGICAL', 'strabismus surgery')]"
"['A', 'Telemedicine', 'System', 'for', 'the', 'Follow', '-', 'up', 'of', 'Patients', 'With', 'SAS', '|', 'Objective', ':', 'Set', 'up', 'an', 'interoperable', 'telemedicine', 'system', 'for', 'the', 'follow', '-', 'up', 'of', 'patients', 'with', 'sleep', 'apnea', 'syndrome', '.']","['O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT01848509,NCT01848509,A Telemedicine System for the Follow-up of Patients With SAS | Objective: Set up an interoperable telemedicine system for the follow-up of patients with sleep apnea syndrome.,"[(2, 21, 'OTHER', 'Telemedicine System'), (57, 60, 'CONDITION', 'SAS'), (84, 117, 'OTHER', 'interoperable telemedicine system'), (153, 173, 'CONDITION', 'sleep apnea syndrome')]"
"['Evaluation', 'of', 'the', 'Safety', ',', 'Tolerability', ',', 'Efficacy', 'and', 'Activity', 'of', 'AMX0035', ',', 'a', 'Fixed', 'Combination', 'of', 'Phenylbutyrate', '(', 'PB', ')', 'and', 'Tauroursodeoxycholic', 'Acid', '(', 'TUDCA', ')', ',', 'for', 'the', 'Treatment', 'of', 'ALS', '|', 'The', 'CENTAUR', 'trial', 'was', 'a', '2:1', '(', 'active', ':', 'placebo', ')', 'randomized', ',', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', 'Phase', 'II', 'trial', 'to', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'AMX0035', 'for', 'the', 'treatment', 'of', 'ALS', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT03127514,NCT03127514,"Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS | The CENTAUR trial was a 2:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and efficacy of AMX0035 for the treatment of ALS.","[(65, 72, 'DRUG', 'AMX0035'), (97, 111, 'DRUG', 'Phenylbutyrate'), (113, 115, 'DRUG', 'PB'), (121, 146, 'DRUG', 'Tauroursodeoxycholic Acid'), (148, 153, 'DRUG', 'TUDCA'), (177, 180, 'CONDITION', 'ALS'), (219, 226, 'CONTROL', 'placebo'), (254, 261, 'CONTROL', 'placebo'), (327, 334, 'DRUG', 'AMX0035'), (356, 359, 'CONDITION', 'ALS')]"
"['The', 'Effect', 'of', 'Desflurane', 'Versus', 'Sevoflurane', 'on', 'Postoperative', 'Recovery', 'in', 'Patients', 'Undergoing', 'Minor-', 'to', 'Moderate', '-', 'risk', 'Noncardiac', 'Surgery', '-', 'a', 'Prospective', 'Double', '-', 'blinded', 'Randomized', 'Clinical', 'Trial', '|', 'Patients', 'over', 'the', 'age', 'of', '65', 'years', 'are', 'at', 'increased', 'risk', 'for', 'developing', 'delirium', 'and', 'cognitive', 'complications', 'in', 'the', 'immediate', 'postoperative', 'period', 'after', 'noncardiac', 'surgeries', ',', 'resulting', 'in', 'increased', 'morbidity', 'and', 'mortality', '.', 'Previous', 'small', 'studies', 'have', 'shown', 'beneficial', 'effects', 'of', 'desflurane', 'on', 'postoperative', 'cognitive', 'recovery', ',', 'which', 'has', 'been', 'explained', 'by', 'the', 'more', 'rapid', 'onset', 'and', 'offset', 'of', 'anesthesia', 'as', 'compared', 'to', 'sevoflurane', '.', 'However', ',', 'there', 'are', 'very', 'limited', 'data', 'on', 'the', 'effect', 'of', 'desflurane', 'on', 'postoperative', 'recovery', 'and', 'time', 'until', 'criteria', 'for', 'discharge', 'from', 'post', '-', 'anesthesia', 'care', 'unit', '(', 'PACU', ')', 'are', 'fulfilled', 'in', 'elderly', 'patients', 'undergoing', 'minor', '-', 'to', 'moderate', '-', 'risk', 'noncardiac', 'surgery', '.', 'Therefore', ',', 'the', 'investigators', 'will', 'test', 'the', 'primary', 'hypothesis', 'that', 'general', 'anesthesia', 'with', 'desflurane', 'significantly', 'reduces', 'the', 'time', 'between', 'discontinuation', 'of', 'volatile', 'anesthetics', 'after', 'the', 'end', 'of', 'surgery', 'and', 'reaching', 'ready', 'for', 'discharge', 'from', 'PACU', 'criteria', ',', 'which', 'are', 'defined', 'as', 'reaching', 'a', 'modified', 'Aldrete', 'score', '≥', '12', ',', 'as', 'compared', 'to', 'sevoflurane', 'in', 'patients', '≥', '65', 'years', 'of', 'age', 'undergoing', 'minor', '-', 'to', 'moderate', '-', 'risk', 'noncardiac', 'surgery', '.']","['O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT05331027,NCT05331027,"The Effect of Desflurane Versus Sevoflurane on Postoperative Recovery in Patients Undergoing Minor- to Moderate-risk Noncardiac Surgery - a Prospective Double-blinded Randomized Clinical Trial | Patients over the age of 65 years are at increased risk for developing delirium and cognitive complications in the immediate postoperative period after noncardiac surgeries, resulting in increased morbidity and mortality. Previous small studies have shown beneficial effects of desflurane on postoperative cognitive recovery, which has been explained by the more rapid onset and offset of anesthesia as compared to sevoflurane. However, there are very limited data on the effect of desflurane on postoperative recovery and time until criteria for discharge from post-anesthesia care unit (PACU) are fulfilled in elderly patients undergoing minor-to moderate-risk noncardiac surgery. Therefore, the investigators will test the primary hypothesis that general anesthesia with desflurane significantly reduces the time between discontinuation of volatile anesthetics after the end of surgery and reaching ready for discharge from PACU criteria, which are defined as reaching a modified Aldrete score ≥ 12, as compared to sevoflurane in patients ≥ 65 years of age undergoing minor-to moderate-risk noncardiac surgery.","[(14, 24, 'DRUG', 'Desflurane'), (32, 43, 'DRUG', 'Sevoflurane'), (93, 135, 'CONDITION', 'Minor- to Moderate-risk Noncardiac Surgery'), (266, 274, 'CONDITION', 'delirium'), (347, 367, 'CONDITION', 'noncardiac surgeries'), (473, 483, 'DRUG', 'desflurane'), (610, 621, 'DRUG', 'sevoflurane'), (677, 687, 'DRUG', 'desflurane'), (835, 876, 'CONDITION', 'minor-to moderate-risk noncardiac surgery'), (969, 979, 'DRUG', 'desflurane'), (1213, 1224, 'DRUG', 'sevoflurane'), (1266, 1307, 'CONDITION', 'minor-to moderate-risk noncardiac surgery')]"
"['Pharmacokinetics', 'of', 'Levodopa', 'After', 'Repeated', 'Doses', 'of', 'Carbidopa', ',', 'ODM-104', 'and', 'Levodopa', ':', 'an', 'Open', ',', 'Randomised', 'Study', 'With', 'Crossover', 'Design', 'in', 'Healthy', 'Males', 'and', 'Females', '|', 'Phase', 'I', 'open', ',', 'randomized', 'cross', '-', 'over', 'pharmacokinetic', 'study', '.']","['O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02554734,NCT02554734,"Pharmacokinetics of Levodopa After Repeated Doses of Carbidopa, ODM-104 and Levodopa: an Open, Randomised Study With Crossover Design in Healthy Males and Females | Phase I open, randomized cross-over pharmacokinetic study.","[(20, 28, 'DRUG', 'Levodopa'), (53, 62, 'DRUG', 'Carbidopa'), (64, 71, 'DRUG', 'ODM-104'), (76, 84, 'DRUG', 'Levodopa')]"
"['The', 'Effect', 'of', 'Traditional', 'Chinese', 'Medicine', '(', 'VGH', '-', 'AD1', ')', 'on', 'Patients', 'With', 'Alzheimer', ""'s"", 'Disease', ':', 'A', 'Double', '-', 'blinded', 'Randomized', 'Placebo', '-', 'controlled', 'Cross', '-', 'over', 'Study', '|', 'This', 'randomized', ',', 'double', '-', 'blinded', ',', 'placebo', '-', 'controlled', ',', 'crossover', 'clinical', 'trial', 'aims', 'to', 'investigate', 'the', 'effect', 'of', 'VGH', '-', 'AD1', ',', 'a', 'scientific', 'Chinese', 'medicine', 'powder', 'prescription', ',', 'on', 'patients', 'with', 'Alzheimer', ""'s"", 'disease', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT04249869,NCT04249869,"The Effect of Traditional Chinese Medicine (VGH-AD1) on Patients With Alzheimer's Disease: A Double-blinded Randomized Placebo-controlled Cross-over Study | This randomized, double-blinded, placebo-controlled, crossover clinical trial aims to investigate the effect of VGH-AD1, a scientific Chinese medicine powder prescription, on patients with Alzheimer's disease.","[(14, 42, 'OTHER', 'Traditional Chinese Medicine'), (44, 51, 'OTHER', 'VGH-AD1'), (70, 89, 'CONDITION', ""Alzheimer's Disease""), (119, 126, 'CONTROL', 'Placebo'), (190, 197, 'CONTROL', 'placebo'), (269, 276, 'OTHER', 'VGH-AD1'), (291, 314, 'OTHER', 'Chinese medicine powder'), (346, 365, 'CONDITION', ""Alzheimer's disease"")]"
"['Dexmedetomidine', 'Versus', 'Triamcinolone', 'Local', 'Injection', 'for', 'Pain', 'Alleviation', 'in', 'Patients', 'With', 'Carpal', 'Tunnel', 'Syndrome', ';', 'A', 'Randomized', 'Clinical', 'Trial', '.', '|', 'Carpal', 'tunnel', 'syndrome', '(', 'CTS', ')', 'is', 'a', 'common', 'mononeuropathy', 'due', 'to', 'entrapment', 'of', 'the', 'median', 'nerve', 'in', 'the', 'carpal', 'tunnel', '.', 'a', 'lot', 'of', 'modalities', 'are', 'available', 'for', 'treatment', 'of', 'mild', 'to', 'moderate', 'CTS', '.']","['B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT05624866,NCT05624866,Dexmedetomidine Versus Triamcinolone Local Injection for Pain Alleviation in Patients With Carpal Tunnel Syndrome; A Randomized Clinical Trial. | Carpal tunnel syndrome (CTS) is a common mononeuropathy due to entrapment of the median nerve in the carpal tunnel. a lot of modalities are available for treatment of mild to moderate CTS.,"[(0, 15, 'DRUG', 'Dexmedetomidine'), (23, 36, 'DRUG', 'Triamcinolone'), (57, 61, 'CONDITION', 'Pain'), (91, 113, 'CONDITION', 'Carpal Tunnel Syndrome'), (146, 168, 'CONDITION', 'Carpal tunnel syndrome'), (170, 173, 'CONDITION', 'CTS'), (187, 201, 'CONDITION', 'mononeuropathy'), (313, 333, 'CONDITION', 'mild to moderate CTS')]"
"['A', 'Randomised', 'Controlled', 'Double', 'Blind', 'Trial', 'Of', 'Therapeutic', 'Ultrasound', 'in', 'Carpal', 'Tunnel', 'Syndrome', '(', 'CTS', ')', '|', 'Carpal', 'Tunnel', 'Syndrome', '(', 'CTS', ')', 'is', 'a', 'recognisable', 'pattern', 'of', 'symptoms', 'and', 'signs', ',', 'which', 'are', 'caused', 'by', 'compression', 'of', 'the', 'median', '(', 'middle', ')', 'nerve', 'as', 'it', 'passes', 'through', 'the', 'carpal', 'tunnel', 'at', 'the', 'wrist', '.', '\n\n', 'This', 'condition', 'affects', 'individuals', 'by', 'causing', 'pain', ',', 'numbness', ',', 'tingling', 'sensations', 'and', 'sometimes', 'weakness', 'in', 'the', 'fingers', 'and', 'may', 'extend', 'to', 'shoulder', 'and', 'neck', 'areas', '.', 'The', 'cause', 'for', 'most', 'cases', 'is', 'unknown', '(', 'idiopathic', ')', 'though', 'some', 'common', 'conditions', 'are', 'associated', 'with', 'an', 'increased', 'incidence', ',', 'including', 'obesity', ',', 'pregnancy', ',', 'hypothyroidism', ',', 'arthritis', ',', 'diabetes', ',', 'and', 'trauma', '.', '\n\n', 'Diagnosis', 'is', 'primarily', 'clinical', 'and', 'the', 'condition', 'is', 'easily', 'recognised', 'from', 'the', 'characteristic', 'symptoms', 'in', 'straightforward', 'cases', 'but', 'diagnostic', 'support', 'is', 'provided', 'by', 'investigations', 'such', 'as', 'nerve', 'conduction', 'studies', 'and', 'ultrasound', 'imaging', '.', '\n\n', 'Treatment', 'may', 'include', 'splinting', ',', 'local', 'steroid', 'injection', 'at', 'wrist', ',', 'activity', 'modification', ',', 'physical', 'or', 'occupational', 'therapy', '(', 'controversial', ')', ',', 'medications', ',', 'and', 'surgery', '.', 'Treatment', 'with', 'local', 'therapeutic', 'ultrasound', 'has', 'been', 'suggested', 'to', 'be', 'effective', 'but', 'existing', 'trials', 'are', 'inconclusive', '.', '\n\n', 'Wrist', 'splinting', 'is', 'only', 'partially', 'effective', 'with', 'a', 'success', 'rate', 'of', '34', '%', ',', 'Steroid', 'injection', 'is', 'followed', 'by', 'frequent', 'relapses', 'and', 'there', 'remains', 'uncertainty', 'about', 'the', 'safety', 'of', 'serial', 'injections', '.', 'Surgery', 'is', 'effective', 'but', 'has', 'a', 'small', 'but', 'significant', 'incidence', 'of', 'permanent', 'complications', '.', 'Any', 'demonstrably', 'effective', 'and', 'safe', 'addition', 'to', 'the', 'therapeutic', 'options', 'would', 'be', 'a', 'significant', 'advance', 'in', 'treatment', '.', 'Therapeutic', 'ultrasound', 'at', 'present', 'appears', 'a', 'promising', 'option', ',', 'having', 'a', 'very', 'good', 'safety', 'record', 'but', 'so', 'far', 'uncertain', 'evidence', 'of', 'efficacy', '.', '\n\n', 'In', 'our', 'trial', 'patients', ',', 'with', 'mild', 'carpal', 'tunnel', 'syndrome', ',', 'confirmed', 'by', 'nerve', 'conduction', 'studies', ',', 'will', 'all', 'be', 'given', 'wrist', 'splints', 'so', 'that', 'no', 'patients', 'will', 'be', 'left', 'untreated', '.', 'They', 'will', 'be', 'randomly', 'allocated', 'to', 'either', 'therapeutic', 'or', 'sham', 'ultrasound', 'therapy', '(', '20', 'sessions', 'over', '7', 'weeks', ')', 'and', 'followed', 'up', 'for', '1year', '.', 'The', 'patients', ',', 'operators', 'of', 'the', 'ultrasound', 'equipment', 'and', 'assessors', 'will', 'all', 'be', 'blind', 'to', 'treatment', 'allocation', '.', '\n\n', 'The', 'effect', 'of', 'treatment', 'on', 'symptoms', 'will', 'be', 'assessed', 'using', 'a', 'validated', 'questionnaire', 'and', 'nerve', 'conduction', 'studies', 'will', 'be', 'repeated', 'at', 'completion', 'of', 'the', 'ultrasound', 'treatment', ',', '6', 'and', '12', 'months', '.', '\n\n', 'This', 'study', 'is', 'designed', 'to', 'find', 'out', 'to', 'whether', 'therapeutic', 'ultrasound', 'is', 'an', 'effective', 'treatment', 'for', 'carpal', 'tunnel', 'syndrome', '(', 'CTS', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT01590745,NCT01590745,"A Randomised Controlled Double Blind Trial Of Therapeutic Ultrasound in Carpal Tunnel Syndrome (CTS) | Carpal Tunnel Syndrome (CTS) is a recognisable pattern of symptoms and signs, which are caused by compression of the median (middle) nerve as it passes through the carpal tunnel at the wrist.

This condition affects individuals by causing pain, numbness, tingling sensations and sometimes weakness in the fingers and may extend to shoulder and neck areas. The cause for most cases is unknown (idiopathic) though some common conditions are associated with an increased incidence, including obesity, pregnancy, hypothyroidism, arthritis, diabetes, and trauma.

Diagnosis is primarily clinical and the condition is easily recognised from the characteristic symptoms in straightforward cases but diagnostic support is provided by investigations such as nerve conduction studies and ultrasound imaging.

Treatment may include splinting, local steroid injection at wrist, activity modification,physical or occupational therapy (controversial), medications, and surgery. Treatment with local therapeutic ultrasound has been suggested to be effective but existing trials are inconclusive.

Wrist splinting is only partially effective with a success rate of 34%, Steroid injection is followed by frequent relapses and there remains uncertainty about the safety of serial injections. Surgery is effective but has a small but significant incidence of permanent complications. Any demonstrably effective and safe addition to the therapeutic options would be a significant advance in treatment. Therapeutic ultrasound at present appears a promising option, having a very good safety record but so far uncertain evidence of efficacy.

In our trial patients, with mild carpal tunnel syndrome, confirmed by nerve conduction studies, will all be given wrist splints so that no patients will be left untreated. They will be randomly allocated to either therapeutic or sham ultrasound therapy (20 sessions over 7 weeks) and followed up for 1year. The patients, operators of the ultrasound equipment and assessors will all be blind to treatment allocation.

The effect of treatment on symptoms will be assessed using a validated questionnaire and nerve conduction studies will be repeated at completion of the ultrasound treatment, 6 and 12 months.

This study is designed to find out to whether therapeutic ultrasound is an effective treatment for carpal tunnel syndrome (CTS).","[(46, 68, 'OTHER', 'Therapeutic Ultrasound'), (72, 94, 'CONDITION', 'Carpal Tunnel Syndrome'), (96, 99, 'CONDITION', 'CTS'), (103, 125, 'CONDITION', 'Carpal Tunnel Syndrome'), (127, 130, 'CONDITION', 'CTS'), (1088, 1110, 'OTHER', 'therapeutic ultrasound'), (1585, 1607, 'OTHER', 'Therapeutic ultrasound'), (1757, 1779, 'CONDITION', 'carpal tunnel syndrome'), (1953, 1976, 'CONTROL', 'sham ultrasound therapy'), (2293, 2313, 'OTHER', 'ultrasound treatment'), (2379, 2401, 'OTHER', 'therapeutic ultrasound'), (2432, 2454, 'CONDITION', 'carpal tunnel syndrome'), (2456, 2459, 'CONDITION', 'CTS')]"
"['Telehealth', 'Virtual', 'Reality', 'Exergaming', 'and', 'Peer', 'Networking', 'Among', 'People', 'With', 'Spinal', 'Cord', 'Injury', '|', 'This', 'pilot', 'feasibility', 'study', 'aims', 'to', 'test', 'whether', 'youth', 'and', 'adults', 'with', 'spinal', 'cord', 'injury', 'can', 'use', 'a', 'group', 'virtual', 'reality', 'gaming', 'intervention', 'to', 'exercise', '.', 'A', 'second', 'purpose', 'is', 'to', 'examine', 'whether', 'there', 'are', 'potential', 'benefits', 'to', 'cardiometabolic', 'health', 'and', 'psychosocial', 'health', '.']","['B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05318079,NCT05318079,Telehealth Virtual Reality Exergaming and Peer Networking Among People With Spinal Cord Injury | This pilot feasibility study aims to test whether youth and adults with spinal cord injury can use a group virtual reality gaming intervention to exercise. A second purpose is to examine whether there are potential benefits to cardiometabolic health and psychosocial health.,"[(0, 37, 'PHYSICAL', 'Telehealth Virtual Reality Exergaming'), (42, 57, 'OTHER', 'Peer Networking'), (76, 94, 'CONDITION', 'Spinal Cord Injury'), (169, 187, 'CONDITION', 'spinal cord injury'), (198, 251, 'PHYSICAL', 'group virtual reality gaming intervention to exercise')]"
"['Comparison', 'Between', 'Natural', 'Sleep', 'Endoscopy', 'and', 'Drug', '-', 'induced', 'Sleep', 'Endoscopy', 'Among', 'Obstructive', 'Sleep', 'Apnea', 'Subjects', 'Referred', 'for', 'Surgical', 'Treatment', '|', 'Drug', 'induced', 'sleep', 'endoscopy', '(', 'DISE', ')', 'has', 'been', 'performed', 'worldwide', 'since', '1991', 'to', 'determine', 'the', 'site', 'and', 'configuration', 'of', 'upper', 'airway', 'obstruction', 'in', 'patients', 'with', 'obstructive', 'sleep', 'apnea', '(', 'OSA', ')', '.', 'However', ',', 'there', 'are', 'no', 'studies', 'comparing', 'DISE', 'to', 'sleep', 'endoscopy', 'during', 'natural', 'sleep', '.', 'Objectives', ':', 'To', 'compare', 'DISE', 'to', 'natural', 'sleep', 'endoscopy', 'in', 'OSA', 'patients', 'referred', 'for', 'surgical', 'treatment', '.', '\n\n', 'Methods', ':', 'OSA', 'patients', 'referred', 'to', 'surgical', 'treatment', '(', 'lateral', 'pharyngoplasty', ')', 'will', 'be', 'enrolled', 'in', 'this', 'study', '.', 'Natural', 'sleep', 'endoscopy', 'will', 'be', 'performed', 'at', 'the', 'sleep', 'lab', 'during', 'the', 'night', '.', 'Propofol', 'induced', 'sleep', 'will', 'be', 'performed', 'at', 'the', 'operating', 'room', 'before', 'surgery', '.', 'The', 'VOTE', '(', 'velum', ',', 'oropharyngeal', 'lateral', 'walls', ',', 'tongue', 'base', 'and', 'epiglottis', ')', 'classification', 'will', 'be', 'used', 'to', 'compare', 'site', 'and', 'configuration', 'of', 'collapse', 'between', 'studies', '.', 'Peak', 'inspiratory', 'flow', 'will', 'also', 'be', 'compared', 'between', 'studies', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03004014,NCT03004014,"Comparison Between Natural Sleep Endoscopy and Drug-induced Sleep Endoscopy Among Obstructive Sleep Apnea Subjects Referred for Surgical Treatment | Drug induced sleep endoscopy (DISE) has been performed worldwide since 1991 to determine the site and configuration of upper airway obstruction in patients with obstructive sleep apnea (OSA). However, there are no studies comparing DISE to sleep endoscopy during natural sleep. Objectives: To compare DISE to natural sleep endoscopy in OSA patients referred for surgical treatment.

Methods: OSA patients referred to surgical treatment (lateral pharyngoplasty) will be enrolled in this study. Natural sleep endoscopy will be performed at the sleep lab during the night. Propofol induced sleep will be performed at the operating room before surgery. The VOTE (velum, oropharyngeal lateral walls, tongue base and epiglottis) classification will be used to compare site and configuration of collapse between studies. Peak inspiratory flow will also be compared between studies.","[(82, 105, 'CONDITION', 'Obstructive Sleep Apnea'), (310, 333, 'CONDITION', 'obstructive sleep apnea'), (335, 338, 'CONDITION', 'OSA'), (485, 488, 'CONDITION', 'OSA'), (541, 544, 'CONDITION', 'OSA')]"
"['The', 'Therapeutic', 'Effect', 'of', 'the', 'Rehabotics', 'Medical', 'Technology', 'Corporation', '(', 'RMTC', ')', 'Finger', '-', 'hand', 'Robot', 'on', 'Upper', '-', 'limb', 'Rehabilitation', 'of', 'Stroke', 'Patients', '|', 'In', 'the', 'present', 'study', ',', 'the', 'RMTC', 'finger', '-', 'hand', 'robot', 'and', 'combined', 'with', 'the', 'mechanism', 'of', 'neuroplasticity', 'will', 'be', 'used', 'on', 'the', 'upper', '-', 'limb', 'rehabilitation', 'of', 'stroke', 'patients', '.', 'The', 'participants', 'will', 'be', 'randomized', 'assigned', 'to', 'treatment', 'group', '(', 'TG', ',', 'robot', 'assisted', 'treatment', ')', 'and', 'control', 'group', '(', 'CG', ',', 'conventional', 'treatment', ')', '.', 'In', 'the', 'experimental', 'group', ',', 'task', 'oriented', 'bi', '-', 'manual', 'training', 'will', 'be', 'applied', 'using', 'the', 'unaffected', 'hand', 'to', 'guide', 'the', 'affected', 'hand', 'by', 'RMTC', 'robot', 'system', '.', 'The', 'investigators', 'will', 'estimate', 'the', 'motor', 'function', 'of', 'distal', 'part', 'of', 'upper', '-', 'limb', 'before', 'and', 'after', 'treatments', '.', 'The', 'results', 'will', 'be', 'compared', 'with', 'the', 'convention', 'rehabilitation', 'treatment', '.', 'The', 'primary', 'outcomes', 'are', 'Fugl', '-', 'Meyer', 'assessment', '(', 'FMA', ')', ';', 'and', 'the', 'secondary', 'outcome', 'measurements', 'are', 'modified', 'Ashworth', 'scale', '(', 'MAS),Action', 'Reach', 'Arm', 'Test', '(', 'ARAT', ')', ',', 'Box', '&', 'block', 'test、Brunnstrom', 'recovery', 'Stage', ',', 'and', 'motor', 'activity', 'log', '(', 'MAL', ')', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03841695,NCT03841695,"The Therapeutic Effect of the Rehabotics Medical Technology Corporation (RMTC) Finger-hand Robot on Upper-limb Rehabilitation of Stroke Patients | In the present study, the RMTC finger-hand robot and combined with the mechanism of neuroplasticity will be used on the upper-limb rehabilitation of stroke patients. The participants will be randomized assigned to treatment group (TG, robot assisted treatment) and control group (CG, conventional treatment). In the experimental group, task oriented bi-manual training will be applied using the unaffected hand to guide the affected hand by RMTC robot system. The investigators will estimate the motor function of distal part of upper-limb before and after treatments. The results will be compared with the convention rehabilitation treatment. The primary outcomes are Fugl-Meyer assessment (FMA); and the secondary outcome measurements are modified Ashworth scale (MAS),Action Reach Arm Test (ARAT), Box & block test、Brunnstrom recovery Stage, and motor activity log (MAL).","[(30, 96, 'OTHER', 'Rehabotics Medical Technology Corporation (RMTC) Finger-hand Robot'), (100, 125, 'PHYSICAL', 'Upper-limb Rehabilitation'), (129, 135, 'CONDITION', 'Stroke'), (173, 195, 'OTHER', 'RMTC finger-hand robot'), (267, 292, 'PHYSICAL', 'upper-limb rehabilitation'), (296, 302, 'CONDITION', 'stroke'), (382, 406, 'OTHER', 'robot assisted treatment'), (431, 453, 'CONTROL', 'conventional treatment'), (483, 515, 'OTHER', 'task oriented bi-manual training'), (588, 605, 'OTHER', 'RMTC robot system'), (754, 789, 'CONTROL', 'convention rehabilitation treatment')]"
"['Video', 'Game', 'Rehabilitation', 'for', 'Outpatient', 'Stroke', '(', 'VIGoROUS', '):', 'A', 'Multi', '-', 'center', 'Comparative', 'Effectiveness', 'Trial', 'of', 'In', '-', 'home', 'Gamified', 'Constraint', '-', 'induced', 'Movement', 'Therapy', 'for', 'Rehabilitation', 'of', 'Chronic', 'Upper', 'Extremity', 'Hemiparesis', '.', '|', 'The', 'current', 'proposal', 'aims', 'to', 'conduct', 'a', 'multi', '-', 'site', 'randomized', 'controlled', 'trial', 'comparing', 'virtual', '-', 'reality', 'gaming', 'delivery', 'of', 'Constraint', 'Induced', 'Movement', 'therapy', '(', 'CI', 'therapy', ')', 'with', '(', '1', ')', 'traditional', 'clinic', '-', 'based', 'CI', 'therapy', 'of', 'equal', 'total', 'active', 'therapy', 'duration', 'and', '(', '2', ')', 'a', 'control', 'group', 'equating', 'the', 'dose', 'of', 'in', '-', 'person', 'therapy', '.', 'Individuals', 'with', 'chronic', 'stroke', 'will', 'be', 'randomized', 'to', 'one', 'of', 'four', 'different', 'interventions', ':', '(', '1', ')', 'traditional', 'clinic', '-', 'based', 'CI', 'therapy', '(', '35', 'therapist', '/', 'client', 'contact', 'hours', ')', ',', '(', '2', ')', 'therapist', '-', 'as', '-', 'consultant', 'virtual', 'reality', 'CI', 'therapy', '(', '5', 'therapist', '/', 'client', 'contact', 'hours', 'in', 'the', 'clinic', 'and', '15', 'hours', 'of', 'independent', 'game', 'play', 'at', 'home', ')', ',', '(', '3', ')', 'therapist', '-', 'as', '-', 'consultant', 'virtual', 'reality', 'CI', 'therapy', 'with', 'additional', 'therapist', 'contact', 'via', 'telerehabilitation', '(', '5', 'therapist', '/', 'client', 'contact', 'hours', 'in', 'the', 'clinic', ',', '2.6', 'therapist', 'contact', 'hours', 'via', 'teleconference', ',', 'and', '15', 'hours', 'of', 'independent', 'game', 'play', 'in', 'the', 'home', ')', ',', 'and', '(', '4', ')', '5', 'hours', 'of', 'standard', 'occupational', 'therapy', '(', 'OT', ')', '/', 'physical', 'therapy', '(', 'PT', ')', '.', 'After', '6', '-', 'month', 'follow', '-', 'up', ',', 'individuals', 'assigned', 'to', 'standard', 'OT', '/', 'PT', 'will', 'cross', 'over', 'to', 'a', 'modified', 'gaming', 'therapy', 'condition', '(', 'a', 'stand', '-', 'alone', 'application', 'of', 'the', 'rehabilitation', 'game', 'without', 'additional', 'therapist', 'contact', ')', '.']","['O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02631850,NCT02631850,"Video Game Rehabilitation for Outpatient Stroke (VIGoROUS): A Multi-center Comparative Effectiveness Trial of In-home Gamified Constraint-induced Movement Therapy for Rehabilitation of Chronic Upper Extremity Hemiparesis. | The current proposal aims to conduct a multi-site randomized controlled trial comparing virtual-reality gaming delivery of Constraint Induced Movement therapy (CI therapy) with (1) traditional clinic-based CI therapy of equal total active therapy duration and (2) a control group equating the dose of in-person therapy. Individuals with chronic stroke will be randomized to one of four different interventions: (1) traditional clinic-based CI therapy (35 therapist/client contact hours), (2) therapist-as-consultant virtual reality CI therapy (5 therapist/client contact hours in the clinic and 15 hours of independent game play at home), (3) therapist-as-consultant virtual reality CI therapy with additional therapist contact via telerehabilitation (5 therapist/client contact hours in the clinic, 2.6 therapist contact hours via teleconference, and 15 hours of independent game play in the home), and (4) 5 hours of standard occupational therapy (OT) / physical therapy (PT). After 6-month follow-up, individuals assigned to standard OT/PT will cross over to a modified gaming therapy condition (a stand-alone application of the rehabilitation game without additional therapist contact).","[(41, 47, 'CONDITION', 'Stroke'), (118, 162, 'PHYSICAL', 'Gamified Constraint-induced Movement Therapy'), (185, 220, 'CONDITION', 'Chronic Upper Extremity Hemiparesis'), (312, 334, 'OTHER', 'virtual-reality gaming'), (347, 382, 'PHYSICAL', 'Constraint Induced Movement therapy'), (384, 394, 'PHYSICAL', 'CI therapy'), (405, 440, 'CONTROL', 'traditional clinic-based CI therapy'), (561, 575, 'CONDITION', 'chronic stroke'), (639, 674, 'CONTROL', 'traditional clinic-based CI therapy'), (716, 766, 'PHYSICAL', 'therapist-as-consultant virtual reality CI therapy'), (867, 917, 'PHYSICAL', 'therapist-as-consultant virtual reality CI therapy'), (956, 974, 'OTHER', 'telerehabilitation'), (1152, 1172, 'OTHER', 'occupational therapy'), (1174, 1176, 'OTHER', 'OT'), (1180, 1196, 'PHYSICAL', 'physical therapy'), (1198, 1200, 'PHYSICAL', 'PT'), (1261, 1263, 'OTHER', 'OT'), (1264, 1266, 'PHYSICAL', 'PT'), (1288, 1311, 'OTHER', 'modified gaming therapy'), (1356, 1375, 'OTHER', 'rehabilitation game')]"
"['Play', 'Intervention', 'for', 'Dementia', 'for', 'Promoting', 'Cognitive', 'Function', '|', 'This', 'study', 'intends', 'to', 'use', 'Play', 'Intervention', 'for', 'Dementia', '(', 'PID', ')', 'to', 'promote', 'cognitive', 'functions', 'of', 'people', 'with', 'early', 'to', 'moderate', 'dementia', '.', '\n\n', 'This', 'is', 'a', 'cluster', 'randomized', 'controlled', 'trial', 'aims', 'to', 'recruit', '38', 'participants', 'from', 'two', 'study', 'sites', '.', 'Participants', 'will', 'be', 'randomly', 'allocated', 'into', 'intervention', 'or', 'wait', '-', 'list', 'controlled', 'groups', '.', 'Both', 'groups', 'will', 'receive', 'the', 'same', 'content', 'of', 'PID', 'programme', 'at', 'different', 'time', '.', 'The', 'PID', 'consists', 'of', '12', 'weekly', 'sessions', '.', 'Each', 'session', 'lasts', 'for', '45', '-', '75', 'minutes', '.', 'The', 'PID', 'will', 'be', 'facilitated', 'by', 'a', 'play', 'specialist', ',', 'trained', 'elderly', 'volunteers', ',', 'and', 'centre', 'staffs', '.', 'Cognitive', 'functions', 'will', 'be', 'evaluated', 'with', 'Montreal', 'Cognitive', 'Assessment', ',', 'Fuld', 'Object', 'Memory', 'Evaluation', 'and', 'Modified', 'Verbal', 'Fluency', 'Test', ',', 'conducted', 'by', 'a', 'trained', 'research', 'assistant', 'blinded', 'to', 'group', 'allocation', '.', 'Centre', 'staffs', '(', 'not', 'involved', 'in', 'the', 'PID', ')', 'will', 'be', 'interviewed', '.', 'Every', 'alternate', 'session', 'will', 'be', 'video', '-', 'taped', 'for', 'understanding', 'the', 'experience', 'of', 'the', 'participants', 'in', 'the', 'PID', 'programme', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O']",NCT02846415,NCT02846415,"Play Intervention for Dementia for Promoting Cognitive Function | This study intends to use Play Intervention for Dementia (PID) to promote cognitive functions of people with early to moderate dementia.

This is a cluster randomized controlled trial aims to recruit 38 participants from two study sites. Participants will be randomly allocated into intervention or wait-list controlled groups. Both groups will receive the same content of PID programme at different time. The PID consists of 12 weekly sessions. Each session lasts for 45-75 minutes. The PID will be facilitated by a play specialist, trained elderly volunteers, and centre staffs. Cognitive functions will be evaluated with Montreal Cognitive Assessment, Fuld Object Memory Evaluation and Modified Verbal Fluency Test, conducted by a trained research assistant blinded to group allocation. Centre staffs (not involved in the PID) will be interviewed. Every alternate session will be video-taped for understanding the experience of the participants in the PID programme.","[(0, 30, 'OTHER', 'Play Intervention for Dementia'), (92, 122, 'OTHER', 'Play Intervention for Dementia'), (124, 127, 'OTHER', 'PID'), (175, 201, 'CONDITION', 'early to moderate dementia'), (365, 374, 'CONTROL', 'wait-list'), (439, 452, 'OTHER', 'PID programme'), (476, 479, 'OTHER', 'PID'), (554, 557, 'OTHER', 'PID'), (891, 894, 'OTHER', 'PID'), (1021, 1034, 'OTHER', 'PID programme')]"
"['Local', 'Site', 'Tolerability', 'of', 'Multiple', 'Dose', 'Treatment', 'With', 'Deltoid', 'Intramuscular', 'Injection', 'of', 'RISPERDAL', 'CONSTA', 'in', 'Subjects', 'With', 'Chronic', 'Schizophrenia', '.', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'examine', 'the', 'discontinuation', 'rate', 'of', 'schizophrenia', 'patients', 'receiving', 'multiple', 'sequential', '2', 'mL', 'injections', 'of', 'long', 'acting', 'injectable', 'risperidone', '(', 'an', 'atypical', 'antipsychotic', 'medication', ')', 'when', 'administered', 'into', 'the', 'deltoid', 'muscle', 'once', 'every', '2', 'weeks', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00828958,NCT00828958,Local Site Tolerability of Multiple Dose Treatment With Deltoid Intramuscular Injection of RISPERDAL CONSTA in Subjects With Chronic Schizophrenia. | The purpose of this study is to examine the discontinuation rate of schizophrenia patients receiving multiple sequential 2 mL injections of long acting injectable risperidone (an atypical antipsychotic medication) when administered into the deltoid muscle once every 2 weeks.,"[(91, 100, 'DRUG', 'RISPERDAL'), (125, 146, 'CONDITION', 'Chronic Schizophrenia'), (218, 231, 'CONDITION', 'schizophrenia'), (313, 324, 'DRUG', 'risperidone')]"
"['Fetoscopic', 'Spina', 'Bifida', 'Repair', 'Using', 'a', 'Cryopreserved', 'Human', 'Umbilical', 'Cord', 'Allograft', '(', 'NEOX', 'Cord', '1', 'K', '®', ')', 'as', 'a', 'Meningeal', 'Patch', '|', 'To', 'fetoscopically', 'use', 'cryopreserved', 'human', 'umbilical', 'cord', 'allografts', ',', 'named', 'NEOX', 'Cord', '1', 'K', '®', ',', 'as', 'a', 'spinal', 'cord', 'cover', 'of', 'spina', 'bifida', 'defects', '.', 'This', 'procedure', 'will', 'be', 'performed', 'to', 'create', 'a', 'watertight', 'seal', 'covering', 'over', 'the', 'spinal', 'cord', 'in', 'order', 'to', 'decrease', 'the', 'incidence', 'rates', 'of', 'postnatal', 'morbidities', '.', 'For', 'larger', 'skin', 'defects', ',', 'NEOX', 'Cord', '1', 'K', '®', 'may', 'be', 'used', 'as', 'a', 'skin', 'cover', '.']","['B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04243889,NCT04243889,"Fetoscopic Spina Bifida Repair Using a Cryopreserved Human Umbilical Cord Allograft (NEOX Cord 1K®) as a Meningeal Patch | To fetoscopically use cryopreserved human umbilical cord allografts, named NEOX Cord 1K®, as a spinal cord cover of spina bifida defects. This procedure will be performed to create a watertight seal covering over the spinal cord in order to decrease the incidence rates of postnatal morbidities. For larger skin defects, NEOX Cord 1K® may be used as a skin cover.","[(0, 30, 'SURGICAL', 'Fetoscopic Spina Bifida Repair'), (39, 83, 'SURGICAL', 'Cryopreserved Human Umbilical Cord Allograft'), (85, 97, 'SURGICAL', 'NEOX Cord 1K'), (145, 191, 'SURGICAL', 'cryopreserved human umbilical cord allografts,'), (198, 210, 'SURGICAL', 'NEOX Cord 1K'), (239, 251, 'CONDITION', 'spina bifida'), (430, 442, 'CONDITION', 'skin defects'), (444, 456, 'SURGICAL', 'NEOX Cord 1K')]"
"['Systemic', 'Hemodynamics', 'and', 'Cerebral', 'Blood', 'Flow', 'in', 'Persons', 'With', 'Tetraplegia', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'how', 'blood', 'pressure', 'and', 'blood', 'flow', 'are', 'controlled', 'during', 'head', '-', 'up', 'tilt', 'in', 'a', 'semi', '-', 'upright', 'position', '.', 'In', 'this', 'investigation', 'we', 'are', 'studying', 'blood', 'pressure', 'and', 'blood', 'flow', 'to', 'the', 'brain', ',', 'with', 'and', 'without', 'a', 'medication', 'which', 'lowers', 'blood', 'pressure', '(', 'Vasotec', ')', '.', 'We', 'will', 'determine', 'how', 'persons', 'with', 'a', 'spinal', 'cord', 'injury', 'are', 'able', 'to', 'maintain', 'blood', 'flow', 'to', 'the', 'brain', '(', 'not', 'get', 'dizzy', ')', 'as', 'they', 'assume', 'a', 'more', 'upright', 'position', 'and', 'their', 'blood', 'pressure', 'decreases', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00248807,NCT00248807,"Systemic Hemodynamics and Cerebral Blood Flow in Persons With Tetraplegia | The purpose of this study is to determine how blood pressure and blood flow are controlled during head-up tilt in a semi-upright position. In this investigation we are studying blood pressure and blood flow to the brain, with and without a medication which lowers blood pressure (Vasotec). We will determine how persons with a spinal cord injury are able to maintain blood flow to the brain (not get dizzy) as they assume a more upright position and their blood pressure decreases.","[(62, 73, 'CONDITION', 'Tetraplegia'), (356, 363, 'DRUG', 'Vasotec'), (403, 421, 'CONDITION', 'spinal cord injury')]"
"['Impact', 'of', 'an', 'Orthotic', 'Garment', 'on', 'Gross', 'Motor', 'Skill', 'Acquisition', 'for', 'Infants', 'With', 'Down', 'Syndrome', '|', 'Infants', 'with', 'Down', 'syndrome', '(', 'DS', ')', 'develop', 'slower', 'than', 'their', 'typically', 'developing', 'peers', '.', 'Physical', 'therapist', '(', 'PT', ')', 'supervised', 'home', 'programs', 'have', 'the', 'potential', 'to', 'optimize', 'gross', 'motor', 'development', 'in', 'a', 'financially', 'feasible', 'way', '.', 'An', 'inexpensive', 'orthotic', 'garment', '(', 'Hip', 'Helpers', '®', ')', 'is', 'commonly', 'employed', 'by', 'PTs', 'as', 'a', 'home', 'program', 'supplement', ',', 'but', 'its', 'effectiveness', 'has', 'not', 'yet', 'been', 'investigated', '.', 'The', 'garment', 'is', 'worn', 'as', 'pliable', 'shorts', 'over', 'a', 'child', ""'s"", 'lower', 'extremities', 'to', 'keep', 'upper', 'legs', 'together', ',', 'promoting', 'a', 'narrow', 'base', 'of', 'support', '.', 'This', 'encourages', 'activation', 'of', 'upright', 'postural', 'muscles', 'to', 'improve', 'gross', 'motor', 'skill', 'development', '.', 'The', 'purpose', 'of', 'this', 'randomized', 'controlled', 'study', 'is', 'to', 'investigate', 'the', 'impact', 'of', 'a', 'home', 'program', 'using', 'the', 'Hip', 'Helpers', '®', 'orthotic', 'garment', 'on', 'gross', 'motor', 'skill', 'acquisition', 'in', 'infants', 'with', 'DS', '.', 'We', 'hypothesize', 'that', 'the', 'addition', 'of', 'a', 'structured', 'home', 'program', 'using', 'Hip', 'Helpers', '®', ',', 'supervised', 'by', 'a', 'PT', 'and', 'implemented', 'by', 'parents', ',', 'will', 'increase', 'the', 'rate', 'at', 'which', 'infants', 'with', 'DS', 'acquire', 'gross', 'motor', 'skills', '.', 'Thirty', '-', 'four', 'participants', ',', 'consisting', 'of', 'children', 'who', 'are', 'at', 'least', 'three', '-', 'months', '-', 'old', 'and', 'are', 'not', 'yet', 'able', 'maintain', 'sitting', 'independently', ',', 'will', 'be', 'randomly', 'assigned', 'to', 'a', 'control', '(', 'n=17', ')', 'or', 'intervention', 'group', '(', 'n=17', ')', '.', 'PTs', 'at', 'pediatric', 'therapy', 'agencies', 'will', 'initiate', 'the', 'home', 'program', 'and', 'administer', 'the', 'Gross', 'Motor', 'Function', 'Measure-88', '(', 'GMFM-88', ')', 'at', 'regular', 'intervals', 'to', 'monitor', 'gross', 'motor', 'skill', 'acquisition', 'until', 'the', 'child', 'is', 'able', 'to', 'take', 'three', 'independent', 'steps', '.', 'Groups', 'will', 'be', 'compared', 'on', 'the', 'length', 'of', 'time', 'elapsed', 'between', 'the', 'acquisition', 'of', 'identified', 'gross', 'motor', 'skills', 'using', 'independent', 't', '-', 'tests', '.', 'GMFM-88', 'scores', 'will', 'be', 'compared', 'between', 'the', 'two', 'groups', 'at', 'different', 'ages', 'to', 'identify', 'trends', 'using', 'independent', 't', '-', 'tests', '.', 'The', 'contribution', 'of', 'this', 'project', 'will', 'be', 'significant', 'by', 'informing', 'physical', 'therapists', 'about', 'the', 'effectiveness', 'of', 'an', 'inexpensive', 'orthotic', 'garment', 'used', 'in', 'a', 'supervised', 'home', 'program', 'on', 'gross', 'motor', 'outcomes', 'in', 'infants', 'with', 'DS', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT04603352,NCT04603352,"Impact of an Orthotic Garment on Gross Motor Skill Acquisition for Infants With Down Syndrome | Infants with Down syndrome (DS) develop slower than their typically developing peers. Physical therapist (PT) supervised home programs have the potential to optimize gross motor development in a financially feasible way. An inexpensive orthotic garment (Hip Helpers®) is commonly employed by PTs as a home program supplement, but its effectiveness has not yet been investigated. The garment is worn as pliable shorts over a child's lower extremities to keep upper legs together, promoting a narrow base of support. This encourages activation of upright postural muscles to improve gross motor skill development. The purpose of this randomized controlled study is to investigate the impact of a home program using the Hip Helpers® orthotic garment on gross motor skill acquisition in infants with DS. We hypothesize that the addition of a structured home program using Hip Helpers®, supervised by a PT and implemented by parents, will increase the rate at which infants with DS acquire gross motor skills. Thirty-four participants, consisting of children who are at least three-months-old and are not yet able maintain sitting independently, will be randomly assigned to a control (n=17) or intervention group (n=17). PTs at pediatric therapy agencies will initiate the home program and administer the Gross Motor Function Measure-88 (GMFM-88) at regular intervals to monitor gross motor skill acquisition until the child is able to take three independent steps. Groups will be compared on the length of time elapsed between the acquisition of identified gross motor skills using independent t-tests. GMFM-88 scores will be compared between the two groups at different ages to identify trends using independent t-tests. The contribution of this project will be significant by informing physical therapists about the effectiveness of an inexpensive orthotic garment used in a supervised home program on gross motor outcomes in infants with DS.","[(13, 29, 'OTHER', 'Orthotic Garment'), (80, 93, 'CONDITION', 'Down Syndrome'), (109, 122, 'CONDITION', 'Down syndrome'), (124, 126, 'CONDITION', 'DS'), (182, 230, 'PHYSICAL', 'Physical therapist (PT) supervised home programs'), (332, 348, 'OTHER', 'orthotic garment'), (350, 361, 'OTHER', 'Hip Helpers'), (397, 409, 'PHYSICAL', 'home program'), (790, 802, 'PHYSICAL', 'home program'), (813, 842, 'OTHER', 'Hip Helpers® orthotic garment'), (892, 894, 'CONDITION', 'DS'), (945, 957, 'PHYSICAL', 'home program'), (964, 975, 'OTHER', 'Hip Helpers'), (1070, 1072, 'CONDITION', 'DS'), (1268, 1275, 'CONTROL', 'control'), (1365, 1377, 'PHYSICAL', 'home program'), (1943, 1959, 'OTHER', 'orthotic garment'), (1981, 1993, 'PHYSICAL', 'home program'), (2034, 2036, 'CONDITION', 'DS')]"
"['Enhancing', 'Function', 'Using', 'the', 'RF', 'Microstimulator', 'Gait', 'System', 'Following', 'Stroke', '2008', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'investigate', 'new', 'Technology', 'for', 'recovery', 'of', 'ankle', 'walking', 'function', 'after', 'stroke', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT00864708,NCT00864708,Enhancing Function Using the RF Microstimulator Gait System Following Stroke 2008 | The purpose of the study is to investigate new Technology for recovery of ankle walking function after stroke.,"[(29, 59, 'OTHER', 'RF Microstimulator Gait System'), (70, 76, 'CONDITION', 'Stroke'), (131, 154, 'OTHER', 'Technology for recovery'), (187, 193, 'CONDITION', 'stroke')]"
"['A', 'High', '-', 'Performance', 'ECoG', '-', 'based', 'Neural', 'Interface', 'for', 'Communication', 'and', 'Neuroprosthetic', 'Control', '|', 'Test', 'the', 'feasibility', 'of', 'using', 'electrocorticography', '(', 'ECoG', ')', 'signals', 'to', 'control', 'complex', 'devices', 'for', 'motor', 'and', 'speech', 'control', 'in', 'adults', 'severely', 'affected', 'by', 'neurological', 'disorders', '.']","['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03698149,NCT03698149,A High-Performance ECoG-based Neural Interface for Communication and Neuroprosthetic Control | Test the feasibility of using electrocorticography (ECoG) signals to control complex devices for motor and speech control in adults severely affected by neurological disorders.,"[(2, 46, 'OTHER', 'High-Performance ECoG-based Neural Interface')]"
"['Effectiveness', 'of', 'Dry', 'Needling', 'and', 'Intramuscular', 'Electrostimulation', 'in', 'the', 'Treatment', 'of', 'Myofascial', 'Trigger', 'Points', 'in', 'Patients', 'With', 'Neck', 'Pain', '|', 'Hypothesis', 'The', 'application', 'of', 'intramuscular', 'electrostimulation', 'will', 'be', 'more', 'effectiveness', 'than', 'the', 'dry', 'needling', 'in', 'myofascial', 'trigger', 'points', 'treatment', '.', '\n\n', 'Objetives', ':', '\n\n', 'To', 'determine', 'the', 'effectiveness', 'of', 'intramuscular', 'electrostimulation', 'in', 'the', 'treatment', 'of', 'trigger', 'points', 'of', 'the', 'levator', 'scapula', 'muscle', 'for', 'the', 'improvement', 'of', 'pain', 'in', 'mechanical', 'cervicalgia', '.', '\n\n', 'Participants', ':', 'Subjects', 'with', 'diagnosed', 'of', 'myofascial', 'pain', 'syndrome', 'in', 'cervical', 'region', 'and', 'active', 'trigger', 'points', 'in', 'levator', 'scapulae', 'muscle', ',', 'randomly', 'assigned', 'to', 'experimental', 'or', 'control', 'group', '.', '\n\n', 'Intervention', ':', 'Control', 'group', ':', 'one', 'session', 'of', 'dry', 'needling', 'in', 'active', 'trigger', 'points', ';', 'experimental', 'group', ':', 'one', 'session', 'of', 'intramuscular', 'stimulation', 'in', 'active', 'trigger', 'points', '.', '\n\n', 'Main', 'Outcomes', 'Measures', ':', 'Pain', ',', 'pressure', 'pain', 'threshold', '(', 'PPT', ')', ',', 'active', 'cervical', 'range', 'of', 'motion', 'and', 'strength', 'muscle', '.', 'The', 'measures', 'will', 'be', 'taken', 'before', ',', 'after', 'and', 'one', 'week', 'after', 'the', 'interventions', '.']","['O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03025230,NCT03025230,"Effectiveness of Dry Needling and Intramuscular Electrostimulation in the Treatment of Myofascial Trigger Points in Patients With Neck Pain | Hypothesis The application of intramuscular electrostimulation will be more effectiveness than the dry needling in myofascial trigger points treatment.

Objetives:

To determine the effectiveness of intramuscular electrostimulation in the treatment of trigger points of the levator scapula muscle for the improvement of pain in mechanical cervicalgia.

Participants: Subjects with diagnosed of myofascial pain syndrome in cervical region and active trigger points in levator scapulae muscle, randomly assigned to experimental or control group.

Intervention: Control group: one session of dry needling in active trigger points; experimental group: one session of intramuscular stimulation in active trigger points.

Main Outcomes Measures: Pain, pressure pain threshold (PPT), active cervical range of motion and strength muscle . The measures will be taken before, after and one week after the interventions.","[(17, 29, 'CONTROL', 'Dry Needling'), (34, 66, 'OTHER', 'Intramuscular Electrostimulation'), (87, 112, 'CONDITION', 'Myofascial Trigger Points'), (130, 139, 'CONDITION', 'Neck Pain'), (172, 204, 'OTHER', 'intramuscular electrostimulation'), (241, 253, 'CONTROL', 'dry needling'), (257, 282, 'CONDITION', 'myofascial trigger points'), (394, 438, 'CONDITION', 'trigger points of the levator scapula muscle'), (462, 466, 'CONDITION', 'pain'), (470, 492, 'CONDITION', 'mechanical cervicalgia'), (536, 560, 'CONDITION', 'myofascial pain syndrome'), (591, 632, 'CONDITION', 'trigger points in levator scapulae muscle'), (731, 743, 'CONTROL', 'dry needling'), (805, 830, 'OTHER', 'intramuscular stimulation')]"
"['Tryptophan', 'Depletion', 'in', 'Parkinson', ""'s"", 'Disease', 'Patients', 'Treated', 'With', 'Deep', 'Brain', 'Stimulation', 'of', 'the', 'Subthalamic', 'Nucleus', ':', 'Effects', 'on', 'Mood', 'and', 'Motor', 'Functions', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'assess', 'the', 'effect', 'of', 'tryptophan', 'depletion', 'on', 'mood', 'and', 'behavior', 'in', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', 'patients', 'treated', 'with', 'deep', 'brain', 'stimulation', '(', 'DBS', ')', 'of', 'the', 'subthalamic', 'nucleus', '(', 'STN', ')', '.', 'By', 'doing', 'this', ',', 'the', 'investigators', 'hope', 'to', 'be', 'able', 'to', 'identify', 'risk', 'factors', 'for', 'and', 'mechanisms', 'underlying', 'psychiatric', 'side', 'effects', 'of', 'STN', 'DBS', '.', 'The', 'study', 'will', 'be', 'an', 'intervention', 'study', 'with', 'a', 'placebo', 'controlled', ',', 'randomized', 'cross', '-', 'over', 'design', '.']","['B-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02632279,NCT02632279,"Tryptophan Depletion in Parkinson's Disease Patients Treated With Deep Brain Stimulation of the Subthalamic Nucleus: Effects on Mood and Motor Functions | The purpose of this study is to assess the effect of tryptophan depletion on mood and behavior in Parkinson's disease (PD) patients treated with deep brain stimulation (DBS) of the subthalamic nucleus (STN). By doing this, the investigators hope to be able to identify risk factors for and mechanisms underlying psychiatric side effects of STN DBS. The study will be an intervention study with a placebo controlled, randomized cross-over design.","[(0, 20, 'OTHER', 'Tryptophan Depletion'), (24, 43, 'CONDITION', ""Parkinson's Disease""), (66, 88, 'CONDITION', 'Deep Brain Stimulation'), (208, 228, 'OTHER', 'tryptophan depletion'), (253, 272, 'CONDITION', ""Parkinson's disease""), (274, 276, 'CONDITION', 'PD'), (300, 322, 'CONDITION', 'deep brain stimulation'), (324, 327, 'CONDITION', 'DBS'), (499, 502, 'CONDITION', 'DBS'), (551, 558, 'CONTROL', 'placebo')]"
"['A', 'Multi', '-', 'Center', ',', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', ',', 'Five', '-', 'Arm', 'Parallel', '-', 'Group', 'Trial', 'to', 'Investigate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Four', 'Different', 'Transdermal', 'Doses', 'of', 'Rotigotine', 'in', 'Subjects', 'With', 'Idiopathic', 'Restless', 'Legs', 'Syndrome', '|', 'Subjects', 'who', 'meet', 'the', 'diagnosis', 'of', 'idiopathic', 'restless', 'legs', 'syndrome', '(', 'RLS', ')', 'based', 'on', 'the', '4', 'cardinal', 'clinical', 'features', 'according', 'to', 'the', 'International', 'Restless', 'Legs', 'Syndrome', 'Study', 'Group', '(', 'IRLSSG', ')', 'are', 'allowed', 'to', 'enroll', 'in', 'this', 'trial', '.', '\n\n', 'The', 'primary', 'objective', 'of', 'this', 'trial', 'is', 'to', 'demonstrate', 'that', 'rotigotine', '(', 'SPM', '936', ')', 'is', 'efficacious', 'in', 'subjects', 'with', 'idiopathic', 'restless', 'legs', 'syndrome', '.', 'Additional', 'objectives', 'are', 'to', 'investigate', 'the', 'safety', 'and', 'tolerability', 'of', 'rotigotine', '.', '\n\n', 'Subjects', 'will', 'be', 'randomized', 'to', 'receive', 'either', 'placebo', ',', '1.125', ',', '2.25', ',', '4.5', ',', 'or', '6.75mg', '/', 'day', 'rotigotine', 'in', 'a', '1:1:1:1:1', '(', 'active', ':', 'placebo', ')', 'fashion', '.', 'Approximately', '600', 'subjects', 'will', 'be', 'enrolled', 'in', 'this', 'trial', ',', 'participating', 'at', 'approximately', '60', 'sites', '.', 'The', 'maximum', 'duration', 'of', 'the', 'trial', 'is', 'approximately', '8', 'months', '(', 'consisting', 'of', 'a', '4', '-', 'week', 'Titration', 'Period', ',', 'a', '6', '-', 'month', 'Maintenance', 'Period', ',', 'a', '7', '-', 'day', 'Taper', 'Period', ',', 'and', 'a', '30', '-', 'day', 'Safety', 'Follow', '-', 'Up', 'Period', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00135993,NCT00135993,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Five-Arm Parallel-Group Trial to Investigate the Efficacy and Safety of Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome | Subjects who meet the diagnosis of idiopathic restless legs syndrome (RLS) based on the 4 cardinal clinical features according to the International Restless Legs Syndrome Study Group (IRLSSG) are allowed to enroll in this trial.

The primary objective of this trial is to demonstrate that rotigotine (SPM 936) is efficacious in subjects with idiopathic restless legs syndrome. Additional objectives are to investigate the safety and tolerability of rotigotine.

Subjects will be randomized to receive either placebo, 1.125, 2.25, 4.5, or 6.75mg/day rotigotine in a 1:1:1:1:1 (active:placebo) fashion. Approximately 600 subjects will be enrolled in this trial, participating at approximately 60 sites. The maximum duration of the trial is approximately 8 months (consisting of a 4-week Titration Period, a 6-month Maintenance Period, a 7-day Taper Period, and a 30-day Safety Follow-Up Period).","[(42, 49, 'CONTROL', 'Placebo'), (170, 180, 'DRUG', 'Rotigotine'), (198, 231, 'CONDITION', 'Idiopathic Restless Legs Syndrome'), (269, 302, 'CONDITION', 'idiopathic restless legs syndrome'), (304, 307, 'CONDITION', 'RLS'), (523, 533, 'DRUG', 'rotigotine'), (535, 542, 'DRUG', 'SPM 936'), (576, 610, 'CONDITION', 'idiopathic restless legs syndrome.'), (683, 693, 'DRUG', 'rotigotine'), (742, 749, 'CONTROL', 'placebo'), (783, 793, 'DRUG', 'rotigotine')]"
"['Effects', 'of', 'Exergames', 'on', 'Post', '-', 'stroke', 'Shoulder', 'Pain', 'and', 'Motor', 'Function', '|', 'This', 'study', 'is', 'to', 'investigate', 'the', 'effects', 'of', 'exergame', 'on', 'shoulder', 'pain', 'and', 'motor', 'function', 'of', 'upper', 'extremity', 'in', 'individuals', 'with', 'stroke', '.']","['O', 'O', 'B-PHYS', 'O', 'O', 'O', 'B-COND', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT03716206,NCT03716206,Effects of Exergames on Post-stroke Shoulder Pain and Motor Function | This study is to investigate the effects of exergame on shoulder pain and motor function of upper extremity in individuals with stroke.,"[(11, 20, 'PHYSICAL', 'Exergames'), (29, 35, 'CONDITION', 'stroke'), (36, 49, 'CONDITION', 'Shoulder Pain'), (115, 123, 'PHYSICAL', 'exergame'), (127, 140, 'CONDITION', 'shoulder pain'), (199, 205, 'CONDITION', 'stroke')]"
"['Post', '-', 'prandial', 'Hypotension', 'and', 'Sleepiness', 'in', 'Parkinson', ""'s"", 'Disease', 'and', 'Other', 'Synucleinopathies', ':', 'the', 'Model', 'of', 'an', 'Oral', 'Glucose', 'Load', '|', 'Excessive', 'daytime', 'sleepiness', '(', 'EDS', ')', 'is', 'observed', 'in', '30', 'to', '50', '%', 'of', 'patients', 'with', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', 'patients', ',', 'Dementia', 'with', 'Lewy', 'Bodies', '(', 'DLB', ')', 'and', 'Multiple', 'System', 'Atrophy', '(', 'MSA', ')', '.', 'It', 'is', 'a', 'major', 'complain', 'and', 'represents', 'a', 'socially', 'relevant', 'problem', 'as', 'unintended', 'episodes', 'of', 'sleep', 'can', 'also', 'occur', 'while', 'driving', 'for', 'example', '.', 'Arterial', 'hypotension', 'is', 'frequently', 'observed', 'in', 'patients', 'with', 'PD', ',', 'DLB', 'and', 'MSA', 'and', 'considered', 'as', 'a', 'marker', 'of', 'autonomic', 'failure', '.', 'Sleepiness', 'is', 'known', 'to', 'occur', 'preferentially', 'when', 'patients', 'are', 'having', 'arterial', 'hypotension', 'whatever', 'the', 'cause', '(', 'i.e.', 'postprandial', 'period', ',', 'administration', 'of', 'hypotensive', 'medication', 'such', 'as', 'dopamine', 'agonists', ')', '.', 'We', 'hypothesize', 'that', 'arterial', 'hypotension', 'is', 'associated', 'with', 'abnormal', 'sleepiness', '.', 'We', 'have', 'observed', 'this', 'association', 'in', 'an', 'on', '-', 'going', 'epidemiological', 'survey', 'Hyperglycaemia', 'induced', 'by', 'oral', 'glucose', 'load', '-', 'a', 'standardized', 'model', 'simulating', 'food', 'intake', 'during', 'a', 'meal', '-', 'provokes', 'arterial', 'hypotension', 'in', 'the', 'majority', 'of', 'Parkinson', ""'s"", 'disease', 'patients', 'with', 'dysautonomia', '.', 'It', 'can', 'be', 'hypothesised', 'that', 'sleep', 'attacks', 'in', 'these', 'patients', 'could', 'be', 'mediated', 'by', 'this', 'fall', 'in', 'blood', 'pressure', '.']","['B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02021903,NCT02021903,"Post-prandial Hypotension and Sleepiness in Parkinson's Disease and Other Synucleinopathies: the Model of an Oral Glucose Load | Excessive daytime sleepiness (EDS) is observed in 30 to 50 % of patients with Parkinson's disease (PD) patients, Dementia with Lewy Bodies (DLB) and Multiple System Atrophy (MSA). It is a major complain and represents a socially relevant problem as unintended episodes of sleep can also occur while driving for example. Arterial hypotension is frequently observed in patients with PD, DLB and MSA and considered as a marker of autonomic failure. Sleepiness is known to occur preferentially when patients are having arterial hypotension whatever the cause (i.e. postprandial period, administration of hypotensive medication such as dopamine agonists). We hypothesize that arterial hypotension is associated with abnormal sleepiness. We have observed this association in an on-going epidemiological survey Hyperglycaemia induced by oral glucose load - a standardized model simulating food intake during a meal - provokes arterial hypotension in the majority of Parkinson's disease patients with dysautonomia. It can be hypothesised that sleep attacks in these patients could be mediated by this fall in blood pressure.","[(0, 25, 'CONDITION', 'Post-prandial Hypotension'), (30, 40, 'CONDITION', 'Sleepiness'), (44, 63, 'CONDITION', ""Parkinson's Disease""), (74, 91, 'CONDITION', 'Synucleinopathies'), (129, 157, 'CONDITION', 'Excessive daytime sleepiness'), (159, 162, 'CONDITION', 'EDS'), (207, 226, 'CONDITION', ""Parkinson's disease""), (228, 230, 'CONDITION', 'PD'), (242, 267, 'CONDITION', 'Dementia with Lewy Bodies'), (269, 272, 'CONDITION', 'DLB'), (278, 301, 'CONDITION', 'Multiple System Atrophy'), (303, 306, 'CONDITION', 'MSA'), (449, 469, 'CONDITION', 'Arterial hypotension'), (510, 512, 'CONDITION', 'PD'), (514, 517, 'CONDITION', 'DLB'), (522, 525, 'CONDITION', 'MSA'), (575, 585, 'CONDITION', 'Sleepiness'), (644, 664, 'CONDITION', 'arterial hypotension'), (800, 820, 'CONDITION', 'arterial hypotension'), (849, 859, 'CONDITION', 'sleepiness'), (1048, 1068, 'CONDITION', 'arterial hypotension'), (1088, 1107, 'CONDITION', ""Parkinson's disease""), (1164, 1177, 'CONDITION', 'sleep attacks')]"
"['A', 'Prospective', 'International', 'Multicentre', 'Randomised', 'Controlled', 'Single', 'Blind', 'Clinical', 'Investigation', 'of', 'Magnetically', 'Enhanced', 'Diffusion', 'for', 'Acute', 'Ischaemic', 'Stroke', '(', 'MEDIS', ')', '|', 'The', 'objective', 'of', 'the', 'MEDIS', 'study', 'is', 'to', 'determine', 'if', 'subjects', 'experiencing', 'an', 'Acute', 'Ischaemic', 'Stroke', 'due', 'to', 'large', 'vessel', 'occlusion', ',', 'treated', 'with', 'IV', 'tPA', 'combined', 'with', 'the', 'MED', 'procedure', 'have', 'a', 'greater', 'likelihood', 'of', 'recanalisation', '30', '-', '90', 'minutes', 'after', 'the', 'completion', 'of', 'tPA', 'infusion', 'than', 'subjects', 'treated', 'with', 'IV', 'tPA', '(', 'plus', 'sham', 'device', ')', '.', 'Safety', 'of', 'the', 'MED', 'System', 'Procedure', 'will', 'be', 'evaluated', 'by', 'the', 'incidence', 'of', 'symptomatic', 'PH-2', 'haemorrhagic', 'transformation', 'within', '24', 'hours', 'following', 'the', 'procedure', '.', 'Lastly', ',', 'a', 'health', 'economics', 'study', 'will', 'be', 'conducted', 'to', 'estimate', 'health', 'care', 'costs', 'for', 'each', 'treatment', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03098732,NCT03098732,"A Prospective International Multicentre Randomised Controlled Single Blind Clinical Investigation of Magnetically Enhanced Diffusion for Acute Ischaemic Stroke (MEDIS) | The objective of the MEDIS study is to determine if subjects experiencing an Acute Ischaemic Stroke due to large vessel occlusion, treated with IV tPA combined with the MED procedure have a greater likelihood of recanalisation 30-90 minutes after the completion of tPA infusion than subjects treated with IV tPA (plus sham device). Safety of the MED System Procedure will be evaluated by the incidence of symptomatic PH-2 haemorrhagic transformation within 24 hours following the procedure. Lastly, a health economics study will be conducted to estimate health care costs for each treatment.","[(101, 132, 'OTHER', 'Magnetically Enhanced Diffusion'), (137, 159, 'CONDITION', 'Acute Ischaemic Stroke'), (247, 269, 'CONDITION', 'Acute Ischaemic Stroke'), (277, 299, 'CONDITION', 'large vessel occlusion'), (317, 320, 'DRUG', 'tPA'), (339, 342, 'OTHER', 'MED'), (435, 438, 'DRUG', 'tPA'), (478, 481, 'DRUG', 'tPA'), (488, 499, 'CONTROL', 'sham device'), (516, 519, 'OTHER', 'MED')]"
"['Metformin', 'to', 'Prevent', 'Inactivity', '-', 'induced', 'Loss', 'of', 'Muscle', 'Health', 'During', 'Aging', '|', 'Muscle', 'atrophy', 'and', 'insulin', 'resistance', 'are', 'common', 'after', 'bed', 'rest', 'in', 'healthy', 'older', 'adults', '.', 'Metformin', 'treatment', 'has', 'been', 'shown', 'to', 'improve', 'insulin', 'sensitivity', 'and', 'attenuate', 'muscle', 'loss', 'in', 'insulin', 'resistance', 'adults', 'though', 'the', 'mechanisms', 'are', 'not', 'fully', 'known', '.', 'Metformin', 'used', 'as', 'a', 'preventive', 'strategy', 'to', 'maintain', 'muscle', 'and', 'metabolic', 'health', 'in', 'bed', 'ridden', 'older', 'adults', 'has', 'not', 'been', 'investigated', '.']","['B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03107884,NCT03107884,Metformin to Prevent Inactivity-induced Loss of Muscle Health During Aging | Muscle atrophy and insulin resistance are common after bed rest in healthy older adults. Metformin treatment has been shown to improve insulin sensitivity and attenuate muscle loss in insulin resistance adults though the mechanisms are not fully known. Metformin used as a preventive strategy to maintain muscle and metabolic health in bed ridden older adults has not been investigated.,"[(0, 9, 'DRUG', 'Metformin'), (40, 61, 'CONDITION', 'Loss of Muscle Health'), (77, 91, 'CONDITION', 'Muscle atrophy'), (96, 114, 'CONDITION', 'insulin resistance'), (166, 175, 'DRUG', 'Metformin'), (246, 257, 'CONDITION', 'muscle loss'), (261, 279, 'CONDITION', 'insulin resistance'), (330, 339, 'DRUG', 'Metformin')]"
"['Evaluation', 'of', 'Bioequivalence', 'of', 'Lamotrigine', 'Tablets', 'in', 'Epileptic', 'Patients', '|', 'In', 'this', 'study', ',', 'brand', 'name', 'lamotrigine', '(', 'LAMICTAL', ')', 'and', 'generic', 'lamotrigine', 'will', 'be', 'compared', 'in', 'patients', 'with', 'epilepsy', '.', 'Both', 'the', 'brand', 'name', 'and', 'generic', 'lamotrigine', 'are', 'approved', 'by', 'the', 'Food', 'and', 'Drug', 'Administration', '(', 'FDA', ')', 'and', 'are', 'commonly', 'used', 'to', 'treat', 'epilepsy', '.', 'Some', 'physicians', 'and', 'patients', 'with', 'epilepsy', 'have', 'believed', 'that', 'brand', 'and', 'generic', 'lamotrigine', 'have', 'had', 'clinically', 'significant', 'differences', 'in', 'efficacy', 'and', 'tolerability', '.', 'The', 'brand', 'name', 'and', 'generic', 'tablets', 'have', 'been', 'shown', 'to', 'be', 'the', 'same', 'when', 'blood', 'levels', 'were', 'measured', 'in', 'healthy', 'volunteers', 'without', 'epilepsy', ',', 'but', 'these', 'drugs', 'have', 'not', 'yet', 'been', 'compared', 'in', 'patients', 'with', 'epilepsy', '.', 'This', 'study', 'will', 'do', 'this', 'comparison', ',', 'by', 'switching', 'patients', 'between', 'brand', 'and', 'generic', 'in', 'a', 'very', 'structured', 'manner', ',', 'and', 'seeing', 'if', 'the', 'drugs', 'are', 'the', 'same', ',', 'primarily', 'in', 'terms', 'of', 'blood', 'levels', '.', 'Other', 'comparisons', 'will', 'also', 'be', 'made', 'secondarily', ',', 'looking', 'for', 'any', 'differences', 'in', 'adverse', 'effects', 'and', 'seizure', 'control', '.']","['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT01995825,NCT01995825,"Evaluation of Bioequivalence of Lamotrigine Tablets in Epileptic Patients | In this study, brand name lamotrigine (LAMICTAL) and generic lamotrigine will be compared in patients with epilepsy. Both the brand name and generic lamotrigine are approved by the Food and Drug Administration (FDA) and are commonly used to treat epilepsy. Some physicians and patients with epilepsy have believed that brand and generic lamotrigine have had clinically significant differences in efficacy and tolerability. The brand name and generic tablets have been shown to be the same when blood levels were measured in healthy volunteers without epilepsy, but these drugs have not yet been compared in patients with epilepsy. This study will do this comparison, by switching patients between brand and generic in a very structured manner, and seeing if the drugs are the same, primarily in terms of blood levels. Other comparisons will also be made secondarily, looking for any differences in adverse effects and seizure control.","[(32, 43, 'DRUG', 'Lamotrigine'), (55, 64, 'CONDITION', 'Epileptic'), (102, 113, 'DRUG', 'lamotrigine'), (115, 123, 'DRUG', 'LAMICTAL'), (137, 148, 'DRUG', 'lamotrigine'), (183, 191, 'CONDITION', 'epilepsy'), (225, 236, 'DRUG', 'lamotrigine'), (323, 331, 'CONDITION', 'epilepsy'), (367, 375, 'CONDITION', 'epilepsy'), (413, 424, 'DRUG', 'lamotrigine'), (627, 635, 'CONDITION', 'epilepsy'), (697, 705, 'CONDITION', 'epilepsy'), (994, 1001, 'CONDITION', 'seizure')]"
"['Safety', 'and', 'Tolerability', 'of', 'a', 'Protocol', 'of', 'Targeted', 'Temperature', 'Management', 'After', 'Intracerebral', 'Hemorrhage', '|', 'Early', 'hematoma', 'growth', '(', 'HG', ')', 'after', 'spontaneous', 'intra', '-', 'cerebral', '/', 'intra', '-', 'parenchymal', 'hemorrhage', '(', 'IPH', ')', 'is', 'common', 'and', 'associated', 'with', 'neurological', 'deterioration', 'and', 'poor', 'clinical', 'outcome', '.', 'Temperature', 'modulation', 'to', 'hypothermia', '(', 'Temperature', ',', '32', '-', '34', '°', 'C', ')', 'has', 'been', 'associated', 'with', 'reduction', 'or', 'improvement', 'of', 'physiopathologic', 'processes', 'associated', 'with', 'inflammatory', 'activation', 'and', 'degradation', 'of', 'blood', '-', 'brain', 'barrier', 'after', 'all', 'types', 'of', 'brain', 'injury', '.', 'In', 'this', 'sense', ',', 'we', 'believe', 'that', 'the', 'initiation', 'of', 'an', 'ultra', '-', 'early', 'protocol', 'of', 'active', 'temperature', 'modulation', 'or', 'Targeted', 'Temperature', 'Management', '(', 'TTM', ')', 'to', 'mild', 'induced', 'hypothermia', '(', 'MIH', ',', '32', '-', '34', '°', 'C', ')', 'may', 'be', 'associated', 'with', 'good', 'safety', 'and', 'tolerability', 'profile', ',', 'less', 'HG', 'and', 'cerebral', 'edema', 'after', 'IPH', 'by', 'modulation', 'of', 'systemic', 'and', 'local', 'inflammatory', 'responses', ',', 'so', 'we', 'hypothesize', 'that', 'TTM', 'to', 'MIH', 'will', 'be', 'a', 'safe', '/', 'tolerable', 'and', 'effective', 'therapy', 'to', 'limit', 'HG', 'and', 'cerebral', 'edema', 'after', 'IPH', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O']",NCT01866384,NCT01866384,"Safety and Tolerability of a Protocol of Targeted Temperature Management After Intracerebral Hemorrhage | Early hematoma growth (HG) after spontaneous intra-cerebral/intra-parenchymal hemorrhage (IPH) is common and associated with neurological deterioration and poor clinical outcome. Temperature modulation to hypothermia (Temperature, 32-34°C) has been associated with reduction or improvement of physiopathologic processes associated with inflammatory activation and degradation of blood-brain barrier after all types of brain injury. In this sense, we believe that the initiation of an ultra-early protocol of active temperature modulation or Targeted Temperature Management (TTM) to mild induced hypothermia (MIH, 32-34°C) may be associated with good safety and tolerability profile, less HG and cerebral edema after IPH by modulation of systemic and local inflammatory responses, so we hypothesize that TTM to MIH will be a safe/tolerable and effective therapy to limit HG and cerebral edema after IPH.","[(41, 72, 'OTHER', 'Targeted Temperature Management'), (79, 103, 'CONDITION', 'Intracerebral Hemorrhage'), (106, 127, 'CONDITION', 'Early hematoma growth'), (129, 131, 'CONDITION', 'HG'), (139, 194, 'CONDITION', 'spontaneous intra-cerebral/intra-parenchymal hemorrhage'), (196, 199, 'CONDITION', 'IPH'), (285, 307, 'OTHER', 'Temperature modulation'), (311, 322, 'OTHER', 'hypothermia'), (647, 678, 'OTHER', 'Targeted Temperature Management'), (680, 683, 'OTHER', 'TTM'), (688, 712, 'OTHER', 'mild induced hypothermia'), (714, 717, 'OTHER', 'MIH'), (794, 796, 'CONDITION', 'HG'), (801, 815, 'CONDITION', 'cerebral edema'), (822, 825, 'CONDITION', 'IPH'), (909, 912, 'OTHER', 'TTM'), (916, 919, 'OTHER', 'MIH'), (976, 978, 'CONDITION', 'HG'), (983, 997, 'CONDITION', 'cerebral edema'), (1004, 1007, 'CONDITION', 'IPH')]"
"['A', 'Phase', '3', ',', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', ',', 'Parallel', ',', 'Fixed', '-', 'Dose', 'Study', 'to', 'Assess', 'the', 'Efficacy', ',', 'Safety', ',', 'and', 'Tolerability', 'of', 'NBI-98854', 'for', 'the', 'Treatment', 'of', 'Tardive', 'Dyskinesia', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'efficacy', ',', 'safety', ',', 'and', 'tolerability', 'of', 'NBI-98854', 'administered', 'once', 'daily', 'for', 'the', 'treatment', 'of', 'Tardive', 'Dyskinesia', '(', 'TD', ')', 'symptoms', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O']",NCT02274558,NCT02274558,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia | The purpose of this study is to evaluate the efficacy, safety, and tolerability of NBI-98854 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.","[(37, 44, 'CONTROL', 'Placebo'), (136, 145, 'DRUG', 'NBI-98854'), (167, 185, 'CONDITION', 'Tardive Dyskinesia'), (271, 280, 'DRUG', 'NBI-98854'), (326, 344, 'CONDITION', 'Tardive Dyskinesia'), (346, 348, 'CONDITION', 'TD')]"
"['Fingolimod', 'as', 'a', 'Treatment', 'of', 'Cerebral', 'Edema', 'After', 'Intracerebral', 'Hemorrhage', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'test', 'the', 'safety', 'and', 'effectiveness', 'of', 'a', 'single', 'dose', 'of', 'fingolimod', 'in', 'patients', 'with', 'primary', 'spontaneous', 'intracerebral', 'hemorrhage', '(', 'ICH', ')', '.']","['B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT04088630,NCT04088630,Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage | The purpose of this study is to test the safety and effectiveness of a single dose of fingolimod in patients with primary spontaneous intracerebral hemorrhage (ICH).,"[(0, 10, 'DRUG', 'Fingolimod'), (29, 43, 'CONDITION', 'Cerebral Edema'), (50, 74, 'CONDITION', 'Intracerebral Hemorrhage'), (163, 173, 'DRUG', 'fingolimod'), (191, 235, 'CONDITION', 'primary spontaneous intracerebral hemorrhage'), (237, 240, 'CONDITION', 'ICH')]"
"['Pre', '-', 'recovery', 'Percutaneous', 'Biopsy', 'of', 'Livers', 'in', 'Neurological', 'Death', 'Organ', 'Donors', '-', 'A', 'Pilot', 'Study', '|', 'This', 'study', ""'s"", 'objective', 'is', 'to', 'obtain', 'preliminary', 'data', 'to', 'test', 'the', 'hypotheses', 'that', 'percutaneous', 'liver', 'biopsy', 'in', 'brain', 'death', 'donors', 'is', 'safe', 'and', 'provides', 'reliable', 'histological', 'information', '.', 'Furthermore', ',', 'that', 'information', 'when', 'disseminated', 'fully', 'and', 'widely', 'many', 'hours', 'before', 'organ', 'recovery', 'would', 'not', 'only', 'decrease', 'economic', 'costs', 'of', 'wasteful', 'recovery', 'of', 'livers', 'that', 'are', 'not', 'ultimately', 'transplanted', 'but', 'also', 'increase', 'transplantation', 'and', 'decrease', 'cold', 'ischemia', 'times', 'of', 'recovered', 'livers', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01810640,NCT01810640,"Pre-recovery Percutaneous Biopsy of Livers in Neurological Death Organ Donors - A Pilot Study | This study's objective is to obtain preliminary data to test the hypotheses that percutaneous liver biopsy in brain death donors is safe and provides reliable histological information. Furthermore, that information when disseminated fully and widely many hours before organ recovery would not only decrease economic costs of wasteful recovery of livers that are not ultimately transplanted but also increase transplantation and decrease cold ischemia times of recovered livers.","[(13, 42, 'OTHER', 'Percutaneous Biopsy of Livers'), (46, 64, 'CONDITION', 'Neurological Death'), (177, 202, 'OTHER', 'percutaneous liver biopsy'), (206, 217, 'CONDITION', 'brain death')]"
"['Phase', '1', ':', 'A', 'Multi', '-', 'Centered', ',', 'Randomized', ',', 'Blinded', ',', 'Placebo', '-', 'Controlled', ',', 'Serial', '-', 'Cohort', ',', 'Multiple', 'Ascending', 'Dose', 'Study', 'of', 'the', 'Safety', ',', 'Tolerability', ',', 'Pharmacokinetics', 'and', 'Efficacy', 'of', 'BG00010', '(', 'Neublastin', ')', 'in', 'Subjects', 'With', 'Sciatica', '|', 'The', 'primary', 'objective', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'safety', ',', 'tolerability', ',', 'and', 'pharmacokinetic', '(', 'PK', ')', 'profile', 'of', '3', 'intravenous', '(', 'IV', ')', 'injections', 'of', 'BG00010', 'given', 'on', '2', 'fixed', 'schedules', ';', 'weekly', 'and', 'as', 'frequently', 'as', 'every', '48', 'hours', '(', 'but', 'no', 'more', 'than', '3', 'times', 'per', 'week', ')', '.', '\n\n', 'Secondary', 'objectives', 'of', 'this', 'study', 'in', 'this', 'study', 'population', 'are', 'to', 'explore', 'the', 'repeated', '-', 'dose', 'immunogenicity', 'of', 'BG00010', 'and', 'to', 'explore', 'the', 'potential', 'of', 'BG00010', 'to', 'reduce', 'pain', 'following', 'multiple', '-', 'dose', 'administration', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01405833,NCT01405833,"Phase 1: A Multi-Centered, Randomized, Blinded, Placebo-Controlled, Serial-Cohort, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of BG00010 (Neublastin) in Subjects With Sciatica | The primary objective of the study is to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of 3 intravenous (IV) injections of BG00010 given on 2 fixed schedules; weekly and as frequently as every 48 hours (but no more than 3 times per week).

Secondary objectives of this study in this study population are to explore the repeated-dose immunogenicity of BG00010 and to explore the potential of BG00010 to reduce pain following multiple-dose administration.","[(48, 55, 'CONTROL', 'Placebo'), (175, 182, 'DRUG', 'BG00010'), (184, 194, 'DRUG', 'Neublastin'), (213, 221, 'CONDITION', 'Sciatica'), (369, 376, 'DRUG', 'BG00010'), (597, 604, 'DRUG', 'BG00010'), (637, 644, 'DRUG', 'BG00010'), (655, 659, 'CONDITION', 'pain')]"
"['Context', '-', 'Aware', 'Mobile', 'Intervention', 'for', 'Social', 'Recovery', 'in', 'Serious', 'Mental', 'Illness', '|', 'This', 'open', 'trial', 'will', 'test', 'a', 'new', 'technology', '-', 'supported', 'blended', 'intervention', ',', 'mobile', 'Social', 'Interaction', 'Therapy', 'by', 'Exposure', '(', 'mSITE', ')', ',', 'that', 'targets', 'social', 'engagement', 'in', 'consumers', 'with', 'serious', 'mental', 'illness', '.']","['B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT05660070,NCT05660070,"Context-Aware Mobile Intervention for Social Recovery in Serious Mental Illness | This open trial will test a new technology-supported blended intervention, mobile Social Interaction Therapy by Exposure (mSITE), that targets social engagement in consumers with serious mental illness.","[(0, 33, 'BEHAVIOURAL', 'Context-Aware Mobile Intervention'), (57, 79, 'CONDITION', 'Serious Mental Illness'), (114, 155, 'BEHAVIOURAL', 'technology-supported blended intervention'), (157, 202, 'BEHAVIOURAL', 'mobile Social Interaction Therapy by Exposure'), (204, 209, 'BEHAVIOURAL', 'mSITE'), (261, 283, 'CONDITION', 'serious mental illness')]"
"['Transcranial', 'Direct', 'Current', 'Stimulation', '(', 'tDCS', ')', 'of', 'the', 'Lesioned', 'or', 'Non', '-', 'lesioned', 'Hemisphere', 'Plus', 'Computer', '-', 'assisted', 'Arm', 'Trainer', ':', 'a', 'Randomized', ',', 'Placebo', '-', 'controlled', 'Double', '-', 'blind', 'Multi', '-', 'centre', 'Study', 'in', 'Patients', 'With', 'Severe', 'Arm', 'Paresis', 'Early', 'After', 'Stroke', '|', 'Transcranial', 'galvanic', 'stimulation', '(', 'tDCS', ')', 'seems', 'to', 'promote', 'motor', 'recovery', 'after', 'stroke', 'by', 'stimulating', '(', 'anodal', ')', 'or', 'inhibiting', '(', 'cathodal', ')', 'neural', 'circuits', 'in', 'the', 'brain', '.', 'In', 'the', 'treatment', 'of', 'severe', 'arm', 'paresis', 'after', 'stroke', ',', 'robot', '-', 'assisted', 'arm', 'training', '(', 'AT', ')', 'proved', 'to', 'be', 'effective', ',', 'but', 'nevertheless', 'only', 'a', 'few', 'patients', 'could', 'use', 'their', 'affected', 'hand', 'functionally', 'in', 'daily', 'life', 'after', 'robot', 'training', '.', 'Therefore', 'the', 'present', 'study', 'intends', 'to', 'combine', 'both', 'approaches', ',', 'tDCS', '+', 'AT', ',', 'applied', 'at', 'the', 'same', 'time', 'every', 'day', 'for', 'six', 'weeks', '.', 'The', 'study', 'has', 'three', 'treatment', 'arms', ',', 'two', 'groups', 'will', 'receive', 'the', 'tDCS', ',', 'either', 'anodal', 'of', 'the', 'lesioned', 'or', 'cathodal', 'of', 'the', 'non', '-', 'lesioned', 'hemisphere', '.', 'The', 'anodal', 'stimulation', 'is', 'expected', 'to', 'facilitate', 'the', 'activity', 'of', 'the', 'arm', 'motor', 'area', 'of', 'the', 'lesioned', 'side', 'directly', ',', 'while', 'the', 'cathodal', 'stimulation', 'of', 'the', 'non', '-', 'lesioned', 'hemisphere', 'is', 'expected', 'to', 'facilitate', 'the', 'lesioned', 'side', 'indirectly', 'by', 'decreasing', 'inhibitory', 'inputs', '.', 'The', 'third', 'group', 'will', 'receive', 'a', 'sham', '-', 'stimulation', '.', 'All', 'patients', 'will', 'work', 'with', 'the', 'AT', 'simultaneously', 'to', 'the', 'tDCS', ',', 'respectively', 'sham', '-', 'tDCS', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'B-COND', 'I-COND', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O']",NCT00407667,NCT00407667,"Transcranial Direct Current Stimulation (tDCS) of the Lesioned or Non-lesioned Hemisphere Plus Computer-assisted Arm Trainer: a Randomized, Placebo-controlled Double-blind Multi-centre Study in Patients With Severe Arm Paresis Early After Stroke | Transcranial galvanic stimulation (tDCS) seems to promote motor recovery after stroke by stimulating (anodal) or inhibiting (cathodal) neural circuits in the brain. In the treatment of severe arm paresis after stroke, robot-assisted arm training (AT) proved to be effective, but nevertheless only a few patients could use their affected hand functionally in daily life after robot training. Therefore the present study intends to combine both approaches, tDCS + AT, applied at the same time every day for six weeks. The study has three treatment arms, two groups will receive the tDCS, either anodal of the lesioned or cathodal of the non-lesioned hemisphere. The anodal stimulation is expected to facilitate the activity of the arm motor area of the lesioned side directly, while the cathodal stimulation of the non-lesioned hemisphere is expected to facilitate the lesioned side indirectly by decreasing inhibitory inputs. The third group will receive a sham-stimulation. All patients will work with the AT simultaneously to the tDCS, respectively sham-tDCS.","[(0, 39, 'OTHER', 'Transcranial Direct Current Stimulation'), (41, 45, 'OTHER', 'tDCS'), (95, 124, 'PHYSICAL', 'Computer-assisted Arm Trainer'), (140, 147, 'CONTROL', 'Placebo'), (208, 226, 'CONDITION', 'Severe Arm Paresis'), (227, 245, 'CONDITION', 'Early After Stroke'), (248, 281, 'OTHER', 'Transcranial galvanic stimulation'), (283, 287, 'OTHER', 'tDCS'), (327, 333, 'CONDITION', 'stroke'), (433, 451, 'CONDITION', 'severe arm paresis'), (452, 464, 'CONDITION', 'after stroke'), (466, 493, 'PHYSICAL', 'robot-assisted arm training'), (495, 497, 'PHYSICAL', 'AT'), (623, 637, 'PHYSICAL', 'robot training'), (703, 707, 'OTHER', 'tDCS'), (710, 712, 'PHYSICAL', 'AT'), (828, 832, 'OTHER', 'tDCS'), (1204, 1220, 'CONTROL', 'sham-stimulation'), (1254, 1256, 'PHYSICAL', 'AT'), (1279, 1283, 'OTHER', 'tDCS'), (1298, 1307, 'CONTROL', 'sham-tDCS')]"
"['Phase', '0', 'Evaluation', 'of', '[', '18F]MNI-958', 'as', 'a', 'Potential', 'PET', 'Radioligand', 'for', 'Imaging', 'Tau', 'Protein', 'in', 'the', 'Brain', 'of', 'Patients', 'With', 'Probable', 'Alzheimer', ""'s"", 'Disease', 'or', 'Progressive', 'Supranuclear', 'Palsy', 'Compared', 'With', 'Healthy', 'Volunteers', '|', 'The', 'overall', 'goal', 'of', 'this', 'imaging', 'trial', 'is', 'to', 'evaluate', '[', '18F]MNI-958', ',', 'a', 'tau', 'targeted', 'PET', 'radioligand', ',', 'in', 'individuals', 'with', 'Alzheimer', ""'s"", 'disease', '(', 'AD', ')', ',', 'Progressive', 'Supranuclear', 'Palsy', '(', 'PSP', ')', ',', 'and', 'healthy', 'volunteers', '(', 'HV', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03058965,NCT03058965,"Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Probable Alzheimer's Disease or Progressive Supranuclear Palsy Compared With Healthy Volunteers | The overall goal of this imaging trial is to evaluate [18F]MNI-958, a tau targeted PET radioligand, in individuals with Alzheimer's disease (AD), Progressive Supranuclear Palsy (PSP), and healthy volunteers (HV).","[(120, 182, 'CONDITION', ""Probable Alzheimer's Disease or Progressive Supranuclear Palsy""), (338, 357, 'CONDITION', ""Alzheimer's disease""), (359, 361, 'CONDITION', 'AD'), (364, 394, 'CONDITION', 'Progressive Supranuclear Palsy'), (396, 399, 'CONDITION', 'PSP')]"
"['Behavioral', 'and', 'Neuroimaging', 'Changes', 'After', 'Cognitive', 'Rehab', 'in', 'TBI', 'and', 'MCI', '|', 'Memory', 'deficits', 'are', 'common', 'after', 'traumatic', 'brain', 'injuries', '(', 'TBI', ')', 'and', 'are', 'characteristic', 'of', 'various', 'forms', 'of', 'dementia', ',', 'such', 'as', 'Alzheimer', ""'s"", 'disease', 'and', 'its', 'common', 'precursor', 'mild', 'cognitive', 'impairment', '(', 'MCI', ')', '.', 'This', 'project', 'intends', 'to', 'assess', 'the', 'efficacy', 'of', 'cognitive', 'rehabilitation', 'in', 'these', 'patient', 'populations', '.', 'We', 'will', 'also', 'use', 'neuroimaging', '(', 'functional', 'magnetic', 'resonance', 'imaging', '-', 'fMRI', ')', 'to', 'assess', 'changes', 'in', 'brain', 'activity', 'that', 'occur', 'following', 'cognitive', 'rehabilitation', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O']",NCT00714571,NCT00714571,"Behavioral and Neuroimaging Changes After Cognitive Rehab in TBI and MCI | Memory deficits are common after traumatic brain injuries (TBI) and are characteristic of various forms of dementia, such as Alzheimer's disease and its common precursor mild cognitive impairment (MCI). This project intends to assess the efficacy of cognitive rehabilitation in these patient populations. We will also use neuroimaging (functional magnetic resonance imaging - fMRI) to assess changes in brain activity that occur following cognitive rehabilitation.","[(42, 57, 'OTHER', 'Cognitive Rehab'), (61, 64, 'CONDITION', 'TBI'), (69, 72, 'CONDITION', 'MCI'), (75, 90, 'CONDITION', 'Memory deficits'), (108, 132, 'CONDITION', 'traumatic brain injuries'), (134, 137, 'CONDITION', 'TBI'), (182, 190, 'CONDITION', 'dementia'), (200, 219, 'CONDITION', ""Alzheimer's disease""), (245, 270, 'CONDITION', 'mild cognitive impairment'), (272, 275, 'CONDITION', 'MCI'), (325, 349, 'OTHER', 'cognitive rehabilitation'), (514, 538, 'OTHER', 'cognitive rehabilitation')]"
"['Nicotine', 'Replacement', 'Therapy', 'in', 'the', 'Intensive', 'Care', 'Unit', ':', 'a', 'Randomized', ',', 'Controlled', 'Pilot', 'Study', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'transdermal', 'nicotine', 'replacement', 'therapy', 'is', 'safe', 'and', 'effective', 'for', 'treating', 'nicotine', 'withdrawal', 'symptoms', 'in', 'the', 'critically', 'ill', 'smoking', 'patient', '.']","['B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O']",NCT01362959,NCT01362959,"Nicotine Replacement Therapy in the Intensive Care Unit: a Randomized, Controlled Pilot Study | The purpose of this study is to determine whether transdermal nicotine replacement therapy is safe and effective for treating nicotine withdrawal symptoms in the critically ill smoking patient.","[(0, 8, 'DRUG', 'Nicotine'), (158, 166, 'DRUG', 'nicotine'), (222, 230, 'DRUG', 'nicotine'), (231, 241, 'CONDITION', 'withdrawal'), (258, 272, 'CONDITION', 'critically ill')]"
"['Efficacy', 'of', 'START', '(', 'Startle', 'Rehabilitation', 'Therapy', ')', 'in', 'the', 'Treatment', 'Stroke', '-', 'induced', 'Aphasia', '/', 'Apraxia', '|', 'A', 'stratified', ',', 'parallel', '-', 'group', ',', 'double', '-', 'blind', ',', 'randomized', 'controlled', 'trial', 'of', 'remotely', 'delivered', 'START', 'treatment', 'to', 'individuals', 'with', 'severe', '-', 'to', '-', 'moderate', 'stroke', '(', 'with', 'recruitment', 'focused', 'on', 'individuals', 'with', 'low', 'SES', ')', 'will', 'be', 'conducted', '.', 'Subjects', 'and', 'assessors', 'will', 'be', 'blinded', 'to', 'the', 'condition', 'making', 'the', 'experiment', 'double', 'blind', '.', 'Specifically', ',', 'subjects', 'will', 'be', 'told', 'that', 'we', 'are', 'exploring', 'a', 'new', 'therapy', 'that', 'using', 'different', 'sounds', 'to', 'improve', 'therapy', '.', 'Parallel', 'group', 'design', 'will', 'ensure', 'that', 'subjects', 'in', 'the', 'Control', 'group', 'are', 'unaware', 'that', 'their', '""', 'sounds', '""', 'are', 'softer', 'than', 'the', 'START', 'group', '.', 'Trainers', 'may', 'become', 'aware', 'that', 'a', 'loud', 'sound', 'is', 'present', 'thus', 'a', 'unique', 'Assessor', 'will', 'evaluate', 'clinical', 'performance', 'before', 'and', 'after', 'training', 'making', 'the', 'study', 'double', '-', 'blind', '.', 'Fifty', '-', 'four', 'subjects', 'will', 'undergo', 'baseline', 'testing', 'in', 'the', 'laboratory', 'to', 'establish', 'their', 'capacity', 'for', 'functional', 'and', 'expressive', 'speech', 'as', 'well', 'as', 'their', 'self', '-', 'reported', 'health', '-', 'related', 'quality', 'of', 'life', '(', 'power', 'analysis', 'below', ')', '.', 'Next', ',', 'subjects', 'will', 'participate', 'in', 'a', 'high', '-', 'frequency', ',', 'word', '-', 'picture', 'verification/', 'auditory', '-', 'repetition', 'treatment', ',', '2', 'hr', '/', 'day', 'for', '5', 'consecutive', 'days', 'focusing', 'on', 'expression', 'of', 'words', 'of', 'functional', 'significance', '(', 'e.g.', ',', 'water', ',', 'fall', ')', '.', 'Subjects', 'will', 'either', 'receive', 'training', 'with', 'START', 'or', 'without', '(', 'Control', ')', '.', 'Subjects', 'will', 'be', 're', '-', 'tested', 'immediately', 'following', 'training', 'as', 'well', 'as', 'one', '-', 'month', 'post', 'to', 'assess', 'retention', '.', 'Aim', '1', 'will', 'evaluate', 'capacity', 'of', 'START', 'to', 'enhance', 'SLT', 'outcomes', 'by', 'assessing', 'the', '%', 'change', 'in', 'clinical', 'assessment', 'of', 'functional', 'and', 'expressive', 'speech', '.', 'Our', 'preliminary', 'data', 'points', 'to', 'a', 'robust', 'response', '[', 'details', ']', '.', 'Aim', '2', 'will', 'focus', 'on', 'the', 'capacity', 'of', 'these', 'changes', 'to', '1', ')', 'be', 'retained', 'and', '2', ')', 'impact', 'subject', ""'s"", 'reported', 'quality', 'of', 'life', '.', 'NOTE', ':', 'While', 'we', 'are', 'planning', 'in', '-', 'person', 'baseline', ',', 'end', ',', 'and', 'retention', 'testing', ',', 'in', 'response', 'to', 'COVID', ',', 'we', 'have', 'established', 'remote', 'clinical', 'screening', 'using', 'peer', '-', 'reviewed', 'validated', 'techniques', 'for', 'WAB', 'and', 'ABA-2', '(', 'see', 'Alternative', 'Solutions', ')', '.', 'All', 'preliminary', 'data', 'collected', 'for', 'this', 'proposal', 'were', 'collected', 'remotely', 'via', 'no', '-', 'contact', 'protocols', '.']","['O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04816799,NCT04816799,"Efficacy of START (Startle Rehabilitation Therapy) in the Treatment Stroke-induced Aphasia/Apraxia | A stratified, parallel-group, double-blind, randomized controlled trial of remotely delivered START treatment to individuals with severe-to-moderate stroke (with recruitment focused on individuals with low SES) will be conducted. Subjects and assessors will be blinded to the condition making the experiment double blind. Specifically, subjects will be told that we are exploring a new therapy that using different sounds to improve therapy. Parallel group design will ensure that subjects in the Control group are unaware that their ""sounds"" are softer than the START group. Trainers may become aware that a loud sound is present thus a unique Assessor will evaluate clinical performance before and after training making the study double-blind. Fifty-four subjects will undergo baseline testing in the laboratory to establish their capacity for functional and expressive speech as well as their self-reported health-related quality of life (power analysis below). Next, subjects will participate in a high-frequency, word-picture verification/ auditory-repetition treatment, 2 hr/day for 5 consecutive days focusing on expression of words of functional significance (e.g., water, fall). Subjects will either receive training with START or without (Control). Subjects will be re-tested immediately following training as well as one-month post to assess retention. Aim 1 will evaluate capacity of START to enhance SLT outcomes by assessing the % change in clinical assessment of functional and expressive speech. Our preliminary data points to a robust response [details]. Aim 2 will focus on the capacity of these changes to 1) be retained and 2) impact subject's reported quality of life. NOTE: While we are planning in-person baseline, end, and retention testing, in response to COVID, we have established remote clinical screening using peer-reviewed validated techniques for WAB and ABA-2 (see Alternative Solutions). All preliminary data collected for this proposal were collected remotely via no-contact protocols.","[(12, 17, 'OTHER', 'START'), (19, 49, 'OTHER', 'Startle Rehabilitation Therapy'), (68, 74, 'CONDITION', 'Stroke'), (83, 90, 'CONDITION', 'Aphasia'), (91, 98, 'CONDITION', 'Apraxia'), (195, 200, 'OTHER', 'START'), (231, 256, 'CONDITION', 'severe-to-moderate stroke'), (500, 541, 'OTHER', 'using different sounds to improve therapy'), (636, 654, 'CONTROL', 'sounds"" are softer'), (664, 669, 'OTHER', 'START'), (1103, 1175, 'OTHER', 'high-frequency, word-picture verification/ auditory-repetition treatment'), (1332, 1337, 'OTHER', 'START'), (1341, 1348, 'CONTROL', 'without'), (1350, 1357, 'CONTROL', 'Control'), (1497, 1502, 'OTHER', 'START')]"
"['Effect', 'of', 'Randomized', 'Patient', '-', 'Triggered', 'Sensory', 'Cues', 'for', 'Freezing', 'of', 'Gait', 'in', 'Parkinson', ""'s"", 'Disease', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', '(', '1', ')', 'to', 'determine', 'if', 'patient', 'triggered', 'sensory(auditory', ',', 'visual', 'and', 'tactile', ')', 'cues', 'can', 'help', 'treat', 'freezing', 'of', 'gait', 'in', 'Parkinson', ""'s"", 'disease', ',', 'and', '(', '2', ')', 'to', 'assess', 'if', 'unexpected', '(', 'randomized', ')', 'cues', 'are', 'more', 'effective', 'than', 'anticipated', 'ones', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00322426,NCT00322426,"Effect of Randomized Patient-Triggered Sensory Cues for Freezing of Gait in Parkinson's Disease | The purpose of this study is (1) to determine if patient triggered sensory(auditory, visual and tactile) cues can help treat freezing of gait in Parkinson's disease, and (2) to assess if unexpected (randomized) cues are more effective than anticipated ones.","[(21, 51, 'OTHER', 'Patient-Triggered Sensory Cues'), (56, 72, 'CONTROL', 'Freezing of Gait'), (76, 95, 'CONDITION', ""Parkinson's Disease""), (147, 207, 'OTHER', 'patient triggered sensory(auditory, visual and tactile) cues'), (223, 239, 'CONTROL', 'freezing of gait'), (243, 262, 'CONDITION', ""Parkinson's disease""), (285, 313, 'OTHER', 'unexpected (randomized) cues')]"
"['Feasibility', 'and', 'Acceptability', 'of', 'Transcutaneous', 'Vagal', 'Nerve', 'Stimulation', 'in', 'Recovery', 'of', 'Upper', 'Limb', 'Function', 'Post', 'Stroke', '|', 'This', 'study', 'will', 'find', 'out', 'whether', 'electrical', 'stimulation', 'of', 'a', 'nerve', 'called', 'the', '""', 'vagus', '""', 'nerve', 'is', 'acceptable', 'for', 'patients', 'undergoing', 'physiotherapy', 'for', 'arm', 'weakness', 'after', 'a', 'stroke', '.', '20', 'patients', 'will', 'be', 'recruited', 'if', 'they', 'had', 'a', 'stroke', 'between', '4', 'and', '48', 'months', 'previously', 'and', 'have', 'been', 'left', 'with', 'reduced', 'function', 'in', 'the', 'affected', 'arm', '.', 'Patients', 'will', 'receive', '3', 'sessions', 'of', 'physiotherapy', 'per', 'week', 'for', '6', 'weeks', '.', 'Each', 'session', 'will', 'last', '1', 'hour', 'during', 'which', 'the', 'patient', 'will', 'be', 'asked', 'to', 'perform', 'specific', 'movements', 'e.g.', 'shuffling', 'cards', ',', 'reaching', 'for', 'a', 'shelf', '.', 'With', 'each', 'arm', 'movement', 'the', 'therapist', 'will', 'turn', 'on', 'a', 'stimulator', 'which', 'is', 'worn', 'clipped', 'to', 'the', 'patients', 'ear', '.', 'This', 'will', 'deliver', 'a', 'short', 'burst', 'of', 'electricity', 'creating', 'a', 'mild', 'tingling', 'sensation', '.', '\n\n', 'At', 'the', 'end', 'of', 'the', 'session', ',', 'the', 'stimulator', 'will', 'be', 'removed', 'and', 'the', 'patient', 'will', 'be', 'asked', 'to', 'rate', 'the', 'level', 'of', 'any', 'discomfort', 'or', 'fatigue', 'they', 'experienced', 'as', 'well', 'as', 'any', 'other', 'side', 'effects', '.', 'The', 'therapist', 'will', 'also', 'record', 'whether', 'the', 'stimulator', 'device', 'interfered', 'with', 'the', 'therapy', 'in', 'any', 'way', '.', 'A', 'heart', 'tracing', 'will', 'be', 'performed', 'at', 'each', 'visit', 'to', 'check', 'the', 'heart', 'rhythm', '.', 'At', 'the', 'start', 'and', 'end', 'of', 'the', '6', 'week', 'course', 'of', 'physiotherapy', ',', 'patients', 'arm', 'weakness', 'and', 'level', 'of', 'arm', 'function', 'will', 'be', 'assessed', ',', 'as', 'well', 'as', 'their', 'general', 'levels', 'of', 'fatigue', ',', 'mood', 'and', 'quality', 'of', 'life', '.', 'These', 'will', 'be', 'reassessed', 'at', '1', 'month', 'and', '6', 'months', 'after', 'the', 'course', 'of', 'physiotherapy', 'has', 'ended', '.', 'The', 'investigators', 'will', 'also', 'interview', 'patients', 'to', 'establish', 'how', 'they', 'found', 'the', 'treatment', 'itself', '.', 'If', 'the', 'vagal', 'nerve', 'stimulation', 'combined', 'with', 'physiotherapy', 'is', 'acceptable', 'to', 'patients', 'and', 'therapists', 'and', 'there', 'are', 'no', 'safety', 'concerns', ',', 'the', 'investigators', 'will', 'plan', 'a', 'larger', 'trial', 'of', 'this', 'treatment', 'in', 'stroke', 'patients', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT03170791,NCT03170791,"Feasibility and Acceptability of Transcutaneous Vagal Nerve Stimulation in Recovery of Upper Limb Function Post Stroke | This study will find out whether electrical stimulation of a nerve called the ""vagus"" nerve is acceptable for patients undergoing physiotherapy for arm weakness after a stroke. 20 patients will be recruited if they had a stroke between 4 and 48 months previously and have been left with reduced function in the affected arm. Patients will receive 3 sessions of physiotherapy per week for 6 weeks. Each session will last 1 hour during which the patient will be asked to perform specific movements e.g. shuffling cards, reaching for a shelf. With each arm movement the therapist will turn on a stimulator which is worn clipped to the patients ear. This will deliver a short burst of electricity creating a mild tingling sensation.

At the end of the session, the stimulator will be removed and the patient will be asked to rate the level of any discomfort or fatigue they experienced as well as any other side effects. The therapist will also record whether the stimulator device interfered with the therapy in any way. A heart tracing will be performed at each visit to check the heart rhythm. At the start and end of the 6 week course of physiotherapy, patients arm weakness and level of arm function will be assessed, as well as their general levels of fatigue, mood and quality of life. These will be reassessed at 1 month and 6 months after the course of physiotherapy has ended. The investigators will also interview patients to establish how they found the treatment itself. If the vagal nerve stimulation combined with physiotherapy is acceptable to patients and therapists and there are no safety concerns, the investigators will plan a larger trial of this treatment in stroke patients.","[(33, 71, 'OTHER', 'Transcutaneous Vagal Nerve Stimulation'), (107, 118, 'CONDITION', 'Post Stroke'), (290, 296, 'CONDITION', 'stroke'), (342, 348, 'CONDITION', 'stroke'), (408, 444, 'CONDITION', 'reduced function in the affected arm'), (482, 495, 'PHYSICAL', 'physiotherapy'), (1081, 1098, 'OTHER', 'stimulator device'), (1259, 1272, 'PHYSICAL', 'physiotherapy'), (1283, 1295, 'CONDITION', 'arm weakness'), (1479, 1492, 'PHYSICAL', 'physiotherapy'), (1608, 1631, 'OTHER', 'vagal nerve stimulation'), (1646, 1659, 'PHYSICAL', 'physiotherapy'), (1799, 1805, 'CONDITION', 'stroke')]"
"['The', 'Feasibility', 'of', 'Transcranial', 'Direct', 'Current', 'Stimulation', 'as', 'an', 'Adjunct', 'to', 'Outpatient', 'Physiotherapy', 'in', 'Children', 'With', 'Acquired', 'Brain', 'Injury', '|', 'This', 'study', 'will', 'evaluate', 'the', 'feasibility', 'of', 'transcranial', 'direct', 'current', 'stimulation', '(', 'tDCS', ')', 'as', 'an', 'adjunct', 'to', 'an', 'outpatient', 'motor', 'skills', '-', 'based', 'physiotherapy', 'intervention', 'for', 'children', 'and', 'youth', 'with', 'acquired', 'brain', 'injury', '.', 'Up', 'to', '10', 'children', '(', 'age', '5', '-', '18', 'years', ')', 'with', 'childhood', 'onset', 'stroke', 'or', 'traumatic', 'brain', 'injury', 'will', 'be', 'randomly', 'allocated', 'to', 'receive', 'active', 'or', 'sham', 'anodal', 'tDCS', 'immediately', 'prior', 'to', 'the', 'physiotherapy', 'session', '.', 'These', 'sessions', 'will', 'occur', 'twice', 'weekly', 'for', 'a', 'total', 'of', '10', 'sessions', '.', 'Assessment', 'of', 'gross', 'motor', 'outcome', 'measures', 'will', 'occur', 'immediately', 'before', 'and', 'after', 'the', 'combined', 'tDCS', 'and', 'physiotherapy', 'treatment', 'protocol', '.', 'The', 'preliminary', 'treatment', 'effect', 'between', 'the', 'two', 'treatment', 'groups', 'will', 'be', 'compared', 'and', 'other', 'feasibility', 'indicators', 'will', 'be', 'evaluated', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05637957,NCT05637957,The Feasibility of Transcranial Direct Current Stimulation as an Adjunct to Outpatient Physiotherapy in Children With Acquired Brain Injury | This study will evaluate the feasibility of transcranial direct current stimulation (tDCS) as an adjunct to an outpatient motor skills-based physiotherapy intervention for children and youth with acquired brain injury. Up to 10 children (age 5-18 years) with childhood onset stroke or traumatic brain injury will be randomly allocated to receive active or sham anodal tDCS immediately prior to the physiotherapy session. These sessions will occur twice weekly for a total of 10 sessions. Assessment of gross motor outcome measures will occur immediately before and after the combined tDCS and physiotherapy treatment protocol. The preliminary treatment effect between the two treatment groups will be compared and other feasibility indicators will be evaluated.,"[(19, 58, 'OTHER', 'Transcranial Direct Current Stimulation'), (76, 100, 'PHYSICAL', 'Outpatient Physiotherapy'), (118, 139, 'CONDITION', 'Acquired Brain Injury'), (186, 225, 'OTHER', 'transcranial direct current stimulation'), (227, 231, 'OTHER', 'tDCS'), (253, 309, 'PHYSICAL', 'outpatient motor skills-based physiotherapy intervention'), (338, 359, 'CONDITION', 'acquired brain injury'), (417, 423, 'CONDITION', 'stroke'), (427, 449, 'CONDITION', 'traumatic brain injury'), (498, 514, 'CONTROL', 'sham anodal tDCS'), (540, 561, 'OTHER', 'physiotherapy session'), (726, 730, 'OTHER', 'tDCS'), (735, 767, 'OTHER', 'physiotherapy treatment protocol')]"
"['A', 'Phase', '4', ',', 'Open', '-', 'Label', 'Study', 'to', 'Evaluate', 'the', 'Safety', 'and', 'Tolerability', 'of', 'Daily', 'Dosing', 'of', 'Rimegepant', 'in', 'Episodic', 'Migraine', 'Prevention', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'further', 'evaluate', 'the', 'long', '-', 'term', 'safety', 'and', 'tolerability', 'of', 'daily', 'dosing', 'of', 'rimegepant', 'for', 'the', 'prevention', 'of', 'episodic', 'migraine', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT05207865,NCT05207865,"A Phase 4, Open-Label Study to Evaluate the Safety and Tolerability of Daily Dosing of Rimegepant in Episodic Migraine Prevention | The purpose of this study is to further evaluate the long-term safety and tolerability of daily dosing of rimegepant for the prevention of episodic migraine.","[(87, 97, 'DRUG', 'Rimegepant'), (101, 118, 'CONDITION', 'Episodic Migraine'), (238, 248, 'DRUG', 'rimegepant'), (271, 288, 'CONDITION', 'episodic migraine')]"
"['Neural', 'Signatures', 'of', 'Tremor', ',', 'Bradykinesia', 'and', 'Freezing', 'in', 'the', 'Subthalamic', 'Region', 'on', 'Parkinson', ""'s"", 'Disease', 'and', 'Their', 'Acute', 'and', 'Long', '-', 'Term', 'Modulation', 'by', 'Subthalamic', 'Deep', 'Brain', 'Stimulation', '.', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'provide', 'objective', 'measurements', 'of', 'abnormal', 'movements', 'of', 'the', 'body', 'in', 'correlation', 'with', 'neural', 'activity', 'of', 'the', 'brain', 'and', 'track', 'how', 'these', 'change', 'over', 'time', '.', 'This', 'may', 'allow', 'for', 'the', 'development', 'of', 'objective', 'evaluation', 'of', 'the', 'neural', 'activity', 'causing', 'abnormal', 'movements', ',', 'which', 'may', 'lead', 'to', 'the', 'ability', 'of', 'the', 'DBS', 'system', 'to', 'stimulate', 'the', 'brain', 'by', 'sensing', 'the', 'abnormal', 'neural', 'activity', 'that', 'is', 'causing', 'abnormal', 'movements', '.']","['O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01990313,NCT01990313,"Neural Signatures of Tremor, Bradykinesia and Freezing in the Subthalamic Region on Parkinson's Disease and Their Acute and Long-Term Modulation by Subthalamic Deep Brain Stimulation. | The purpose of this study is to provide objective measurements of abnormal movements of the body in correlation with neural activity of the brain and track how these change over time. This may allow for the development of objective evaluation of the neural activity causing abnormal movements, which may lead to the ability of the DBS system to stimulate the brain by sensing the abnormal neural activity that is causing abnormal movements.","[(21, 27, 'CONDITION', 'Tremor'), (29, 41, 'CONDITION', 'Bradykinesia'), (46, 80, 'CONDITION', 'Freezing in the Subthalamic Region'), (84, 103, 'CONDITION', ""Parkinson's Disease""), (160, 182, 'OTHER', 'Deep Brain Stimulation'), (517, 520, 'OTHER', 'DBS')]"
"['Effect', 'of', 'Normal', 'and', 'High', 'Protein', 'Diets', 'in', 'Lean', 'Mass', ',', 'Adiposity', ',', 'and', 'Strength', 'in', 'Postmenopausal', 'Women', 'Practitioners', 'of', 'Resistance', 'Exercise', '|', 'This', 'study', 'evaluates', 'the', 'effect', 'of', 'different', 'types', 'of', 'diets', '(', 'high', 'and', 'normal', 'protein', ')', 'on', 'lean', 'and', 'fat', 'mass', ',', 'and', 'strength', 'in', 'postmenopausal', 'women', 'practitioners', 'of', 'resistance', 'exercise', '.', 'Two', 'groups', 'will', 'be', 'created', ':', 'high', 'protein', '(', '1.2', 'protein', 'g', '/', 'body', 'mass', '/', 'day', ')', 'and', 'normal', 'protein', '(', '0.8', 'protein', 'g', '/', 'body', 'mass', '/', 'day', ')', '.', 'The', 'same', 'training', 'will', 'be', 'performed', 'for', 'both', 'groups', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03024125,NCT03024125,"Effect of Normal and High Protein Diets in Lean Mass, Adiposity, and Strength in Postmenopausal Women Practitioners of Resistance Exercise | This study evaluates the effect of different types of diets (high and normal protein) on lean and fat mass, and strength in postmenopausal women practitioners of resistance exercise. Two groups will be created: high protein (1.2 protein g/body mass/day) and normal protein (0.8 protein g/body mass/day). The same training will be performed for both groups.","[(10, 39, 'OTHER', 'Normal and High Protein Diets'), (54, 63, 'CONDITION', 'Adiposity'), (81, 95, 'CONDITION', 'Postmenopausal'), (202, 225, 'OTHER', 'high and normal protein'), (265, 279, 'CONDITION', 'postmenopausal'), (352, 364, 'OTHER', 'high protein'), (399, 413, 'CONTROL', 'normal protein')]"
"['Interventional', 'Testing', 'of', 'Gene', '-', 'environment', 'Interactions', 'Via', 'the', 'Verifomics', 'Mobile', 'Application', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'study', 'interactions', 'between', 'genes', ',', 'lifestyle', 'environmental', 'factors', 'like', 'foods', ',', 'nutritional', 'supplements', 'and', 'non', '-', 'invasive', 'medical', 'devices', 'and', 'health', 'factors', 'that', 'can', 'be', 'measured', 'without', 'specialized', 'medical', 'equipment', 'in', 'order', 'to', 'develop', 'lifestyle', 'recommendations', 'tailored', 'to', 'individual', 'genetics', 'for', 'a', 'host', 'of', 'common', 'chronic', 'health', 'conditions', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02758990,NCT02758990,"Interventional Testing of Gene-environment Interactions Via the Verifomics Mobile Application | The purpose of this study is to study interactions between genes, lifestyle environmental factors like foods, nutritional supplements and non-invasive medical devices and health factors that can be measured without specialized medical equipment in order to develop lifestyle recommendations tailored to individual genetics for a host of common chronic health conditions.",[]
"['A', 'Phase', '1', 'Study', 'Evaluating', 'the', 'Safety', ',', 'Tolerability', 'and', 'Pharmacokinetics', 'of', 'ABT-888', 'in', 'Combination', 'With', 'Whole', 'Brain', 'Radiation', 'Therapy', 'in', 'Subjects', 'With', 'Brain', 'Metastases', '|', 'This', 'Phase', 'I', 'clinical', 'trial', 'is', 'studying', 'the', 'side', 'effects', 'and', 'best', 'dose', 'of', 'ABT-888', 'when', 'given', 'together', 'with', 'Whole', 'Brain', 'Radiation', 'Therapy', '(', 'WBRT', ')', 'in', 'treating', 'patients', 'with', 'brain', 'metastases', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT00649207,NCT00649207,"A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination With Whole Brain Radiation Therapy in Subjects With Brain Metastases | This Phase I clinical trial is studying the side effects and best dose of ABT-888 when given together with Whole Brain Radiation Therapy (WBRT) in treating patients with brain metastases.","[(76, 83, 'DRUG', 'ABT-888'), (104, 133, 'RADIOTHERAPY', 'Whole Brain Radiation Therapy'), (151, 167, 'CONDITION', 'Brain Metastases'), (244, 251, 'DRUG', 'ABT-888'), (277, 306, 'RADIOTHERAPY', 'Whole Brain Radiation Therapy'), (308, 312, 'RADIOTHERAPY', 'WBRT'), (340, 356, 'CONDITION', 'brain metastases')]"
"['Effect', 'of', 'Total', 'Intravenous', 'Anesthesia', 'With', 'Remimazolam', 'vs', 'Sevoflurane', 'Inhalation', 'Anesthesia', 'on', 'Incidence', 'of', 'Emergence', 'Agitation', 'and', 'Complications', 'in', 'Children', 'Undergoing', 'Ophthalmic', 'Surgery', '|', 'As', 'a', 'novel', 'ultra', '-', 'short', '-', 'acting', 'benzodiazepines', 'drugs', ',', 'Remimazolam', 'has', 'been', 'accepted', 'for', 'induction', 'and', 'maintenance', 'of', 'clinical', 'anesthesia', '.', 'Compared', 'to', 'the', 'traditional', 'benzodiazepines', 'drugs', ',', 'Remimazolam', 'combines', 'the', 'safety', 'of', 'midazolam', 'with', 'the', 'effectiveness', 'of', 'propofol', ',', 'and', 'also', 'has', 'the', 'advantages', 'of', 'acting', 'quickly', ',', 'short', 'half', '-', 'life', ',', 'no', 'injection', 'pain', ',', 'slight', 'respiratory', 'depression', ',', 'independent', 'of', 'liver', 'and', 'kidney', 'metabolism', ',', 'long', '-', 'term', 'infusion', 'without', 'accumulation', ',', 'and', 'has', 'a', 'specific', 'antagonist', ':', 'flumazenil', '.', 'This', 'study', 'aims', 'to', 'investigate', 'whether', 'Remimazolam', 'reduces', 'the', 'incidence', 'of', 'emergence', 'agitation', 'in', 'children', 'after', 'ophthalmic', 'surgery', ',', 'compared', 'to', 'sevoflurane', '(', 'RCT', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O']",NCT05527314,NCT05527314,"Effect of Total Intravenous Anesthesia With Remimazolam vs Sevoflurane Inhalation Anesthesia on Incidence of Emergence Agitation and Complications in Children Undergoing Ophthalmic Surgery | As a novel ultra-short-acting benzodiazepines drugs, Remimazolam has been accepted for induction and maintenance of clinical anesthesia. Compared to the traditional benzodiazepines drugs, Remimazolam combines the safety of midazolam with the effectiveness of propofol, and also has the advantages of acting quickly, short half-life, no injection pain, slight respiratory depression, independent of liver and kidney metabolism, long-term infusion without accumulation, and has a specific antagonist: flumazenil. This study aims to investigate whether Remimazolam reduces the incidence of emergence agitation in children after ophthalmic surgery, compared to sevoflurane (RCT).","[(44, 55, 'DRUG', 'Remimazolam'), (59, 70, 'DRUG', 'Sevoflurane'), (119, 128, 'CONDITION', 'Agitation'), (170, 188, 'CONDITION', 'Ophthalmic Surgery'), (221, 236, 'DRUG', 'benzodiazepines'), (244, 255, 'DRUG', 'Remimazolam'), (356, 371, 'DRUG', 'benzodiazepines'), (379, 390, 'DRUG', 'Remimazolam'), (741, 752, 'DRUG', 'Remimazolam'), (778, 797, 'CONDITION', 'emergence agitation'), (816, 834, 'CONDITION', 'ophthalmic surgery'), (848, 859, 'DRUG', 'sevoflurane')]"
"['EEG', 'Monitoring', 'Under', 'Anaesthesia', 'in', 'Children', ':', 'Towards', 'Personalized', 'Anaesthesia', 'Care', '|', 'Electroencephalographic', 'recordings', '(', 'EEG', ')', 'present', 'an', 'opportunity', 'to', 'monitor', 'changes', 'in', 'human', 'brain', 'electrical', 'activity', 'during', 'changing', 'states', 'of', 'consciousness', 'during', 'general', 'anesthesia', '.', '\n\n', 'The', 'investigators', 'aim', 'to', 'determine', 'if', 'EEG', '-', 'guided', 'anaesthesia', 'using', 'the', 'Masimo', 'Sedline', 'Root', 'monitor', 'will', 'result', 'in', 'different', 'anaesthetic', 'requirements', ',', 'different', 'anaesthetic', 'depth', ',', 'and', 'emergence', 'characteristics', 'in', 'children', 'under', '16', 'years', 'of', 'age', '.', '\n\n', '200', 'children', 'under', '16', 'years', 'undergoing', 'routine', 'general', 'anaesthesia', 'under', 'sevoflurane', 'will', 'be', 'randomized', 'to', 'either', 'EEG', 'monitoring', 'or', 'routine', 'care', '.', 'We', 'will', 'compare', 'the', 'anaesthetic', 'requirements', ',', 'the', 'patient', 'state', 'index', ',', 'number', 'of', 'episodes', 'of', 'burst', 'suppression', 'and', 'the', 'incidence', 'and', 'severity', 'of', 'emergence', 'delrium', 'between', 'the', 'two', 'groups', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O']",NCT04103138,NCT04103138,"EEG Monitoring Under Anaesthesia in Children: Towards Personalized Anaesthesia Care | Electroencephalographic recordings (EEG) present an opportunity to monitor changes in human brain electrical activity during changing states of consciousness during general anesthesia.

The investigators aim to determine if EEG-guided anaesthesia using the Masimo Sedline Root monitor will result in different anaesthetic requirements, different anaesthetic depth, and emergence characteristics in children under 16 years of age.

200 children under 16 years undergoing routine general anaesthesia under sevoflurane will be randomized to either EEG monitoring or routine care. We will compare the anaesthetic requirements, the patient state index, number of episodes of burst suppression and the incidence and severity of emergence delrium between the two groups.","[(808, 825, 'CONDITION', 'emergence delrium')]"
"['Comparative', 'Effectiveness', 'of', 'Family', 'Problem', '-', 'Solving', 'Therapy', '(', 'F', '-', 'PST', ')', 'for', 'Adolescent', 'TBI', '|', 'Traumatic', 'brain', 'injury', '(', 'TBI', ')', 'is', 'the', 'most', 'common', 'cause', 'of', 'acquired', 'disability', 'in', 'youth', 'and', 'a', 'source', 'of', 'significant', 'morbidity', 'and', 'family', 'burden', '.', 'Novel', 'behavior', 'problems', 'are', 'among', 'the', 'most', 'common', 'and', 'problematic', 'consequences', ',', 'yet', 'many', 'youth', 'fail', 'to', 'receive', 'needed', 'psychological', 'services', 'due', 'to', 'lack', 'of', 'identification', 'and', 'access', '.', 'Linking', 'youth', 'with', 'TBI', 'to', 'effective', 'treatments', 'could', 'improve', 'functional', 'outcomes', ',', 'reduce', 'family', 'burden', ',', 'and', 'increase', 'treatment', 'satisfaction', '.', 'The', 'investigators', 'overarching', 'aim', 'is', 'to', 'compare', 'the', 'effectiveness', ',', 'feasibility', ',', 'and', 'acceptability', 'of', 'three', 'formats', 'of', 'family', 'problem', 'solving', 'therapy', '(', 'F', '-', 'PST', ')', 'for', 'improving', 'functional', 'outcomes', 'of', 'complicated', 'mild', 'to', 'severe', 'adolescent', 'TBI', ':', 'therapist', '-', 'guided', ',', 'face', '-', 'to', '-', 'face', ';', 'therapist', '-', 'guided', 'online', ';', 'and', 'self', '-', 'guided', ',', 'online', 'F', '-', 'PST', '.']","['O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'B-BEH', 'I-BEH', 'I-BEH', 'O']",NCT02368366,NCT02368366,"Comparative Effectiveness of Family Problem-Solving Therapy (F-PST) for Adolescent TBI | Traumatic brain injury (TBI) is the most common cause of acquired disability in youth and a source of significant morbidity and family burden. Novel behavior problems are among the most common and problematic consequences, yet many youth fail to receive needed psychological services due to lack of identification and access. Linking youth with TBI to effective treatments could improve functional outcomes, reduce family burden, and increase treatment satisfaction. The investigators overarching aim is to compare the effectiveness, feasibility, and acceptability of three formats of family problem solving therapy (F-PST) for improving functional outcomes of complicated mild to severe adolescent TBI: therapist-guided, face-to-face; therapist-guided online; and self-guided, online F-PST.","[(29, 59, 'BEHAVIOURAL', 'Family Problem-Solving Therapy'), (61, 66, 'BEHAVIOURAL', 'F-PST'), (83, 86, 'CONDITION', 'TBI'), (89, 111, 'CONDITION', 'Traumatic brain injury'), (113, 116, 'CONDITION', 'TBI'), (434, 437, 'CONDITION', 'TBI'), (674, 704, 'BEHAVIOURAL', 'family problem solving therapy'), (706, 711, 'BEHAVIOURAL', 'F-PST'), (762, 791, 'CONDITION', 'mild to severe adolescent TBI'), (793, 823, 'BEHAVIOURAL', 'therapist-guided, face-to-face'), (825, 848, 'BEHAVIOURAL', 'therapist-guided online'), (854, 873, 'BEHAVIOURAL', 'self-guided, online'), (874, 879, 'BEHAVIOURAL', 'F-PST')]"
"['Effects', 'of', 'Long', 'Term', 'Adaptive', 'Servo', 'Ventilation', 'Therapy', 'on', 'Myocardial', 'Energetics', 'and', 'Sympathetic', 'Nerve', 'Function', 'in', 'Heart', 'Failure', 'and', 'Sleep', 'Apnea', '.', 'The', 'AMEND', 'Sub', '-', 'study', '|', 'Obstructive', 'sleep', 'apnea', '(', 'OSA', ')', ',', 'central', 'sleep', 'apnea', '(', 'CSA', ')', 'and', 'heart', 'failure', '(', 'HF', ')', 'are', 'states', 'of', 'metabolic', 'demand', 'and', 'sympathetic', 'nervous', 'system', '(', 'SNS', ')', 'activation', '.', 'In', 'patients', 'with', 'sleep', 'apnea', 'and', 'HF', ',', 'continuous', 'positive', 'airway', 'pressure', '(', 'CPAP', ')', 'initially', 'may', 'reduce', 'left', 'ventricular', '(', 'LV)stroke', 'volume', '(', 'SV', ')', 'but', 'subsequently', 'improves', 'and', 'LV', 'function', '.', 'This', 'may', 'relate', 'to', 'an', 'early', 'beneficial', 'effect', 'on', 'myocardial', 'energetics', 'through', 'early', 'reduction', 'in', 'metabolic', 'demand', 'that', 'subsequently', 'leads', 'to', 'improved', 'efficiency', 'of', 'LV', 'contraction', '.', 'However', ',', 'it', 'is', 'not', 'clear', 'whether', 'long', '-', 'term', 'adaptive', 'servo', '-', 'ventilation', '(', 'ASV', ')', 'favorably', 'affects', 'cardiac', 'energetics', '.', 'Any', 'such', 'benefit', 'may', 'also', 'relate', 'to', 'reduced', 'sympathetic', 'nervous', 'system', '(', 'SNS', ')', 'activation', '.', 'However', 'its', 'effect', 'on', 'myocardial', 'SNS', 'function', 'is', 'also', 'not', 'well', 'studied', '.', '\n\n', 'In', 'a', 'pilot', 'study', 'we', 'demonstrated', 'early', '(', '6', 'week', ')', 'beneficial', 'effects', 'of', 'CPAP', 'in', 'patients', 'with', 'OSA', 'and', 'HF', '.', 'The', 'current', 'proposal', '(', 'AMEND', ')', 'is', 'a', 'unique', 'substudy', 'of', 'the', 'recently', 'funded', 'ADVENT', '-', 'HF', 'trial', '(', 'Adaptive', 'Servo', 'Ventilation', 'for', 'Therapy', 'of', 'Sleep', 'Apnea', 'in', 'HeartFailure', ')', '(', 'NCT01128816', ';', 'CIHR', ';', 'D.', 'Bradley', ',', 'PI', ')', '.', '\n\n', 'We', 'propose', 'to', 'evaluate', 'the', 'long', '-', 'term', '(', '6', 'month', ')', 'effects', 'of', 'ASV', 'on', 'daytime', '1', ')', 'oxidative', 'metabolism', ';', '2', ')', 'the', 'work', 'metabolic', 'index', '(', 'WMI', ')', 'as', 'an', 'estimate', 'of', 'mechanical', 'efficiency', ';', '3', ')', 'myocardial', 'sympathetic', 'nerve', '(', 'SN', ')', 'pre', '-', 'synaptic', 'function', ';', 'and', '4', ')', 'heart', 'rate', '(', 'HR', ')', 'variability', 'in', 'patients', 'with', 'HF', 'and', 'coexisting', 'OSA', 'or', 'CSA', '.', 'In', 'conjunction', 'with', 'echocardiographic', 'measures', 'of', 'LV', 'stroke', 'work', ',', 'positron', 'emission', 'tomography', '(', 'PET', ')', 'derived', '[', '11C', ']', 'acetate', 'kinetics', 'will', 'be', 'used', 'as', 'a', 'measure', 'of', 'oxidative', 'metabolism', ',', 'to', 'determine', 'the', 'WMI', '.', '[', '11C', ']', 'hydroxyephedrine', '(', 'HED', ')', 'retention', 'will', 'be', 'used', 'to', 'measure', 'cardiac', 'SN', 'pre', '-', 'synaptic', 'function', '.', '\n\n', 'Primary', 'Hypotheses', ':', 'In', 'patients', 'with', 'chronic', 'stable', 'HF', 'and', 'CSA', 'or', 'OSA', 'without', 'excessive', 'daytime', 'sleepiness', '(', 'EDS', ')', ',', 'long', '-', 'term', '(', '6', '-', 'month', ')', 'ASV', 'therapy', 'yields', ':', '\n\n', 'Beneficial', 'effects', 'on', 'daytime', 'myocardial', 'metabolism', 'leading', 'to', 'a', 'reduction', 'in', 'the', 'rate', 'of', 'oxidative', 'metabolism', 'as', 'measured', 'by', '[', '11C]acetate', 'kinetics', 'using', 'PET', 'imaging', ';', '\n', 'Improvement', 'in', 'energy', 'transduction', 'from', 'oxidative', 'metabolism', 'to', 'stroke', 'work', 'as', 'measured', 'by', 'an', 'increase', 'in', 'the', 'daytime', 'work', '-', 'metabolic', 'index', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02116140,NCT02116140,"Effects of Long Term Adaptive Servo Ventilation Therapy on Myocardial Energetics and Sympathetic Nerve Function in Heart Failure and Sleep Apnea. The AMEND Sub-study | Obstructive sleep apnea (OSA), central sleep apnea (CSA) and heart failure (HF) are states of metabolic demand and sympathetic nervous system (SNS) activation. In patients with sleep apnea and HF, continuous positive airway pressure (CPAP) initially may reduce left ventricular (LV)stroke volume (SV) but subsequently improves and LV function. This may relate to an early beneficial effect on myocardial energetics through early reduction in metabolic demand that subsequently leads to improved efficiency of LV contraction. However, it is not clear whether long-term adaptive servo-ventilation (ASV) favorably affects cardiac energetics. Any such benefit may also relate to reduced sympathetic nervous system (SNS) activation. However its effect on myocardial SNS function is also not well studied.

In a pilot study we demonstrated early (6 week) beneficial effects of CPAP in patients with OSA and HF. The current proposal (AMEND) is a unique substudy of the recently funded ADVENT-HF trial (Adaptive Servo Ventilation for Therapy of Sleep Apnea in HeartFailure) (NCT01128816; CIHR; D. Bradley, PI).

We propose to evaluate the long-term (6 month) effects of ASV on daytime 1) oxidative metabolism; 2) the work metabolic index (WMI) as an estimate of mechanical efficiency; 3) myocardial sympathetic nerve (SN) pre-synaptic function; and 4) heart rate (HR) variability in patients with HF and coexisting OSA or CSA. In conjunction with echocardiographic measures of LV stroke work, positron emission tomography (PET) derived [11C] acetate kinetics will be used as a measure of oxidative metabolism, to determine the WMI. [11C] hydroxyephedrine (HED) retention will be used to measure cardiac SN pre-synaptic function.

Primary Hypotheses: In patients with chronic stable HF and CSA or OSA without excessive daytime sleepiness (EDS), long-term (6-month) ASV therapy yields:

Beneficial effects on daytime myocardial metabolism leading to a reduction in the rate of oxidative metabolism as measured by [11C]acetate kinetics using PET imaging;
Improvement in energy transduction from oxidative metabolism to stroke work as measured by an increase in the daytime work-metabolic index.","[(21, 55, 'OTHER', 'Adaptive Servo Ventilation Therapy'), (115, 128, 'CONDITION', 'Heart Failure'), (133, 144, 'CONDITION', 'Sleep Apnea'), (168, 191, 'CONDITION', 'Obstructive sleep apnea'), (193, 196, 'CONDITION', 'OSA'), (199, 218, 'CONDITION', 'central sleep apnea'), (220, 223, 'CONDITION', 'CSA'), (229, 242, 'CONDITION', 'heart failure'), (244, 246, 'CONDITION', 'HF'), (345, 356, 'CONDITION', 'sleep apnea'), (361, 363, 'CONDITION', 'HF'), (365, 400, 'OTHER', 'continuous positive airway pressure'), (402, 406, 'OTHER', 'CPAP'), (736, 762, 'OTHER', 'adaptive servo-ventilation'), (764, 767, 'OTHER', 'ASV'), (1039, 1043, 'OTHER', 'CPAP'), (1061, 1064, 'CONDITION', 'OSA'), (1069, 1071, 'CONDITION', 'HF'), (1163, 1189, 'OTHER', 'Adaptive Servo Ventilation'), (1205, 1216, 'CONDITION', 'Sleep Apnea'), (1220, 1232, 'CONDITION', 'HeartFailure'), (1330, 1333, 'OTHER', 'ASV'), (1557, 1559, 'CONDITION', 'HF'), (1575, 1578, 'CONDITION', 'OSA'), (1582, 1585, 'CONDITION', 'CSA'), (1927, 1944, 'CONDITION', 'chronic stable HF'), (1949, 1952, 'CONDITION', 'CSA'), (1956, 1959, 'CONDITION', 'OSA'), (2024, 2027, 'OTHER', 'ASV')]"
"['Diet', 'Induced', 'Ketosis', 'for', 'Brain', 'Injury', '-', 'A', 'Feasibility', 'Study', ':', 'A', 'Ketogenic', 'Diet', 'With', 'MCT', 'Supplementation', 'as', 'a', 'Potential', 'Treatment', 'for', 'Brain', 'Injury', 'in', 'Adults', '|', 'Each', 'year', ',', 'approx', '.', '100', 'patients', 'with', 'severe', 'brain', 'injury', 'is', 'admitted', 'to', 'the', 'Clinic', 'for', 'Neurorehabilitation', '/', 'TBI', 'Unit', ',', 'Rigshospitalet', '.', 'Severe', 'brain', 'injury', 'results', 'in', 'local', 'oxygen', 'deficiency', 'and', 'acid', 'formation', 'in', 'the', 'brain', ',', 'which', 'together', 'destroys', 'brain', 'cells', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'investigate', 'whether', 'it', 'is', 'possible', 'to', 'carry', 'out', 'a', 'ketogenic', 'diet', 'therapy', 'for', 'patients', 'with', 'severe', 'brain', 'injury', 'for', 'six', 'weeks', '.', 'Ketosis', 'has', 'been', 'shown', 'to', 'be', 'neuroprotective', 'during', 'and', 'after', 'severe', 'brain', 'injury', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT04308577,NCT04308577,"Diet Induced Ketosis for Brain Injury - A Feasibility Study: A Ketogenic Diet With MCT Supplementation as a Potential Treatment for Brain Injury in Adults | Each year, approx. 100 patients with severe brain injury is admitted to the Clinic for Neurorehabilitation/TBI Unit, Rigshospitalet. Severe brain injury results in local oxygen deficiency and acid formation in the brain, which together destroys brain cells. The purpose of this study is to investigate whether it is possible to carry out a ketogenic diet therapy for patients with severe brain injury for six weeks. Ketosis has been shown to be neuroprotective during and after severe brain injury.","[(0, 20, 'OTHER', 'Diet Induced Ketosis'), (25, 37, 'CONDITION', 'Brain Injury'), (63, 77, 'OTHER', 'Ketogenic Diet'), (83, 102, 'OTHER', 'MCT Supplementation'), (132, 144, 'CONDITION', 'Brain Injury'), (194, 213, 'CONDITION', 'severe brain injury'), (290, 309, 'CONDITION', 'Severe brain injury'), (497, 519, 'OTHER', 'ketogenic diet therapy'), (538, 557, 'CONDITION', 'severe brain injury'), (573, 580, 'OTHER', 'Ketosis'), (635, 654, 'CONDITION', 'severe brain injury')]"
"['Effects', 'of', 'Psilocybin', 'in', 'Anorexia', 'Nervosa', '|', 'This', 'open', '-', 'label', 'pilot', 'study', 'seeks', 'to', 'investigate', 'the', 'safety', 'and', 'efficacy', 'of', 'psilocybin', 'in', 'persons', 'with', 'chronic', 'anorexia', 'nervosa', '(', 'AN', ')', '.', 'Psilocybin', 'has', 'previously', 'been', 'demonstrated', 'to', 'decrease', 'depression', 'and', 'anxiety', 'and', 'increase', 'long', '-', 'term', 'positive', 'behavior', 'change', 'in', 'other', 'populations', '.', 'The', 'investigators', 'seek', 'to', 'determine', 'whether', 'similar', 'changes', 'can', 'be', 'safely', 'produced', 'in', 'people', 'with', 'AN', 'when', 'psilocybin', 'is', 'administered', 'in', 'a', 'supportive', 'setting', 'with', 'close', 'follow', '-', 'up', '.', 'The', 'investigators', ""'"", 'primary', 'hypotheses', 'are', 'that', 'psilocybin', 'is', 'safe', 'to', 'administer', 'in', 'people', 'with', 'AN', ',', 'that', 'it', 'will', 'reduce', 'measures', 'of', 'anxiety', 'and', 'depression', ',', 'and', 'that', 'it', 'will', 'lead', 'to', 'increased', 'quality', 'of', 'life', '.', 'The', 'investigators', 'will', 'also', 'assess', 'a', 'number', 'of', 'exploratory', 'measures', 'related', 'to', 'eating', 'disorder', 'pathophysiology', '.']","['O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O']",NCT04052568,NCT04052568,"Effects of Psilocybin in Anorexia Nervosa | This open-label pilot study seeks to investigate the safety and efficacy of psilocybin in persons with chronic anorexia nervosa (AN). Psilocybin has previously been demonstrated to decrease depression and anxiety and increase long-term positive behavior change in other populations. The investigators seek to determine whether similar changes can be safely produced in people with AN when psilocybin is administered in a supportive setting with close follow-up. The investigators' primary hypotheses are that psilocybin is safe to administer in people with AN, that it will reduce measures of anxiety and depression, and that it will lead to increased quality of life. The investigators will also assess a number of exploratory measures related to eating disorder pathophysiology.","[(11, 21, 'DRUG', 'Psilocybin'), (25, 41, 'CONDITION', 'Anorexia Nervosa'), (120, 130, 'DRUG', 'psilocybin'), (147, 171, 'CONDITION', 'chronic anorexia nervosa'), (173, 175, 'CONDITION', 'AN'), (178, 188, 'DRUG', 'Psilocybin'), (234, 244, 'CONDITION', 'depression'), (249, 256, 'CONDITION', 'anxiety'), (425, 427, 'CONDITION', 'AN'), (433, 443, 'DRUG', 'psilocybin'), (553, 563, 'DRUG', 'psilocybin'), (601, 603, 'CONDITION', 'AN'), (637, 644, 'CONDITION', 'anxiety'), (649, 659, 'CONDITION', 'depression'), (792, 807, 'CONDITION', 'eating disorder')]"
"['A', 'Long', '-', 'Term', 'Study', 'of', 'MP-214', 'in', 'Patients', 'With', 'Receiving', 'Multiple', 'Drugs', 'Schizophrenia', '|', 'The', 'objective', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'long', '-', 'term', 'safety', ',', 'tolerability', ',', 'and', 'efficacy', 'of', 'MP-214', 'in', 'patients', 'with', 'receiving', 'multiple', 'drugs', 'schizophrenia', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT01626885,NCT01626885,"A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia | The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with receiving multiple drugs schizophrenia.","[(21, 27, 'DRUG', 'MP-214'), (45, 83, 'CONDITION', 'Receiving Multiple Drugs Schizophrenia'), (181, 187, 'DRUG', 'MP-214'), (205, 243, 'CONDITION', 'receiving multiple drugs schizophrenia')]"
"['Combined', 'Virological', 'and', 'Immunological', 'Evaluation', 'of', 'Treatment', 'of', 'Patients', 'With', 'Early', 'HTLV-1', '-', 'Associated', 'Myelopathy', 'With', 'Recombinant', 'Human', 'Interferon', 'Beta-1a', '|', 'HTLV', 'stands', 'for', 'human', 'T', 'cell', 'leukemia', 'virus', '.', 'HTLV-1', 'is', 'a', 'virus', 'that', 'attacks', 'specific', 'kinds', 'of', 'white', 'blood', 'cells', 'called', 'T', 'cells', '.', 'T', 'cells', 'are', 'part', 'of', 'the', 'natural', 'defense', 'system', 'of', 'the', 'body', '.', 'HTLV-1', 'has', 'been', 'associated', 'with', 'leukemia', 'and', 'lymphoma', '.', 'In', 'addition', ',', 'approximately', '1', '%', 'of', 'all', 'patients', 'infected', 'with', 'HTLV-1', 'develops', 'a', 'condition', 'known', 'as', 'HTLV-1', 'associated', 'myelopathy', '(', 'HAM', ')', '/', 'tropical', 'spastic', 'paraparesis', '(', 'TSP', ')', '.', '\n\n', 'Currently', 'there', 'is', 'no', 'clearly', 'defined', ',', 'effective', 'treatment', 'for', 'patients', 'with', 'HAM', '/', 'TSP', '.', 'Steroids', 'have', 'been', 'used', 'as', 'therapy', 'but', 'have', 'only', 'been', 'able', 'to', 'provide', 'temporary', 'relief', 'of', 'symptoms', '.', 'Human', 'interferon', 'is', 'a', 'small', 'protein', 'released', 'from', 'different', 'kinds', 'of', 'cells', 'in', 'the', 'body', '.', 'Interferon', 'has', 'been', 'known', 'to', 'have', 'antiviral', 'and', 'immunological', 'effects', 'and', 'has', 'been', 'used', 'to', 'treat', 'hepatitis', 'and', 'multiple', 'sclerosis', '.', 'Interferon', 'Beta', 'is', 'released', 'from', 'cells', 'called', 'fibroblasts', '.', 'These', 'cells', 'play', 'a', 'role', 'in', 'the', 'production', 'of', 'connective', 'tissue', '.', '\n\n', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'possible', 'role', 'of', 'recombinant', 'interferon', 'beta', '(', 'Avonex', ')', 'in', 'treatment', 'of', 'HAM', '/', 'TSP', '.', 'The', 'study', 'is', 'broken', 'into', 'three', 'phases', ',', 'a', 'pre', '-', 'treatment', 'phase', ',', 'a', 'treatment', 'phase', ',', 'and', 'a', 'post', '-', 'treatment', 'phase', '.', 'The', 'total', 'duration', 'of', 'the', 'study', 'will', 'be', '44', 'weeks', '.', '\n\n', 'Patients', 'participating', 'in', 'this', 'study', 'will', 'receive', 'injections', 'of', 'Avonex', '1', 'to', '2', 'times', 'a', 'week', '.', 'Throughout', 'the', 'study', 'patients', 'will', 'regularly', 'submit', 'blood', 'samples', 'and', 'undergo', 'diagnostic', 'tests', 'such', 'as', 'MRI', 'and', 'measures', 'of', 'somatosensory', 'evoked', 'potentials', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00001785,NCT00001785,"Combined Virological and Immunological Evaluation of Treatment of Patients With Early HTLV-1-Associated Myelopathy With Recombinant Human Interferon Beta-1a | HTLV stands for human T cell leukemia virus. HTLV-1 is a virus that attacks specific kinds of white blood cells called T cells. T cells are part of the natural defense system of the body. HTLV-1 has been associated with leukemia and lymphoma. In addition, approximately 1% of all patients infected with HTLV-1 develops a condition known as HTLV-1 associated myelopathy (HAM) / tropical spastic paraparesis (TSP).

Currently there is no clearly defined, effective treatment for patients with HAM/TSP. Steroids have been used as therapy but have only been able to provide temporary relief of symptoms. Human interferon is a small protein released from different kinds of cells in the body. Interferon has been known to have antiviral and immunological effects and has been used to treat hepatitis and multiple sclerosis. Interferon Beta is released from cells called fibroblasts. These cells play a role in the production of connective tissue.

The purpose of this study is to evaluate the possible role of recombinant interferon beta (Avonex) in treatment of HAM/TSP. The study is broken into three phases, a pre-treatment phase, a treatment phase, and a post-treatment phase. The total duration of the study will be 44 weeks.

Patients participating in this study will receive injections of Avonex 1 to 2 times a week. Throughout the study patients will regularly submit blood samples and undergo diagnostic tests such as MRI and measures of somatosensory evoked potentials.","[(80, 114, 'CONDITION', 'Early HTLV-1-Associated Myelopathy'), (120, 156, 'DRUG', 'Recombinant Human Interferon Beta-1a'), (159, 163, 'CONDITION', 'HTLV'), (175, 202, 'CONDITION', 'human T cell leukemia virus'), (204, 210, 'CONDITION', 'HTLV-1'), (347, 353, 'CONDITION', 'HTLV-1'), (462, 468, 'CONDITION', 'HTLV-1'), (499, 527, 'CONDITION', 'HTLV-1 associated myelopathy'), (529, 532, 'CONDITION', 'HAM'), (536, 564, 'CONDITION', 'tropical spastic paraparesis'), (566, 569, 'CONDITION', 'TSP'), (650, 657, 'CONDITION', 'HAM/TSP'), (978, 993, 'DRUG', 'Interferon Beta'), (1164, 1191, 'DRUG', 'recombinant interferon beta'), (1193, 1199, 'DRUG', 'Avonex'), (1217, 1224, 'CONDITION', 'HAM/TSP'), (1450, 1456, 'DRUG', 'Avonex')]"
"['Effects', 'of', 'a', 'Home', 'Based', 'Walking', 'Program', 'Using', 'Rhythmic', 'Auditory', 'Stimulation', 'on', 'Walking', 'and', 'Cortical', 'Activation', 'in', 'Patients', 'With', 'Multiple', 'Sclerosis', '.', '|', 'Rhythmic', 'Auditory', 'Stimulation', '(', 'RAS', ')', 'is', 'a', 'music', 'therapy', 'technique', 'that', 'provides', 'rhythmic', 'auditory', 'cues', '(', 'like', 'a', 'beat', ')', 'to', 'help', 'improve', 'patients', ""'"", 'movements', ',', 'especially', 'when', 'walking', '.', '\n\n', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'compare', 'the', 'effect', 'on', 'walking', 'performance', 'of', 'a', 'home', 'based', 'walking', 'program', '(', 'HBWP', ')', 'with', 'Rhythmic', 'Auditory', 'Stimulation', '(', 'RAS', ')', ',', 'to', 'that', 'of', 'a', 'HBWP', 'without', 'RAS', ',', 'or', 'to', 'RAS', 'without', 'walking', 'exercise', '.', '\n\n', 'A', 'second', 'part', 'of', 'this', 'study', 'will', 'assess', 'the', 'effects', 'of', 'Rhythmic', 'Auditory', 'Stimulation', '(', 'RAS', ')', 'on', 'brain', 'activity', 'in', 'patients', 'with', 'Multiple', 'Sclerosis', 'while', 'performing', 'mental', 'imagery', 'of', 'walking', '.']","['O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O']",NCT02065284,NCT02065284,"Effects of a Home Based Walking Program Using Rhythmic Auditory Stimulation on Walking and Cortical Activation in Patients With Multiple Sclerosis. | Rhythmic Auditory Stimulation (RAS) is a music therapy technique that provides rhythmic auditory cues (like a beat) to help improve patients' movements, especially when walking.

The purpose of this study is to compare the effect on walking performance of a home based walking program (HBWP) with Rhythmic Auditory Stimulation (RAS), to that of a HBWP without RAS, or to RAS without walking exercise.

A second part of this study will assess the effects of Rhythmic Auditory Stimulation (RAS) on brain activity in patients with Multiple Sclerosis while performing mental imagery of walking.","[(13, 39, 'PHYSICAL', 'Home Based Walking Program'), (46, 75, 'OTHER', 'Rhythmic Auditory Stimulation'), (128, 146, 'CONDITION', 'Multiple Sclerosis'), (150, 179, 'OTHER', 'Rhythmic Auditory Stimulation'), (181, 184, 'OTHER', 'RAS'), (408, 434, 'PHYSICAL', 'home based walking program'), (436, 440, 'PHYSICAL', 'HBWP'), (447, 476, 'OTHER', 'Rhythmic Auditory Stimulation'), (478, 481, 'OTHER', 'RAS'), (497, 513, 'CONTROL', 'HBWP without RAS'), (521, 549, 'CONTROL', 'RAS without walking exercise'), (607, 636, 'OTHER', 'Rhythmic Auditory Stimulation'), (638, 641, 'OTHER', 'RAS'), (678, 696, 'CONDITION', 'Multiple Sclerosis'), (714, 739, 'BEHAVIOURAL', 'mental imagery of walking')]"
"['Phase', '3', ',', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', ',', '8', '-', 'week', 'Clinical', 'Study', 'to', 'Assess', 'the', 'Efficacy', ',', 'Safety', ',', 'and', 'Tolerability', ',', 'of', 'Intranasal', 'Carbetocin', '(', 'LV-101', ')', 'in', 'Prader', '-', 'Willi', 'Syndrome', '(', 'PWS', ')', 'With', 'Long', 'Term', 'Follow', '-', 'Up', '(', 'CARE', '-', 'PWS', ')', '|', 'This', 'Phase', '3', 'study', 'is', 'designed', 'to', 'test', 'the', 'effectiveness', 'of', 'intranasal', 'carbetocin', '(', 'LV-101', ')', 'in', 'participants', 'with', 'Prader', '-', 'Willi', 'syndrome', '(', 'PWS', ')', '.', 'Carbetocin', 'is', 'an', 'oxytocin', 'analog', '(', 'a', 'man', '-', 'made', 'chemical', 'that', 'is', 'like', 'oxytocin', ')', '.', 'This', 'study', 'will', 'also', 'evaluate', 'the', 'safety', 'and', 'tolerability', 'of', 'LV-101', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O']",NCT03649477,NCT03649477,"Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) With Long Term Follow-Up (CARE-PWS) | This Phase 3 study is designed to test the effectiveness of intranasal carbetocin (LV-101) in participants with Prader-Willi syndrome (PWS). Carbetocin is an oxytocin analog (a man-made chemical that is like oxytocin). This study will also evaluate the safety and tolerability of LV-101.","[(35, 42, 'CONTROL', 'Placebo'), (141, 151, 'DRUG', 'Carbetocin'), (153, 159, 'DRUG', 'LV-101'), (164, 185, 'CONDITION', 'Prader-Willi Syndrome'), (187, 190, 'CONDITION', 'PWS'), (301, 311, 'DRUG', 'carbetocin'), (313, 319, 'DRUG', 'LV-101'), (342, 363, 'CONDITION', 'Prader-Willi syndrome'), (365, 368, 'CONDITION', 'PWS'), (371, 381, 'DRUG', 'Carbetocin'), (510, 516, 'DRUG', 'LV-101')]"
"['To', 'evaluate', 'whether', 'there', 'is', 'a', 'difference', 'in', 'symptomatic', 'thromboembolism', 'events', 'in', 'the', 'subset', 'of', 'patients', 'with', 'a', 'history', 'of', ',', 'or', 'risk', 'factors', 'for', 'thromboembolic', 'disease', 'for', 'topically', 'applied', 'tranexamic', 'acid', 'in', 'total', 'joint', 'arthroplasty', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT02644473,NCT02644473,"To evaluate whether there is a difference in symptomatic thromboembolism events in the subset of patients with a history of, or risk factors for thromboembolic disease for topically applied tranexamic acid in total joint arthroplasty.","[(45, 72, 'CONDITION', 'symptomatic thromboembolism'), (145, 167, 'CONDITION', 'thromboembolic disease'), (190, 205, 'DRUG', 'tranexamic acid'), (209, 233, 'CONDITION', 'total joint arthroplasty')]"
"['Efficacy', 'of', 'a', 'Multifactorial', 'and', 'Personalized', 'Program', 'for', 'Fall', 'Prevention', 'in', 'Community', '-', 'dwelling', 'Elderly', 'in', 'Comparison', 'to', 'the', 'Usual', 'Care', ':', 'a', 'Randomized', 'Controlled', 'Trial', '|', 'Randomized', 'Controlled', 'Trial', '(', 'RCT', ')', 'aiming', 'at', 'assessing', 'the', 'efficacy', 'of', 'an', 'interdisciplinary', 'multi', '-', 'component', 'and', 'personalized', 'multi', '-', 'factorial', 'intervention', 'for', 'reducing', 'falls', 'at', 'one', 'year', 'post', '-', 'enrolment', 'in', 'comparison', 'to', 'the', 'usual', 'care', 'in', 'a', 'sample', 'of', 'community', 'dwelling', 'elderly', '(', 'age', '≥65', 'years', ')', ',', 'with', 'or', 'without', 'Parkinson', ""'s"", 'Disease', 'and/or', 'previous', 'Stroke', '.']","['O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'O']",NCT03592420,NCT03592420,"Efficacy of a Multifactorial and Personalized Program for Fall Prevention in Community-dwelling Elderly in Comparison to the Usual Care: a Randomized Controlled Trial | Randomized Controlled Trial (RCT) aiming at assessing the efficacy of an interdisciplinary multi-component and personalized multi-factorial intervention for reducing falls at one year post-enrolment in comparison to the usual care in a sample of community dwelling elderly (age ≥65 years), with or without Parkinson's Disease and/or previous Stroke.","[(14, 73, 'BEHAVIOURAL', 'Multifactorial and Personalized Program for Fall Prevention'), (242, 321, 'BEHAVIOURAL', 'interdisciplinary multi-component and personalized multi-factorial intervention'), (475, 494, 'CONDITION', ""Parkinson's Disease""), (511, 517, 'CONDITION', 'Stroke')]"
"['Therapy', 'With', 'Bromocriptine', 'in', 'Patients', 'With', 'Symptomatic', 'Risperidone', '-', 'Induced', 'Hyperprolactinemia', '|', 'Antipsychotic', 'drugs', 'can', 'cause', 'a', 'clinically', 'relevant', 'hyperprolactinemia', 'due', 'to', 'blocking', 'the', 'dopamine', 'receptors', 'in', 'the', 'pituitary', '.', 'Schizophrenic', 'patients', 'suffering', 'from', 'a', 'neuroleptic', '-', 'induced', 'hyperprolactinemia', 'will', 'be', 'examined', 'endocrinologically', '.', 'Adverse', 'drug', 'effects', 'and', 'diagnoses', 'will', 'be', 'confirmed', 'by', 'measuring', 'hormones', '.']","['O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00315081,NCT00315081,Therapy With Bromocriptine in Patients With Symptomatic Risperidone-Induced Hyperprolactinemia | Antipsychotic drugs can cause a clinically relevant hyperprolactinemia due to blocking the dopamine receptors in the pituitary.Schizophrenic patients suffering from a neuroleptic-induced hyperprolactinemia will be examined endocrinologically. Adverse drug effects and diagnoses will be confirmed by measuring hormones.,"[(13, 26, 'DRUG', 'Bromocriptine'), (56, 67, 'DRUG', 'Risperidone'), (76, 94, 'CONDITION', 'Hyperprolactinemia'), (97, 110, 'DRUG', 'Antipsychotic'), (149, 167, 'CONDITION', 'hyperprolactinemia'), (224, 237, 'CONDITION', 'Schizophrenic'), (264, 302, 'CONDITION', 'neuroleptic-induced hyperprolactinemia')]"
"['Instrumental', 'and', 'Manual', 'Increase', 'of', 'Couch', 'in', 'Neuromuscular', 'Patients', ':', 'Effects', 'of', 'Different', 'Techniques', 'on', 'the', 'Generated', 'Flow', '|', 'Inefficient', 'cough', 'is', 'responsible', 'of', 'respiratory', 'complications', 'in', 'neuromuscular', 'patients', 'which', 'can', 'lead', 'to', 'hospitalisation', 'and', 'can', 'be', 'life', 'threatening', '.', 'Techniques', 'enhancing', 'cough', 'efficiency', 'are', 'successful', 'in', 'improving', 'the', 'clearance', 'of', 'bronchial', 'secretions', 'and', 'help', 'non', 'invasive', 'ventilation', 'efficiency', 'especially', 'in', 'case', 'of', 'acute', 'respiratory', 'failure', '.', 'Combining', 'mechanical', 'exsufflation', 'to', 'the', 'manual', 'techniques', 'of', 'physiotherapy', 'might', 'enhance', 'efficiency', '.', 'Therefore', 'the', 'investigators', 'want', 'to', 'compare', 'cough', 'efficiency', 'under', 'different', 'techniques', 'of', 'instrumental', 'and', 'manual', 'of', 'cough', 'assistance', 'in', 'order', 'to', 'determine', 'the', 'best', 'combination', 'to', 'optimize', 'cough', 'flow', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01518439,NCT01518439,Instrumental and Manual Increase of Couch in Neuromuscular Patients: Effects of Different Techniques on the Generated Flow | Inefficient cough is responsible of respiratory complications in neuromuscular patients which can lead to hospitalisation and can be life threatening. Techniques enhancing cough efficiency are successful in improving the clearance of bronchial secretions and help non invasive ventilation efficiency especially in case of acute respiratory failure. Combining mechanical exsufflation to the manual techniques of physiotherapy might enhance efficiency. Therefore the investigators want to compare cough efficiency under different techniques of instrumental and manual of cough assistance in order to determine the best combination to optimize cough flow.,"[(45, 58, 'CONDITION', 'Neuromuscular'), (125, 142, 'CONDITION', 'Inefficient cough'), (190, 203, 'CONDITION', 'neuromuscular'), (447, 472, 'CONDITION', 'acute respiratory failure'), (484, 507, 'OTHER', 'mechanical exsufflation'), (515, 549, 'OTHER', 'manual techniques of physiotherapy'), (667, 710, 'OTHER', 'instrumental and manual of cough assistance')]"
"['Evaluation', 'of', 'Computer', '-', 'Based', 'Training', 'to', 'Educate', 'Japanese', 'Physicians', 'in', 'the', 'Methods', 'of', 'Interpreting', 'Florbetapir', '(', '18F', ')', 'PET', 'Scans', '|', 'This', 'study', 'is', 'designed', 'to', 'validate', 'the', 'Japanese', 'electronic', 'florbetapir', '(', '18F', ')', 'interpretation', 'training', 'program', 'intended', 'for', 'post', '-', 'approval', 'implementation', 'in', 'Japan', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02029547,NCT02029547,Evaluation of Computer-Based Training to Educate Japanese Physicians in the Methods of Interpreting Florbetapir (18F) PET Scans | This study is designed to validate the Japanese electronic florbetapir (18F) interpretation training program intended for post-approval implementation in Japan.,"[(14, 37, 'OTHER', 'Computer-Based Training'), (76, 127, 'OTHER', 'Methods of Interpreting Florbetapir (18F) PET Scans'), (178, 238, 'OTHER', 'electronic florbetapir (18F) interpretation training program')]"
"['SHARED', 'DECISION', 'MAKING', 'ON', 'A', ""'"", 'LIFE', '-', 'AND', '-', 'CARE', 'PLAN', ""'"", 'IN', 'LONG', '-', 'TERM', 'CARE', 'FACILITIES', '|', 'Shared', 'Decision', 'Making', '(', 'SDM', ')', 'is', 'defined', 'as', 'a', 'process', 'where', 'healthcare', 'professionals', 'and', 'patients', 'make', 'decisions', 'together', ',', 'using', 'the', 'best', 'available', 'evidence', '.', 'SDM', ',', 'as', 'a', 'communication', 'and', 'decision', 'method', ',', 'can', 'be', 'used', 'also', 'with', 'persons', 'suffering', 'from', 'dementia', '.', 'Yet', ',', 'SDM', 'with', 'persons', 'with', 'dementia', 'or', 'even', 'with', 'their', 'family', 'caregivers', 'is', 'not', 'widespread', '.', '\n\n', 'The', 'present', 'research', 'project', 'aims', 'to', 'develop', 'and', 'evaluate', 'an', 'SDM', 'framework', 'in', 'care', 'planning', 'to', 'be', 'implemented', 'in', 'long', '-', 'term', 'care', 'facilities', ',', 'in', 'order', 'to', 'obtain', 'a', 'constantly', 'developing', 'care', 'plan', 'that', 'focuses', 'not', 'only', 'on', 'the', 'medical', ',', 'physical', ',', 'psychosocial', 'and', 'spiritual', 'needs', 'of', 'the', 'resident', ',', 'but', 'that', 'considers', 'and', 'documents', 'his', 'preferences', 'and', 'the', 'actions', 'taken', 'by', 'caregivers', 'to', 'meet', 'them', '.', '\n\n', 'The', 'current', 'project', 'is', 'a', 'controlled', 'exploratory', 'study', '.', 'Case', 'studies', 'that', 'involve', 'a', 'triad', 'in', 'each', 'case', ',', 'composed', 'by', 'the', 'resident', 'with', 'moderate', 'or', 'severe', 'dementia', ',', 'his', 'family', 'caregiver', 'and', 'the', 'professional', 'usually', 'taking', 'care', 'for', 'the', 'resident', ',', 'will', 'be', 'used', '(', 'n=16', 'professionals', ';', 'n=40', 'residents', ';', 'n=40', 'family', 'caregivers', ')', '.', 'Professional', 'caregivers', 'of', 'two', 'nursing', 'homes', ',', 'one', 'located', 'in', 'Italy', 'and', 'one', 'in', 'the', 'Netherlands', ',', 'will', 'receive', 'a', 'specific', 'training', 'in', 'SDM', 'principles', 'and', 'will', 'guide', 'the', 'SDM', 'interview', 'within', 'the', 'triad', '.', 'Primary', 'outcome', 'will', 'be', 'the', 'proportion', 'of', 'residents', 'whose', 'preferences', 'and', 'needs', ',', 'together', 'with', 'the', 'related', 'actions', 'to', 'meet', 'them', ',', 'are', 'known', ',', 'documented', 'and', 'satisfied', 'in', 'their', ""'"", 'life', '-', 'and', '-', 'care', 'plans', ""'"", '.', 'Secondary', 'outcomes', 'are', 'the', 'residents', ""'"", 'and', 'family', 'caregivers', ""'"", 'quality', 'of', 'life', ';', 'the', 'family', 'caregivers', ""'"", 'sense', 'of', 'competence', 'and', 'the', 'healthcare', 'professionals', ""'"", 'job', 'satisfaction', '.', 'Semi', '-', 'structured', 'interviews', 'and', 'focus', 'group', 'interviews', 'will', 'be', 'performed', 'to', 'assess', 'satisfaction', 'with', 'the', 'intervention', 'and', 'barriers', 'and', 'facilitators', 'to', 'its', 'implementation', '.', 'Assessments', 'are', 'performed', 'at', 'baseline', 'and', 'six', 'months', 'after', 'the', 'intervention', '.', '\n\n', 'We', 'hypothesize', 'that', 'the', 'use', 'of', 'the', 'SDM', 'process', 'in', 'care', 'planning', 'will', 'increase', 'the', 'number', 'of', 'met', 'needs', 'and', 'will', 'improve', 'the', 'residents', ""'"", 'and', 'family', 'caregivers', 'quality', 'of', 'life', ',', 'the', 'family', 'caregivers', ""'"", 'sense', 'of', 'competence', 'and', 'the', 'healthcare', 'professionals', ""'"", 'job', 'satisfaction', '.', '\n\n', 'The', 'key', 'element', 'of', 'this', 'study', 'is', 'that', 'it', 'will', 'contribute', 'to', 'our', 'knowledge', 'about', 'the', 'efficacy', 'and', 'feasibility', 'of', 'an', 'SDM', 'framework', 'in', 'care', 'planning', 'in', 'long', '-', 'term', 'care', 'facilities', 'with', 'persons', 'with', 'moderate', 'to', 'severe', 'dementia', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT02118701,NCT02118701,"SHARED DECISION MAKING ON A 'LIFE-AND-CARE PLAN' IN LONG-TERM CARE FACILITIES | Shared Decision Making (SDM) is defined as a process where healthcare professionals and patients make decisions together, using the best available evidence. SDM, as a communication and decision method, can be used also with persons suffering from dementia. Yet, SDM with persons with dementia or even with their family caregivers is not widespread.

The present research project aims to develop and evaluate an SDM framework in care planning to be implemented in long-term care facilities, in order to obtain a constantly developing care plan that focuses not only on the medical, physical, psychosocial and spiritual needs of the resident, but that considers and documents his preferences and the actions taken by caregivers to meet them.

The current project is a controlled exploratory study. Case studies that involve a triad in each case, composed by the resident with moderate or severe dementia, his family caregiver and the professional usually taking care for the resident, will be used (n=16 professionals; n=40 residents; n=40 family caregivers). Professional caregivers of two nursing homes, one located in Italy and one in the Netherlands, will receive a specific training in SDM principles and will guide the SDM interview within the triad. Primary outcome will be the proportion of residents whose preferences and needs, together with the related actions to meet them, are known, documented and satisfied in their 'life-and-care plans'. Secondary outcomes are the residents' and family caregivers' quality of life; the family caregivers' sense of competence and the healthcare professionals' job satisfaction. Semi-structured interviews and focus group interviews will be performed to assess satisfaction with the intervention and barriers and facilitators to its implementation. Assessments are performed at baseline and six months after the intervention.

We hypothesize that the use of the SDM process in care planning will increase the number of met needs and will improve the residents' and family caregivers quality of life, the family caregivers' sense of competence and the healthcare professionals' job satisfaction.

The key element of this study is that it will contribute to our knowledge about the efficacy and feasibility of an SDM framework in care planning in long-term care facilities with persons with moderate to severe dementia.","[(80, 102, 'OTHER', 'Shared Decision Making'), (104, 107, 'OTHER', 'SDM'), (327, 335, 'CONDITION', 'dementia'), (342, 345, 'OTHER', 'SDM'), (364, 372, 'CONDITION', 'dementia'), (491, 494, 'OTHER', 'SDM'), (954, 981, 'CONDITION', 'moderate or severe dementia'), (1269, 1272, 'OTHER', 'SDM'), (1303, 1316, 'OTHER', 'SDM interview'), (1988, 1991, 'OTHER', 'SDM'), (2337, 2340, 'OTHER', 'SDM'), (2415, 2442, 'CONDITION', 'moderate to severe dementia')]"
"['Comparison', 'of', 'Two', 'Noninvasive', 'Positive', 'Pressure', 'Ventilation', 'Devices', 'Using', 'Target', 'Volume', 'Modes', 'in', 'Obesity', 'Hypoventilation', 'Syndrome', '(', 'OHS', '):', 'A', 'Pilot', 'Randomized', 'Crossover', 'Controlled', 'Trial', '|', 'Patients', 'with', 'OHS', 'are', 'efficiently', 'managed', 'with', 'long', 'term', 'home', '-', 'based', 'nocturnal', 'noninvasive', 'positive', 'pressure', 'ventilation', '(', 'NIPPV', ')', '.', 'Several', 'NIPPV', 'devices', 'offer', 'the', 'feature', 'of', 'automatically', 'adjusting', 'pressure', 'support', '(', 'and/or', 'respiratory', 'back', '-', 'up', 'rate', ')', 'on', 'the', 'basis', 'of', 'a', 'pre', '-', 'determined', '""', 'ideal', 'tidal', 'volume', '""', 'or', '""', 'ideal', 'ventilation', '""', '.', 'However', 'algorithms', 'used', 'to', 'achieve', 'these', 'ideal', 'targets', 'are', 'different', 'among', 'different', 'commercialized', 'devices', 'and', 'the', 'relative', 'efficacy', 'from', 'an', 'algorithm', 'compared', 'to', 'another', 'remains', 'unknown', '.', 'The', 'main', 'objective', 'is', 'this', 'study', 'is', 'to', 'compare', 'two', 'commercialized', 'NIPPV', 'that', 'have', 'this', 'option']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O']",NCT01748656,NCT01748656,"Comparison of Two Noninvasive Positive Pressure Ventilation Devices Using Target Volume Modes in Obesity Hypoventilation Syndrome (OHS): A Pilot Randomized Crossover Controlled Trial | Patients with OHS are efficiently managed with long term home-based nocturnal noninvasive positive pressure ventilation (NIPPV). Several NIPPV devices offer the feature of automatically adjusting pressure support (and/or respiratory back-up rate) on the basis of a pre-determined ""ideal tidal volume"" or ""ideal ventilation"". However algorithms used to achieve these ideal targets are different among different commercialized devices and the relative efficacy from an algorithm compared to another remains unknown. The main objective is this study is to compare two commercialized NIPPV that have this option","[(18, 67, 'OTHER', 'Noninvasive Positive Pressure Ventilation Devices'), (97, 129, 'CONDITION', 'Obesity Hypoventilation Syndrome'), (131, 134, 'CONDITION', 'OHS'), (199, 202, 'CONDITION', 'OHS'), (253, 304, 'OTHER', 'nocturnal noninvasive positive pressure ventilation'), (306, 311, 'OTHER', 'NIPPV'), (322, 335, 'OTHER', 'NIPPV devices'), (765, 770, 'OTHER', 'NIPPV')]"
"['Acoustic', '-', 'electric', 'Therapy', 'in', 'Patients', 'With', 'Disorders', 'of', 'Consciousness', '|', 'Altered', 'gamma', 'activity', 'has', 'been', 'observed', 'in', 'several', 'neurological', 'and', 'psychiatric', 'disorders', ',', 'including', 'a', 'reduction', 'in', 'gamma', 'synchronization', 'in', 'patients', 'with', 'disorders', 'of', 'consciousness', '.', 'Modulation', 'of', 'gamma', 'oscillations', 'with', 'rhythmic', 'stimulation', 'has', 'been', 'used', 'as', 'a', 'possible', 'therapeutic', 'tool', '.', 'Hence', ',', 'we', 'try', 'to', 'use', 'acoustic', 'and', 'electric', 'stimulation', 'at', 'gamma', 'frequency', 'to', 'restore', 'brain', 'oscillation', 'and', 'thereby', 'to', 'improve', 'conscious', 'awareness', 'in', 'patients', 'with', 'disorders', 'of', 'consciousness', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT04435301,NCT04435301,"Acoustic-electric Therapy in Patients With Disorders of Consciousness | Altered gamma activity has been observed in several neurological and psychiatric disorders, including a reduction in gamma synchronization in patients with disorders of consciousness. Modulation of gamma oscillations with rhythmic stimulation has been used as a possible therapeutic tool. Hence, we try to use acoustic and electric stimulation at gamma frequency to restore brain oscillation and thereby to improve conscious awareness in patients with disorders of consciousness.","[(0, 25, 'OTHER', 'Acoustic-electric Therapy'), (43, 69, 'CONDITION', 'Disorders of Consciousness'), (228, 254, 'CONDITION', 'disorders of consciousness'), (256, 314, 'OTHER', 'Modulation of gamma oscillations with rhythmic stimulation'), (382, 434, 'OTHER', 'acoustic and electric stimulation at gamma frequency'), (524, 550, 'CONDITION', 'disorders of consciousness')]"
"['An', 'Open', 'Label', ',', 'Prospective', ',', 'Pilot', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Best', 'Physician', ""'s"", 'Choice', 'of', 'Standard', 'of', 'Care', 'Combined', 'With', 'NaviFUS', 'System', 'in', 'Patients', 'With', 'Recurrent', 'Glioblastoma', 'Multiforme', '|', 'This', 'is', 'a', 'prospective', ',', 'single', '-', 'arm', ',', 'two', 'stages', ',', 'open', '-', 'label', ',', 'pilot', 'study', 'to', 'investigate', 'the', 'efficacy', 'and', 'safety', 'of', 'FUS', 'add', '-', 'on', 'bevacizumab', '(', 'BEV', ')', 'in', 'rGBM', 'patients', '.', 'The', 'BEV', 'is', 'the', 'best', 'physician', ""'s"", 'choice', 'of', 'standard', 'of', 'care', 'for', 'rGBM', 'after', 'prior', 'radiotherapy', 'and', 'temozolomide', 'chemotherapy', 'in', 'the', 'LinKou', 'Chang', 'Gung', 'Memorial', 'Hospital', '.', 'Eligible', 'patients', 'will', 'be', 'enrolled', 'through', 'the', 'process', 'of', 'informed', 'consent', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-RADIO', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04446416,NCT04446416,"An Open Label, Prospective, Pilot Study to Evaluate the Efficacy and Safety of Best Physician's Choice of Standard of Care Combined With NaviFUS System in Patients With Recurrent Glioblastoma Multiforme | This is a prospective, single-arm, two stages, open-label, pilot study to investigate the efficacy and safety of FUS add-on bevacizumab (BEV) in rGBM patients. The BEV is the best physician's choice of standard of care for rGBM after prior radiotherapy and temozolomide chemotherapy in the LinKou Chang Gung Memorial Hospital. Eligible patients will be enrolled through the process of informed consent.","[(137, 151, 'OTHER', 'NaviFUS System'), (169, 202, 'CONDITION', 'Recurrent Glioblastoma Multiforme'), (318, 328, 'OTHER', 'FUS add-on'), (329, 340, 'DRUG', 'bevacizumab'), (342, 345, 'DRUG', 'BEV'), (350, 354, 'CONDITION', 'rGBM'), (369, 372, 'DRUG', 'BEV'), (428, 432, 'CONDITION', 'rGBM'), (445, 457, 'RADIOTHERAPY', 'radiotherapy'), (462, 474, 'DRUG', 'temozolomide')]"
"['A', 'Study', 'to', 'Investigate', 'the', 'Genetic', 'Variation', 'of', 'Dopamine', 'Pathway', 'Associated', 'With', 'the', 'Observed', 'Effects', 'of', 'a', 'New', 'Treatment', 'in', 'Former', 'Studies', 'in', 'Patients', 'With', 'Chronic', 'Pain', '|', 'Patients', 'having', 'completed', 'former', 'trials', 'T1001', '-', '01', 'or', 'T1001', '-', '02', 'will', 'undergo', 'one', 'blood', 'sampling', 'for', 'genotyping', 'purposes', '.', 'In', 'addition', 'they', 'will', 'compete', 'the', 'personality', 'questionnaires', 'they', 'had', 'completed', 'in', 'the', 'former', 'trial', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02989792,NCT02989792,A Study to Investigate the Genetic Variation of Dopamine Pathway Associated With the Observed Effects of a New Treatment in Former Studies in Patients With Chronic Pain | Patients having completed former trials T1001-01 or T1001-02 will undergo one blood sampling for genotyping purposes. In addition they will compete the personality questionnaires they had completed in the former trial.,"[(156, 168, 'CONDITION', 'Chronic Pain')]"
"['Major', 'Research', 'Instrumentation', 'Program', ':', 'Development', 'of', 'an', 'Innovative', 'Instrument', 'on', 'Robot', '-', 'Aided', 'Virtual', 'Rehabilitation', 'for', 'Intelligent', 'Physical', 'Training', 'of', 'Individuals', 'With', 'Disabilities', '(', 'iRAPID', ')', '|', 'Investigate', 'development', 'of', 'an', 'Innovative', 'Instrument', 'on', 'Robot', '-', 'Aided', 'and', 'Virtual', 'Reality', 'Rehabilitation', 'for', 'Intelligent', 'Physical', 'Training', '(', 'i.e.', 'gait', 'and', 'stepping', ')', 'of', 'Individuals', 'post', '-', 'stroke', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT04740060,NCT04740060,Major Research Instrumentation Program: Development of an Innovative Instrument on Robot-Aided Virtual Rehabilitation for Intelligent Physical Training of Individuals With Disabilities (iRAPID) | Investigate development of an Innovative Instrument on Robot-Aided and Virtual Reality Rehabilitation for Intelligent Physical Training (i.e. gait and stepping) of Individuals post-stroke.,"[(83, 117, 'PHYSICAL', 'Robot-Aided Virtual Rehabilitation'), (122, 151, 'PHYSICAL', 'Intelligent Physical Training'), (251, 297, 'PHYSICAL', 'Robot-Aided and Virtual Reality Rehabilitation'), (302, 331, 'PHYSICAL', 'Intelligent Physical Training'), (372, 383, 'CONDITION', 'post-stroke')]"
"['A', 'Randomized', 'Controlled', 'Trial', 'of', 'Generic', 'Substitution', 'of', 'Antiepileptic', 'Drugs', '|', 'Background', '.', 'Anecdotal', 'reports', 'and', 'uncontrolled', 'studies', 'have', 'described', 'an', 'association', 'between', 'generic', 'substitution', 'of', 'antiepileptic', 'drugs', '(', 'AEDs', ')', 'and', 'adverse', 'events', ',', 'including', 'loss', 'of', 'seizure', 'control', '.', 'Although', 'these', 'results', 'are', 'likely', 'to', 'be', 'influenced', 'by', 'methodological', 'bias', ',', 'they', 'have', 'led', 'to', 'a', 'strong', 'opposition', ',', 'among', 'physicians', 'and', 'patients', ',', 'to', 'the', 'use', 'of', 'generic', 'products', 'in', 'epilepsy', '.', '\n\n', 'Objectives', '.', 'The', 'primary', 'objective', 'is', 'to', 'assess', 'potential', 'risks', 'associated', 'with', 'substitution', 'of', 'the', 'currently', 'taken', 'AED', 'product', 'with', 'an', 'equivalent', 'product', ',', 'using', 'as', 'endpoint', 'changes', 'in', 'serum', 'drug', 'levels', 'at', 'steady', '-', 'state', 'after', 'substitution', 'compared', 'with', 'baseline', '.', 'Secondary', 'objectives', 'will', 'be', 'the', 'assessment', 'of', 'inter', '-', 'subject', 'variability', 'in', 'serum', 'drug', 'concentration', 'on', 'an', 'unchanged', 'treatment', 'schedule', ',', 'and', 'evaluation', 'of', 'potential', 'short', '-', 'term', 'changes', 'in', 'seizure', 'control', 'and', 'adverse', 'events', 'rate', '.', '\n\n', 'Methods', '.', 'The', 'study', 'will', 'use', 'an', 'experimental', 'randomized', 'open', '-', 'label', 'non', '-', 'inferiority', 'design', '.', 'The', 'population', 'will', 'consist', 'of', '200', 'adults', 'stabilized', 'on', 'chronic', 'treatment', 'with', 'carbamazepine', ',', 'valproic', 'acid', ',', 'topiramate', ',', 'oxcarbazepine', ',', 'levetiracetam', 'or', 'lamotrigine', 'and', 'admitted', 'to', 'hospital', 'for', 'diagnostic', 'evaluation', 'or', 'other', 'indications', ',', 'with', 'no', 'expected', 'treatment', 'changes', 'during', 'the', 'subsequent', '5', 'to', '6', 'days', '.', 'Patients', 'will', 'be', 'randomized', 'to', 'two', 'groups', '.', 'One', 'group', 'will', 'continue', 'to', 'receive', 'the', 'AED', 'products', 'used', 'before', 'enrollment', '(', 'brand', 'or', 'generic', ')', ',', 'whereas', 'the', 'other', 'group', 'will', 'be', 'switched', 'to', 'an', 'alternative', 'equivalent', 'product', '.', 'Dosing', 'schedules', 'of', 'the', 'AEDs', 'being', 'tested', 'as', 'well', 'as', 'comedications', 'will', 'be', 'unaltered', 'throughout', 'the', '6-', 'to', '7day', 'period', 'of', 'the', 'study', '.', 'Serum', 'AED', 'levels', '(', 'mean', 'of', 'two', 'values', 'obtained', 'at', 'peak', 'and', 'trough', ',', 'respectively', 'in', 'the', 'evening', 'and', 'the', 'next', 'morning', ')', 'will', 'be', 'measured', 'on', 'day', '1', '(', 'baseline', ')', 'and', '5', 'days', 'post', '-', 'randomization', '(', '6', 'days', 'for', 'patients', 'receiving', 'AEDs', 'with', 'half', '-', 'lives', 'above', '12', 'h', ')', '.', 'The', 'primary', 'outcome', 'endpoint', 'will', 'be', 'the', 'proportion', 'of', 'patients', 'who', ',', 'post', '-', 'randomization', ',', 'show', 'a', 'greater', 'than', '25', '%', 'change', 'in', 'serum', 'drug', 'concentration', 'compared', 'with', 'baseline', '.', 'Secondary', 'endpoints', 'will', 'include', 'comparison', 'of', 'distributions', 'of', 'rough', 'serum', 'concentration', 'changes', 'between', 'groups', ',', 'other', 'pharmacokinetic', 'parameters', ',', 'time', 'to', 'first', 'seizure', ',', 'total', 'number', 'of', 'seizures', ',', 'and', 'adverse', 'events', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O']",NCT02429596,NCT02429596,"A Randomized Controlled Trial of Generic Substitution of Antiepileptic Drugs | Background. Anecdotal reports and uncontrolled studies have described an association between generic substitution of antiepileptic drugs (AEDs) and adverse events, including loss of seizure control. Although these results are likely to be influenced by methodological bias, they have led to a strong opposition, among physicians and patients, to the use of generic products in epilepsy.

Objectives. The primary objective is to assess potential risks associated with substitution of the currently taken AED product with an equivalent product, using as endpoint changes in serum drug levels at steady-state after substitution compared with baseline. Secondary objectives will be the assessment of inter-subject variability in serum drug concentration on an unchanged treatment schedule, and evaluation of potential short-term changes in seizure control and adverse events rate.

Methods. The study will use an experimental randomized open-label non-inferiority design. The population will consist of 200 adults stabilized on chronic treatment with carbamazepine, valproic acid, topiramate, oxcarbazepine, levetiracetam or lamotrigine and admitted to hospital for diagnostic evaluation or other indications, with no expected treatment changes during the subsequent 5 to 6 days. Patients will be randomized to two groups. One group will continue to receive the AED products used before enrollment (brand or generic), whereas the other group will be switched to an alternative equivalent product. Dosing schedules of the AEDs being tested as well as comedications will be unaltered throughout the 6- to 7day period of the study. Serum AED levels (mean of two values obtained at peak and trough, respectively in the evening and the next morning) will be measured on day 1 (baseline) and 5 days post-randomization (6 days for patients receiving AEDs with half-lives above 12 h). The primary outcome endpoint will be the proportion of patients who, post-randomization, show a greater than 25% change in serum drug concentration compared with baseline. Secondary endpoints will include comparison of distributions of rough serum concentration changes between groups, other pharmacokinetic parameters, time to first seizure, total number of seizures, and adverse events.","[(57, 76, 'DRUG', 'Antiepileptic Drugs'), (196, 215, 'DRUG', 'antiepileptic drugs'), (217, 221, 'DRUG', 'AEDs'), (261, 268, 'CONDITION', 'seizure'), (456, 464, 'CONDITION', 'epilepsy'), (582, 585, 'DRUG', 'AED'), (915, 922, 'CONDITION', 'seizure'), (1126, 1139, 'DRUG', 'carbamazepine'), (1141, 1154, 'DRUG', 'valproic acid'), (1156, 1166, 'DRUG', 'topiramate'), (1168, 1181, 'DRUG', 'oxcarbazepine'), (1183, 1196, 'DRUG', 'levetiracetam'), (1200, 1211, 'DRUG', 'lamotrigine'), (1437, 1440, 'DRUG', 'AED'), (1596, 1600, 'DRUG', 'AEDs'), (1710, 1713, 'DRUG', 'AED'), (1918, 1922, 'DRUG', 'AEDs'), (2286, 2293, 'CONDITION', 'seizure'), (2311, 2319, 'CONDITION', 'seizures')]"
"['An', 'Open', '-', 'Label', 'Controlled', 'Study', 'of', 'Adjunctive', 'Everolimus', '(', 'RAD', '001', ')', 'Therapy', 'for', 'Epilepsy', 'in', 'Children', 'With', 'Sturge', '-', 'Weber', 'Syndrome', '|', 'Sturge', 'Weber', 'Syndrome', '(', 'SWS', ')', 'is', 'a', 'rare', 'disease', 'that', 'affects', 'the', 'patient', ""'s"", 'brain', 'and', 'causes', 'benign', '(', 'non', '-', 'cancerous', ')', 'tumors', 'to', 'grow', 'in', 'the', 'brain', '.', 'One', 'of', 'the', 'symptoms', 'of', 'SWS', 'is', 'epilepsy', '.', 'People', 'with', 'epilepsy', 'have', 'seizures', '.', 'Some', 'patients', 'may', 'also', 'have', 'eye', 'problems', 'and', 'a', 'red', 'mark', 'on', 'their', 'facial', 'skin', '.', '\n\n', 'This', 'study', 'is', 'being', 'done', 'to', 'find', 'out', 'if', 'the', 'study', 'drug', ',', 'everolimus', ',', 'is', 'safe', 'and', 'has', 'helpful', 'effects', 'in', 'patients', 'with', 'SWS', 'who', 'have', 'seizures', 'and', 'are', 'not', 'responding', 'to', 'their', 'current', 'anti', '-', 'epileptic', 'medication', '.', '\n\n', 'The', 'study', 'drug', ',', 'everolimus', '(', 'Afinitor', '®', ')', ',', 'is', 'supplied', 'by', 'Novartis', 'Pharmaceuticals', 'Corporation', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01997255,NCT01997255,"An Open-Label Controlled Study of Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome | Sturge Weber Syndrome (SWS) is a rare disease that affects the patient's brain and causes benign (non-cancerous) tumors to grow in the brain. One of the symptoms of SWS is epilepsy. People with epilepsy have seizures. Some patients may also have eye problems and a red mark on their facial skin.

This study is being done to find out if the study drug, everolimus, is safe and has helpful effects in patients with SWS who have seizures and are not responding to their current anti-epileptic medication.

The study drug, everolimus (Afinitor®), is supplied by Novartis Pharmaceuticals Corporation.","[(45, 55, 'DRUG', 'Everolimus'), (57, 64, 'DRUG', 'RAD 001'), (78, 86, 'CONDITION', 'Epilepsy'), (104, 125, 'CONDITION', 'Sturge-Weber Syndrome'), (128, 149, 'CONDITION', 'Sturge Weber Syndrome'), (151, 154, 'CONDITION', 'SWS'), (293, 296, 'CONDITION', 'SWS'), (300, 308, 'CONDITION', 'epilepsy'), (322, 330, 'CONDITION', 'epilepsy'), (336, 344, 'CONDITION', 'seizures'), (481, 491, 'DRUG', 'everolimus'), (542, 545, 'CONDITION', 'SWS'), (555, 563, 'CONDITION', 'seizures'), (648, 658, 'DRUG', 'everolimus'), (660, 668, 'DRUG', 'Afinitor')]"
"['Neuromodulation', 'Training', 'for', 'Upper', 'Extremity', 'Recovery', 'for', 'Chronic', 'Cervical', 'Spinal', 'Cord', 'Injury', '|', 'This', 'study', 'is', 'to', 'understand', 'how', 'the', 'combination', 'of', 'activity', '-', 'based', 'recovery', 'training', 'and', 'targeted', 'spinal', 'cord', 'transcutaneous', 'stimulation', '(', 'scTS', ')', 'can', 'improve', 'participants', ""'"", 'ability', 'to', 'use', 'their', 'hand', ',', 'arms', ',', 'and', 'core', '.']","['B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04921592,NCT04921592,"Neuromodulation Training for Upper Extremity Recovery for Chronic Cervical Spinal Cord Injury | This study is to understand how the combination of activity-based recovery training and targeted spinal cord transcutaneous stimulation (scTS) can improve participants' ability to use their hand, arms, and core.","[(0, 24, 'OTHER', 'Neuromodulation Training'), (58, 93, 'CONDITION', 'Chronic Cervical Spinal Cord Injury'), (147, 179, 'PHYSICAL', 'activity-based recovery training'), (184, 231, 'OTHER', 'targeted spinal cord transcutaneous stimulation'), (233, 237, 'OTHER', 'scTS')]"
"['A', 'Randomized', ',', 'Open', 'Label', 'Clinical', 'Trial', 'of', 'Sustained', 'Hypernatremia', 'for', 'the', 'Prevention', 'and', 'Treatment', 'of', 'Cerebral', 'Edema', 'in', 'Traumatic', 'Brain', 'Injury', '|', 'Cerebral', 'edema', 'is', 'seen', 'heterogenous', 'group', 'of', 'neurological', 'disease', 'states', 'that', 'mainly', 'fall', 'under', 'the', 'categories', 'of', 'metabolic', ',', 'infectious', ',', 'neoplasia', ',', 'cerebrovascular', ',', 'and', 'traumatic', 'brain', 'injury', 'disease', 'states', '.', 'Regardless', 'of', 'the', 'driving', 'force', ',', 'cerebral', 'edema', 'is', 'defined', 'as', 'the', 'accumulation', 'of', 'fluid', 'in', 'the', 'brain', ""'s"", 'intracellular', 'and', 'extracellular', 'spaces', '.', 'This', 'occurs', 'secondary', 'to', 'alterations', 'in', 'the', 'complex', 'interplay', 'between', 'four', 'distinct', 'fluid', 'compartments', 'within', 'the', 'cranium', '.', 'In', 'any', 'human', 'cranium', ';', 'fluid', 'is', 'contained', 'in', 'the', 'blood', ',', 'the', 'cerebrospinal', 'fluid', ',', 'interstitial', 'fluid', 'of', 'the', 'brain', 'parenchyma', ',', 'and', 'the', 'intracellular', 'fluid', 'of', 'the', 'neurons', 'and', 'glia', '.', 'Fluid', 'movement', 'occurs', 'normally', 'between', 'these', 'compartments', 'and', 'depends', 'on', 'specific', 'concentrations', 'of', 'solutes', '(', 'such', 'as', 'sodium', ')', 'and', 'water', '.', 'In', 'brain', '-', 'injured', 'states', ',', 'the', 'normal', 'regulation', 'of', 'this', 'process', 'is', 'disturbed', 'and', 'cerebral', 'edema', 'can', 'develop', '.', 'Cerebral', 'edema', 'leads', 'to', 'increased', 'intracranial', 'pressure', 'and', 'mortality', 'secondary', 'to', 'brain', 'tissue', 'compression', ',', 'given', 'the', 'confines', 'of', 'the', 'fixed', '-', 'volume', 'cranium', '.', 'Additionally', ',', 'secondary', 'neuronal', 'dysfunction', 'or', 'death', 'can', 'occur', 'at', 'the', 'cellular', 'level', 'secondary', 'to', 'the', 'disruption', 'of', 'ion', 'gradients', 'that', 'control', 'metabolism', 'and', 'function', '.', '\n\n', 'While', 'studies', 'utilizing', 'bolus', 'dosing', 'of', 'hyperosmolar', 'therapy', 'to', 'target', 'signs', 'or', 'symptoms', 'of', 'increased', 'intracranial', 'pressure', 'secondary', 'to', 'cerebral', 'edema', 'are', 'numerous', ',', 'there', 'is', 'a', 'paucity', 'of', 'studies', 'relating', 'to', 'continuous', 'infusion', 'of', 'hyperosmolar', 'therapy', 'for', 'targeted', 'sustained', 'hypernatremia', 'for', 'the', 'prevention', 'and', 'treatment', 'of', 'cerebral', 'edema', '.', 'The', 'investigators', 'hypothesize', 'that', 'induced', ',', 'sustained', 'hypernatremia', 'following', 'traumatic', 'brain', 'injury', 'will', 'decrease', 'the', 'rate', 'of', 'cerebral', 'edema', 'formation', 'and', 'improve', 'patient', 'outcomes', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01605357,NCT01605357,"A Randomized, Open Label Clinical Trial of Sustained Hypernatremia for the Prevention and Treatment of Cerebral Edema in Traumatic Brain Injury | Cerebral edema is seen heterogenous group of neurological disease states that mainly fall under the categories of metabolic, infectious, neoplasia, cerebrovascular, and traumatic brain injury disease states. Regardless of the driving force, cerebral edema is defined as the accumulation of fluid in the brain's intracellular and extracellular spaces. This occurs secondary to alterations in the complex interplay between four distinct fluid compartments within the cranium. In any human cranium; fluid is contained in the blood, the cerebrospinal fluid, interstitial fluid of the brain parenchyma, and the intracellular fluid of the neurons and glia. Fluid movement occurs normally between these compartments and depends on specific concentrations of solutes (such as sodium) and water. In brain-injured states, the normal regulation of this process is disturbed and cerebral edema can develop. Cerebral edema leads to increased intracranial pressure and mortality secondary to brain tissue compression, given the confines of the fixed-volume cranium. Additionally, secondary neuronal dysfunction or death can occur at the cellular level secondary to the disruption of ion gradients that control metabolism and function.

While studies utilizing bolus dosing of hyperosmolar therapy to target signs or symptoms of increased intracranial pressure secondary to cerebral edema are numerous, there is a paucity of studies relating to continuous infusion of hyperosmolar therapy for targeted sustained hypernatremia for the prevention and treatment of cerebral edema. The investigators hypothesize that induced, sustained hypernatremia following traumatic brain injury will decrease the rate of cerebral edema formation and improve patient outcomes.","[(43, 66, 'OTHER', 'Sustained Hypernatremia'), (103, 117, 'CONDITION', 'Cerebral Edema'), (121, 143, 'CONDITION', 'Traumatic Brain Injury'), (146, 160, 'CONDITION', 'Cerebral edema'), (315, 337, 'CONDITION', 'traumatic brain injury'), (387, 401, 'CONDITION', 'cerebral edema'), (936, 949, 'CONDITION', 'brain-injured'), (1013, 1027, 'CONDITION', 'cerebral edema'), (1041, 1055, 'CONDITION', 'Cerebral edema'), (1505, 1519, 'CONDITION', 'cerebral edema'), (1599, 1619, 'OTHER', 'hyperosmolar therapy'), (1633, 1656, 'OTHER', 'sustained hypernatremia'), (1693, 1707, 'CONDITION', 'cerebral edema'), (1753, 1776, 'OTHER', 'sustained hypernatremia'), (1787, 1809, 'CONDITION', 'traumatic brain injury'), (1836, 1850, 'CONDITION', 'cerebral edema')]"
"['A', 'Randomised', 'Controlled', 'Trial', 'Evaluating', 'the', 'Effect', 'of', 'an', 'Individual', 'Auditory', 'Cueing', 'Device', 'on', 'Freezing', 'and', 'Gait', 'Speed', 'in', 'People', 'With', 'Parkinson', ""'s"", 'Disease', '|', 'The', 'primary', 'aim', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'effect', 'of', 'an', 'IACD', 'i.e.', 'Apple', 'iPod', '-', 'shuffle', ',', 'on', 'freezing', 'and', 'gait', 'speed', 'in', 'people', 'with', 'a', 'diagnosis', 'of', 'PD', 'through', 'the', 'implementation', 'of', 'a', 'randomised', 'controlled', 'trial', '.', 'A', 'secondary', 'aim', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'impact', 'of', 'such', 'a', 'device', 'on', 'the', 'quality', 'of', 'life', 'of', 'people', 'with', 'stroke', 'through', 'the', 'administration', 'of', 'a', 'self', '-', 'report', 'questionnaire', '.', 'The', 'IACD', 'will', 'be', 'pre', '-', 'loaded', 'with', 'an', 'individualised', 'auditory', 'cueing', 'frequency', '(', 'metronome', 'sound', ')', 'matched', 'to', 'the', 'walking', 'speed', 'of', 'the', 'individual', 'with', 'PD', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT00727467,NCT00727467,"A Randomised Controlled Trial Evaluating the Effect of an Individual Auditory Cueing Device on Freezing and Gait Speed in People With Parkinson's Disease | The primary aim of the study is to evaluate the effect of an IACD i.e. Apple iPod-shuffle, on freezing and gait speed in people with a diagnosis of PD through the implementation of a randomised controlled trial. A secondary aim of the study is to evaluate the impact of such a device on the quality of life of people with stroke through the administration of a self-report questionnaire. The IACD will be pre-loaded with an individualised auditory cueing frequency (metronome sound) matched to the walking speed of the individual with PD.","[(58, 91, 'OTHER', 'Individual Auditory Cueing Device'), (134, 153, 'CONDITION', ""Parkinson's Disease""), (217, 221, 'OTHER', 'IACD'), (227, 245, 'OTHER', 'Apple iPod-shuffle'), (304, 306, 'CONDITION', 'PD'), (478, 484, 'CONDITION', 'stroke'), (548, 552, 'OTHER', 'IACD'), (580, 610, 'OTHER', 'individualised auditory cueing'), (691, 693, 'CONDITION', 'PD')]"
"['Decreased', 'insulin', 'sensitivity', 'is', 'and', 'independent', 'risk', 'factor', 'for', 'stroke', 'despite', 'glycemic', 'control', '.', 'It', 'is', 'known', 'that', 'physical', 'exercise', 'increases', 'insulin', 'sensitivity', 'in', 'healthy', 'subjects', '.', 'Wether', 'stroke', 'patients', 'can', 'increase', 'insulin', 'sensitivity', 'via', 'physical', 'exercise', 'is', 'not', 'known', '.', '\n\n', 'Chronic', 'low', '-', 'grade', 'inflammation', 'is', 'associated', 'with', 'an', 'increased', 'risk', 'of', 'stroke', '.', 'Physical', 'exercise', 'has', 'shown', 'to', 'increase', 'IL-6', 'directly', 'after', 'exercise', 'in', 'untrained', 'subjects', '.', 'When', 'fitness', 'is', 'increased', 'in', 'each', 'subject', 'then', 'the', 'peak', 'IL-6', 'concentration', 'after', 'exercise', 'decreases', 'and', 'so', 'does', 'the', 'basal', 'level', 'of', 'IL-6', '.', 'It', 'is', 'not', 'known', 'whether', 'stroke', 'patients', 'can', 'increase', 'physical', 'activity', 'level', 'to', 'a', 'degree', 'where', 'chronic', 'inflammation', 'are', 'decreased', '.', '\n\n', 'This', 'study', 'is', 'designed', 'to', 'evaluate', 'if', 'physical', 'exercise', 'after', 'stroke', 'will', 'increases', 'insulin', 'sensitivity', 'and', 'reduce', 'low', '-', 'grade', 'chronic', 'inflammation', '.', '\n\n', 'Stroke', 'patients', 'have', 'been', 'randomized', 'to', 'intervention', 'with', 'physical', 'exercise', 'or', 'control', 'in', 'the', 'ExStroke', 'pilot', 'trial', 'and', 'followed', 'for', '2', 'years', '.', 'Using', 'the', 'study', 'population', 'from', 'the', 'ExStroke', 'pilot', 'trail', 'blood', 'samples', 'will', 'be', 'obtained', 'at', 'the', 'last', 'control', '.', 'Insulin', 'sensitivity', 'can', 'be', 'measured', 'from', 'fasting', 'glucose', 'and', 'insulin', 'using', 'the', 'Homeostasis', 'Model', 'Assessment', '(', 'HOMA', ')', '.', 'Interleukin-6', ',', 'TNF', '-', 'alfa', 'and', 'CRP', 'is', 'measured', 'to', 'estimate', 'chronic', 'inflammation', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT00376207,NCT00376207,"Decreased insulin sensitivity is and independent risk factor for stroke despite glycemic control. It is known that physical exercise increases insulin sensitivity in healthy subjects. Wether stroke patients can increase insulin sensitivity via physical exercise is not known.

Chronic low-grade inflammation is associated with an increased risk of stroke. Physical exercise has shown to increase IL-6 directly after exercise in untrained subjects. When fitness is increased in each subject then the peak IL-6 concentration after exercise decreases and so does the basal level of IL-6. It is not known whether stroke patients can increase physical activity level to a degree where chronic inflammation are decreased.

This study is designed to evaluate if physical exercise after stroke will increases insulin sensitivity and reduce low-grade chronic inflammation.

Stroke patients have been randomized to intervention with physical exercise or control in the ExStroke pilot trial and followed for 2 years. Using the study population from the ExStroke pilot trail blood samples will be obtained at the last control. Insulin sensitivity can be measured from fasting glucose and insulin using the Homeostasis Model Assessment (HOMA). Interleukin-6, TNF-alfa and CRP is measured to estimate chronic inflammation.","[(65, 71, 'CONDITION', 'stroke'), (115, 132, 'PHYSICAL', 'physical exercise'), (191, 197, 'CONDITION', 'stroke'), (244, 261, 'PHYSICAL', 'physical exercise'), (277, 307, 'CONDITION', 'Chronic low-grade inflammation'), (348, 354, 'CONDITION', 'stroke'), (356, 373, 'PHYSICAL', 'Physical exercise'), (609, 615, 'CONDITION', 'stroke'), (680, 700, 'CONDITION', 'chronic inflammation'), (755, 772, 'PHYSICAL', 'physical exercise'), (779, 785, 'CONDITION', 'stroke'), (832, 862, 'CONDITION', 'low-grade chronic inflammation'), (865, 871, 'CONDITION', 'Stroke'), (923, 940, 'PHYSICAL', 'physical exercise'), (944, 951, 'CONTROL', 'control'), (1287, 1307, 'CONDITION', 'chronic inflammation')]"
"['Efficacy', 'And', 'Safety', 'Of', 'Risperidone', 'In', 'The', 'Treatment', 'Of', 'Children', 'With', 'Autistic', 'Disorder', 'And', 'Other', 'Pervasive', 'Developmental', 'Disorders', ':', 'A', 'Canadian', ',', 'Multicenter', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', 'Study', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'an', 'oral', 'solution', 'of', 'risperidone', '(', 'an', 'antipsychotic', 'medication', ')', 'versus', 'placebo', 'in', 'the', 'treatment', 'of', 'behavioral', 'symptoms', 'in', 'children', 'with', 'Pervasive', 'Developmental', 'Disorders', '(', 'PDD', ')', '.']","['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT00261508,NCT00261508,"Efficacy And Safety Of Risperidone In The Treatment Of Children With Autistic Disorder And Other Pervasive Developmental Disorders: A Canadian, Multicenter, Double-Blind, Placebo-Controlled Study | The purpose of the study is to evaluate the effectiveness of an oral solution of risperidone (an antipsychotic medication) versus placebo in the treatment of behavioral symptoms in children with Pervasive Developmental Disorders (PDD).","[(23, 34, 'DRUG', 'Risperidone'), (69, 86, 'CONDITION', 'Autistic Disorder'), (97, 130, 'CONDITION', 'Pervasive Developmental Disorders'), (171, 178, 'CONTROL', 'Placebo'), (279, 290, 'DRUG', 'risperidone'), (295, 319, 'DRUG', 'antipsychotic medication'), (328, 335, 'CONTROL', 'placebo'), (393, 426, 'CONDITION', 'Pervasive Developmental Disorders'), (428, 431, 'CONDITION', 'PDD')]"
"['A', 'Phase', '3', ',', 'Open', '-', 'label', 'Extension', 'Study', 'to', 'Assess', 'the', 'Safety', ',', 'Tolerability', ',', 'and', 'Efficacy', 'of', 'RAD011', '(', 'Cannabidiol', 'Oral', 'Solution', ')', 'in', 'Patients', 'With', 'Prader', '-', 'Willi', 'Syndrome', '|', 'This', 'is', 'a', 'Phase', '3', 'open', '-', 'label', 'extension', '(', 'OLE', ')', 'study', 'in', 'patients', 'diagnosed', 'with', 'Prader', '-', 'Willi', 'Syndrome', '(', 'PWS', ')', 'who', 'completed', 'the', 'Maintenance', 'Period', 'of', 'the', 'randomized', ',', 'placebo', '-', 'controlled', 'Phase', '2/3', 'study', 'SCOUT-015', '.', '\n\n', 'The', 'primary', 'objective', 'of', 'this', 'study', 'is', 'to', 'assess', 'the', 'long', '-', 'term', 'safety', 'and', 'tolerability', 'of', 'RAD011', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O']",NCT05387798,NCT05387798,"A Phase 3, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndrome | This is a Phase 3 open-label extension (OLE) study in patients diagnosed with Prader-Willi Syndrome (PWS) who completed the Maintenance Period of the randomized, placebo-controlled Phase 2/3 study SCOUT-015.

The primary objective of this study is to assess the long-term safety and tolerability of RAD011.","[(90, 96, 'DRUG', 'RAD011'), (98, 109, 'DRUG', 'Cannabidiol'), (142, 163, 'CONDITION', 'Prader-Willi Syndrome'), (244, 265, 'CONDITION', 'Prader-Willi Syndrome'), (267, 270, 'CONDITION', 'PWS'), (465, 471, 'DRUG', 'RAD011')]"
"['Impacting', 'Children', ""'s"", 'Physical', 'and', 'Mental', 'Health', 'Through', 'Kinesiology', 'Support', 'in', 'Clinical', 'Care', '|', 'Over', 'the', 'past', 'four', 'decades', ',', 'it', 'has', 'become', 'clear', 'that', 'childhood', 'physical', 'activity', 'carries', 'with', 'it', 'a', 'myriad', 'of', 'beneficial', 'effects', '.', 'It', 'is', 'closely', 'linked', 'to', 'quality', 'of', 'life', 'and', 'the', 'recognized', 'benefits', 'include', ',', 'but', 'are', 'not', 'limited', 'to', ',', 'optimal', 'growth', 'and', 'development', ',', 'a', 'healthier', 'self', '-', 'concept', ',', 'enhanced', 'peer', 'socialization', ',', 'and', 'decreased', 'anxiety', 'and', 'depression', '.', 'Long', 'term', ',', 'an', 'active', 'lifestyle', 'decreases', 'the', 'risk', 'of', 'many', 'important', 'physical', 'and', 'mental', 'morbidities', '.', 'Thus', ',', 'the', 'observation', 'that', 'children', 'living', 'with', 'medical', 'conditions', 'and', 'disabilities', '(', 'MC&D', ')', 'today', ',', 'although', 'surviving', 'longer', 'thanks', 'to', 'advances', 'in', 'medical', 'care', ',', 'are', 'much', 'less', 'active', 'than', 'their', 'peers', 'is', 'a', 'matter', 'of', 'significant', 'concern', '.', 'Research', 'indicates', 'that', 'the', '350,000', 'Ontario', 'children', 'with', 'MC&D', 'have', 'lower', 'levels', 'of', 'physical', 'activity', ',', 'higher', 'screen', 'time', 'and', 'more', 'frequent', 'sleep', 'problems', '.', '\n\n', 'While', 'the', 'reasons', 'underlying', 'this', 'reality', 'are', 'complex', ',', 'previous', 'research', 'has', 'identified', 'a', 'substantial', 'subset', 'of', 'children', 'who', 'are', 'motivated', 'to', 'be', 'active', 'but', 'lack', 'the', 'confidence', 'to', 'do', 'so', '.', 'Fear', 'of', 'pain', ',', 'concern', 'for', 'MC&D', 'exacerbation', 'and', 'a', 'lack', 'of', 'confidence', 'in', 'individual', 'physical', 'movement', 'capacity', 'contribute', 'to', 'their', 'hesitation', '.', 'Clinical', 'experience', 'suggests', 'that', 'these', 'children', 'represent', '50', '%', 'to', '70', '%', 'of', 'inactive', 'patients', '.', 'Research', 'indicates', 'that', 'being', 'motivated', 'to', 'make', 'a', 'change', 'and', 'having', 'the', 'confidence', 'that', 'the', 'desired', 'change', 'can', 'be', 'achieved', 'are', 'the', 'essential', 'precursors', 'upon', 'which', 'successful', 'behaviour', 'change', 'initiatives', 'are', 'built', '.', 'This', 'randomized', ',', 'controlled', 'trial', 'will', 'explore', 'whether', 'group', 'sessions', 'with', 'a', 'Registered', 'Kinesiologist', 'lead', 'to', 'a', 'direct', 'bolstering', 'of', 'physical', 'activity', 'confidence', ',', 'and', 'in', 'turn', 'to', 'increased', 'and', 'sustained', 'physical', 'activity', 'in', 'these', 'children', '.', 'Such', 'an', 'approach', 'holds', 'the', 'promise', 'of', 'a', 'nonpharmacologic', ',', 'low', 'cost', 'and', 'accessible', 'means', 'of', 'enhancing', 'health', 'that', 'shall', 'be', 'met', 'with', 'a', 'high', 'level', 'of', 'patient', 'and', 'family', 'support', 'while', 'bringing', 'a', 'significant', 'societal', 'and', 'medical', 'return', 'on', 'investment', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04106154,NCT04106154,"Impacting Children's Physical and Mental Health Through Kinesiology Support in Clinical Care | Over the past four decades, it has become clear that childhood physical activity carries with it a myriad of beneficial effects. It is closely linked to quality of life and the recognized benefits include, but are not limited to, optimal growth and development, a healthier self-concept, enhanced peer socialization, and decreased anxiety and depression. Long term, an active lifestyle decreases the risk of many important physical and mental morbidities. Thus, the observation that children living with medical conditions and disabilities (MC&D) today, although surviving longer thanks to advances in medical care, are much less active than their peers is a matter of significant concern. Research indicates that the 350,000 Ontario children with MC&D have lower levels of physical activity, higher screen time and more frequent sleep problems.

While the reasons underlying this reality are complex, previous research has identified a substantial subset of children who are motivated to be active but lack the confidence to do so. Fear of pain, concern for MC&D exacerbation and a lack of confidence in individual physical movement capacity contribute to their hesitation. Clinical experience suggests that these children represent 50% to 70% of inactive patients. Research indicates that being motivated to make a change and having the confidence that the desired change can be achieved are the essential precursors upon which successful behaviour change initiatives are built. This randomized, controlled trial will explore whether group sessions with a Registered Kinesiologist lead to a direct bolstering of physical activity confidence, and in turn to increased and sustained physical activity in these children. Such an approach holds the promise of a nonpharmacologic, low cost and accessible means of enhancing health that shall be met with a high level of patient and family support while bringing a significant societal and medical return on investment.","[(56, 75, 'PHYSICAL', 'Kinesiology Support'), (1631, 1677, 'PHYSICAL', 'group sessions with a Registered Kinesiologist')]"
"['Epilepsy', 'Phase', 'III', 'Trial', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'demonstrate', 'that', 'RWJ-333369', 'is', 'safe', 'and', 'effective', 'as', 'add', '-', 'on', 'treatment', 'of', 'partial', 'onset', 'seizures', '.']","['B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT00433667,NCT00433667,Epilepsy Phase III Trial | The purpose of this study is to demonstrate that RWJ-333369 is safe and effective as add-on treatment of partial onset seizures.,"[(0, 8, 'CONDITION', 'Epilepsy'), (76, 86, 'DRUG', 'RWJ-333369'), (132, 154, 'CONDITION', 'partial onset seizures')]"
"['Intravenous', 'Exenatide', 'Infusion', 'in', 'Critically', 'Ill', 'Patients', 'With', 'Acute', 'Brain', 'Injury', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'assess', 'the', 'feasibility', 'of', 'exenatide', 'infusion', 'for', 'the', 'treatment', 'of', 'high', 'blood', 'sugars', 'following', 'acute', 'brain', 'injury', '.']","['O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT02058940,NCT02058940,Intravenous Exenatide Infusion in Critically Ill Patients With Acute Brain Injury | The purpose of this study is to assess the feasibility of exenatide infusion for the treatment of high blood sugars following acute brain injury.,"[(12, 21, 'DRUG', 'Exenatide'), (34, 48, 'CONDITION', 'Critically Ill'), (63, 81, 'CONDITION', 'Acute Brain Injury'), (142, 151, 'DRUG', 'exenatide'), (182, 199, 'CONDITION', 'high blood sugars'), (210, 228, 'CONDITION', 'acute brain injury')]"
